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Abstract 
Cartilage, which lines joint surfaces to allow near-frictionless movement, lacks the ability to 
adequately repair itself and there are currently no effective, disease-modifying drugs to halt or 
repair the damage. Development of powerful in vitro models to investigate gene expression 
changes during osteoarthritis and chondrogenesis is key in understanding how the disease develops 
and how cartilage might attempt to repair itself. 
In this thesis, an enhanced model of chondrogenesis of the murine ATDC5 chondroprogenitor cell 
line was developed with cells cultured in micromass. Results revealed not only an increase in 
chondrogenesis markers, but markers of growth plate differentiation, including type X collagen, 
were either restricted or repressed, whilst expression of genes rich in articular cartilage were up-
regulated. This suggests that the enhanced ATDC5 model is more reminiscent of articular cartilage, 
making this model suitable for investigations into osteoarthritis - a disease of articular cartilage. 
The role of WNT5A signalling was then investigated (which is up-regulated in osteoarthritic cartilage) 
in a disease-like context by stimulating cultures with cytokines. Microarray analysis unearthed 
interesting and novel results, including a decrease in WNT5A signalling and in expression of 
members of the CCN family. Pathway analysis allowed further exploration of the interrelationship 
between cytokine and WNT signalling. Some changes in gene expression were reminiscent of those 
observed previously in in vivo models of early osteoarthritis. 
Finally, migration studies revealed that non-induced, undifferentiated ATDC5 cells have a migratory 
phenotype reminiscent of chondroprogenitor cells, which have the capacity to migrate to sites of 
cartilage injury in vivo. A novel model of cartilage invasion was also developed, with results 
suggesting WNT5A may be a potential inducer of chondroprogenitor invasion. 
Together, this thesis shows that the ATDC5 model is a good model for investigating articular 
cartilage both in a physiological and pathological setting. 
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1.1 Introduction to cartilage 
Cartilage is a connective tissue found in various locations around the body, including the ear, nose, 
articulated joints and intervertebral discs, comprising primarily of collagens and proteoglycans. It is 
classified into three main types: hyaline cartilage, elastic cartilage and fibrocartilage, with each type 
exhibiting unique properties. Hyaline cartilage is the most prominent form of cartilage in the body, 
forming the framework of the embryonic skeleton to be largely replaced by bone in a process called 
endochondral ossification. As a result, hyaline cartilage is left lining the surfaces of bones in 
articulating joints, and thus is called articular cartilage. The main collagen in hyaline cartilage is type 
II collagen. This is also true for elastic cartilage, which is histologically similar to hyaline cartilage, 
but in addition, also contains elastin fibres, which can be seen by light microscopy (Horton, 1993; 
Worster, et al., 2001). This is the most flexible type of cartilage and is found in areas such as the 
ears and nose. Finally fibrocartilage is the most rigid cartilage and is located in the intervertebral 
discs. Unlike hyaline cartilage and elastic cartilage, the main collagens in fibrocartilage are type I 
collagen with a small proportion of type III collagen (Eyre & Wu, 1983). 
1.1.1 Articular Cartilage 
Articular cartilage is hyaline cartilage that lines the surfaces of articulated joints (Figure 1.1) that 
resists deformation, aiding distribution of load and protecting the underlying bone (Buckwalter & 
Mankin, 1997; Hendren & Beeson, 2009). It is comprised primarily of an extracellular matrix (ECM) 
containing type II collagen; the large aggregating proteoglycan, aggrecan; and water. It is also 
sparsely populated by chondrocytes, which constitute less than 5% of the cartilage volume (Poole, 
et al., 2002). The remainder of the cartilage is inhabited by the extensive ECM. It is the combined 
properties of the constituents of the matrix, as well as the synovial fluid that fills the joint cavity, 
that allow near-frictionless movement of articulated joints in healthy individuals (Wu, et al., 2010). 
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1.1.2 Type II Collagen 
Collagen is an abundant protein in the body, forming one third of the total protein in humans. 
Conservation of collagen proteins has been observed across phyla from simple organisms such as 
sponges, to complex animals such as vertebrates (Boot-Handford & Tuckwell, 2003) and has been 
reported to be discovered in a 65 million year old Tyrannosaurus rex fossil (Shoulders & Raines, 
2009). This high conservation and abundance clearly demonstrates the importance of the collagen 
proteins. 
Figure 1.1 - Anatomy of an articulated joint. Simplified diagrammatic view of an articulated joint 
showing a layer of articular cartilage lining the surfaces of two meeting bones. Physical 
interaction between the bones is prevented by the lining cartilage and allows near-frictionless 
movement in healthy individuals, resisting deformation due to bearing load via the distribution 
of the load across the joint, protecting the underlying bone. Reproduced from (Maen, 2010) 
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Type II collagen is a classical fibrillar collagen, which consist of three helical polypeptide α chains 
that wrap around each other to form the characteristic triple helix. The various types of collagens 
contain either a mixture of different α chains (heterotrimer) or three of the same α chains 
(homotrimer), with type II collagen being a homotrimer consisting of three α1(II) chains (Shoulders 
& Raines, 2009). These chains contain the typical -Gly-X-Y- triple repeat domain, where X is typically 
proline and Y is typically hydroxyproline (Ramachandran, 1956). The repeat of glycine, due to its 
small size, at every third residue enables the α chains to twist around a central axis, wrapping round 
each other to form the triple helix. This structure is stabilised by hydroxyproline, forming hydrogen 
bonds along the helix (Cremer, et al., 1998; Boot-Handford & Tuckwell, 2003). 
Collagen is first synthesised as its separate α chains which undergo post-translational modification 
in the rough endoplasmic reticulum (RER). Once translocated into the endoplasmic reticulum lumen, 
the carboxy terminal non-collagenous (NC1) domain folds and selects other appropriate α chains 
with which to trimerise with, nucleating at the carboxy terminal and ‘zipping up’ the rest of the 
trimer in a C-N direction. For fibrillar collagens, this procollagen remains soluble due to the soluble 
C and N terminal domains. Once secreted and these prodomains cleaved, the insoluble collagenous 
domain containing the -Gly-X-Y- repeat aggregates and overlaps, with lysyl oxidase catalysing cross-
links to stabilise the fibrils (Boot-Handford & Tuckwell, 2003)(Figure 1.2). Many of these collagen 
fibrils then associate to form a collagen fibre. This organised structure is what gives collagen its 
properties, providing strength and resistance to stretching forces. 
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Figure 1.2 - Collagen fibril synthesis. Three translated α chains associate at their C-terminal and 
zips along the chains in a C-N direction, forming a triple helix. Once secreted from the cell, the 
C-terminal and N-terminal domains are cleaved and the individual collagen proteins associate 
together in a staggered formation. Cross-links are then catalysed by lysyl oxidase to form 
collagen fibrils. Figure adapted from Hill (2009). 
Lysyl oxidase 
Nucleation at C-terminal 
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1.1.3 Aggrecan 
Aggrecan is a large proteoglycan and is another important constituent of cartilage, providing the 
cartilage with resistance to compressive forces (Haung & Wu, 2008). Its core protein contains three 
globular domains, termed G1, G2 and G3, rich in cysteine. The G1 and G2 domains are separated 
by an interglobular domain (IGD); and G2 and G3 are separated by a long glycosaminoglycan (GAG)-
attachment region, consisting of three domains, one of which covalently links keratan sulphate (KS) 
and two (CS1 and CS2) that link chondroitin sulphate (CS) chains (Roughley, 2001, 2006) (Figure 1.3). 
As its name suggests, aggrecan aggregates non-covalently onto a central filament of hyaluronan 
(HA) via a link protein in complex with G1, forming a ternary complex between the three 
components, with up to 100 aggrecan molecules radiating from the HA (Mörgelin, et al., 1988; 
Dudhia, 2005; Roughley, 2006). The size of this complex traps aggrecan in the type II collagen 
framework in articular cartilage. However, aggrecan is rarely found in its whole form in cartilage, 
being subject to proteolytic processing of the core protein. This results in aggregation typically of 
G1-containing fragments within the collagen matrix (Roughley, 2006). 
The essential function of aggrecan in cartilage comes from the attachment of GAGs - negatively-
charged linear polysaccharides, KS and CS, forming a bottlebrush structure (Figure 1.3). In the 
presence of HA, many aggrecan monomers aggregate together along the HA core to form a 
bottlebrush superstructure. This creates a high charge density, resulting in a high degree of 
hydration and thus forming an osmotically active complex. This retention of water enables near-
frictionless movement in an articulated joint, forming a hydrated gel-like structure. This osmotically 
active gel-like structure provides osmotic resistance to deswelling under compressive forces, and 
the collagen network provides resistance against swelling pressures. Aggrecan therefore allows 
reversible deformation of cartilage due to compressive forces, allowing the articulated joints to 
bear and distribute load, providing cartilage with one of its most important functions (Dudhia, 2005; 
Horkay, et al., 2008). 
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1.1.4 Chondrocytes and Chondrogenesis 
Articular cartilage is an avascular, aneural and alymphatic connective tissue, and as such, was 
previously thought to be sparsely inhabited by just one cell type known as chondrocytes, which are 
responsible for the production, secretion and regulation of the cartilage matrix (Poole, 1997). It is 
now known that chondroprogenitor cells are also resident within cartilage (Dowthwaite, et al., 
2004), discussed later. This matrix also has an important role in regulating chondrocytic functions, 
with the function of the chondrocyte being dependent on its location (Archer & Francis-West, 2003). 
Chondrocytes are derived from precursor cells known as mesenchymal stem cells (MSCs) in a 
process known as chondrogenesis, which, developmentally, occurs during endochondral 
ossification. This is the process of converting the hyaline collagen anlagen into the skeleton. During 
the first step, mesenchyme aggregates and condenses, regulated by bone morphogenetic proteins 
(BMPs). During this process, the MSCs express the master chondrogenesis transcription factor, sex-
determining region Y box 9 (SOX9), a primary determinant of chondrogenesis. As these cells 
differentiate into chondrocytes, various components of the extensive cartilage ECM are laid down, 
such as type II collagen and aggrecan. 
G1 G2 KS 
IGD 
CS1 CS2 
G3 
Figure 1.3 – Structure of Aggrecan. Aggrecan consists of a large core protein split into three 
main globular domains, G1, G2 and G3. Between G2 and G3 lies a keratan sulphate (KS) domain 
and two chondroitin sulphate domains (CS1 and CS2) which bind their respective 
glycosaminoglycans (GAGs). It is the binding of these GAGs which gives aggrecan its important 
property in cartilage to resist compressive forces. These negatively-charged side chains create a 
high charge density, resulting in the retention of water, creating a gel-like structure, enabling 
the joint to bear and distribute load. Figure reproduced and adapted from (Dudhia, 2005). 
 
8 
 
Most chondrocytes then undergo hypertrophy, withdraw from the cell cycle and subsequently 
commit themselves to apoptosis, allowing the space previously occupied by them to be replaced 
by bone and vascular architecture following the production of vascular endothelial growth factor 
(VEGF) by both hypertrophic chondrocytes and more terminal hypertrophic chondrocytes (Zuscik, 
et al., 2008). However, chondrocytes at the distal ends of long bones proliferate and synthesize 
new cartilage which is substituted by bone by the approaching ossification front. Higher hydrostatic 
pressure at the joint surface slows the growth of cartilage and the ossification front stabilizes, 
defining the thickness of the articular cartilage that now lines the surface of the newly formed bone 
(Carter, et al., 2004). 
Chondrocytes in articular cartilage are maintained in four distinct areas: the superficial zone, the 
intermediate zone, the radial zone and the zone of calcified cartilage. As previously mentioned, the 
function of chondrocytes depends on its location. In the superficial zone, there are 1-2 layers of 
flattened chondrocytes expressing a variety of genes, including proteoglycan 4 (PRG4, also known 
as lubricin), SOX9 and type II collagen (COL2A1). Chondrocytes in the intermediate zone are 
rounded and express many of the same genes as in the superficial zone with the exception of PRG4. 
In the radial zone, chondrocytes express markers of mature differentiation and hypertrophy, such 
as type X collagen (COL10A1) and alkaline phosphatase (ALPL) (Zuscik, et al., 2008) (Figure 1.4).  
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Figure 1.4 – Cellular zones of articular cartilage. Diagram showing the different zones within 
articular cartilage, highlighting the different gene expression of the chondrocytes shown in each 
zone. Figure modified from Zuscik, et al. (2008) 
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1.2 WNT Signalling 
The WNT family of secreted glycoproteins, named after the discovery of the homologous 
Drosophila wingless (Wg) and murine mouse mammary tumour virus integration site 1 (Int1), and 
its various pathways are well known for their role in developmental biology, with a variety of 
functions, including axis formation (Zeng, et al., 1997; Liu, et al., 1999) and cell fate determination 
(Dorsky, et al., 1998). Dysregulation of WNT signalling can have a number of effects, ranging from 
formation of a secondary axis during development (Zeng, et al., 1997), to tumourigenesis (Caldwell, 
et al., 2004; Gatcliffe, et al., 2008).  
WNT signalling can be split into two broad pathways – the canonical signalling pathway (also known 
as β-catenin-dependent pathway) and the non-canonical pathway (also known as the β-catenin-
independent pathway). 
1.2.1 Canonical WNT Pathway 
The canonical WNT pathway is transduced by the Frizzled (FZD) family of seven pass 
transmembrane receptors along with low-density lipoprotein receptor (LDRL)-related protein 
(LRP)5/6 (Tamai, et al., 2000). In the absence of a WNT ligand binding to its receptors, β-catenin 
present in the cytoplasm is continually phosphorylated by glycogen synthase kinase 3 (GSK3) and 
casein kinase 1 (CK1) as a complex with axin and adenomatosis polyposis coli (APC), commonly 
collectively referred to as the destruction complex. Association with β-transducin repeat-containing 
protein (β-TrCP), an E3 ubiquitin ligase, marks it for ubiquitination and subsequent proteolysis by 
the proteasome. 
A canonical WNT ligand binding to FZD and LRP5/6 results in phosphorylation of LRP5/6 by CK1 and 
GSK3. GSK3 is recruited by axin (MacDonald, et al., 2009) and phosphorylates LRP5/6 at a PPP(S/T)P 
motif (Zeng, et al., 2005), providing a docking site for axin, forming a positive feedback loop to 
enhance the signal. Axin and dishevelled (DVL) associate and DVL binds to the activated FZD. 
Activation of DVL inhibits GSK3 and thus inhibits the phosphorylation of β-catenin that marked it 
for degradation. β-catenin is then allowed to stabilise in the cytoplasm where it can translocate to 
the nucleus, associating with T cell-specific/lymphoid enhancer binding factor (TCF/LEF), activating 
gene transcription (Sethi & Videl-Puig, 2010; Clark, et al., 2012; Staines, et al., 2012; Kim, et al., 
2013c) (Figure 1.5) 
  
 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 Non-canonical WNT Pathway 
The non-canonical WNT signalling pathway (β-catenin-independent pathway) has not been subject 
to as extensive study as the canonical pathway, and can be further subdivided into more specific 
pathways (Sethi & Videl-Puig, 2010). Broadly, this can be split into two main pathways, the calcium-
dependent pathway (WNT/Ca2+) and the planar cell polarity pathway (PCP). 
In the WNT/Ca2+ pathway, WNT binding to FZD triggers an increase in cytoplasmic Ca2+ levels via 
phospholipase C (PLC), which in turn activates effectors such as Ca2+/calmodulin-dependent kinase 
II (CAMKII), calcineurin and protein kinase C (PKC). Calcineurin activation may then also activate the 
transcription factor nuclear factor of activated T-cells (NFAT). PKC and CAMKII can also inhibit β-
catenin signalling in the canonical WNT signalling pathway (Niehrs, 2012)(Figure 1.6). 
Figure 1.5 – Canonical WNT Pathway. Simplified cartoon showing that in the absence of WNT, 
β-catenin is phosphorylated by GSK3 and marked for degradation. In the presence of WNT, the 
GSK3 complex is dissociated and inhibited from marking β-catenin for degradation, which 
subsequently stabilises in the cytoplasm and translocates to the nucleus where it can activate 
transcription of WNT-responsive genes via TCF/LEF. Comprised using information from Nusse 
(2005), Sethi and Videl-Puig (2010), Clark, et al. (2012) and Kim, et al. (2013c). 
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In the PCP pathway, WNT binding to FZD activates small GTPases such as RhoA and RAC1, which in 
turn can activate RHO kinase (ROCK) and c-Jun-N-terminal kinase (JNK), leading to activation of JNK-
dependent transcription factors such as activating transcription factor 2 (ATF2) (Niehrs, 
2012)(Figure 1.6). 
1.2.3 WNT5A/ROR2 Signalling 
The WNT ligand WNT5A was traditionally thought to be a non-canonical WNT, although research 
has shown that WNT5A can activate the canonical WNT pathway via FZD4 (Mikels & Nusse, 2006) 
and therefore its effects may be dependent on the receptors present.  
Primarily, WNT5A is known to activate the non-canonical WNT signalling pathway by binding to and 
activating receptor tyrosine kinase-like orphan receptor 2 (ROR2), a single-pass transmembrane 
receptor, which may work independently or in a complex with FZD to activate JNK-mediated 
signalling (Oishi, et al., 2003; Clark, et al., 2012; Niehrs, 2012) (Figure 1.6).  
  Figure 1.6 – WNT5A Signalling Pathways. Simplified cartoon of WNT5A signalling in the planar 
cell polarity (PCP) pathway (A) and calcium-dependent pathway (B) – two “non-canonical” WNT 
signalling pathways. A) In the PCP pathway, WNT5A acts via small GTPases to mediate changes 
in the cytoskeleton and activate JNK-mediated transcription factors. B) In the calcium-
dependent pathway, WNT5A-mediated increases in intracellular Ca2+ concentrations may also 
result in changes in the cytoskeleton as well as inhibition of β-catenin signalling via PKC and 
CAMKII. Gene expression may also be modulated by NFAT transcription factor. Comprised using 
information from Niehrs (2012). 
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Knockout mice of WNT5A and ROR2 phenotypically mimic each other, suggesting an intricate 
relationship between ROR2 and WNT5A signalling. Both knockout mice die shortly after birth with 
respiratory dysfunction and also exhibit craniofacial defects such as cleft palate, limb shortening 
and tail shortening (Oishi, et al., 2003; Schwabe, et al., 2004; He, et al., 2008). Both WNT5A and 
ROR2 have been implicated in Robinow syndrome, a disease that primarily results in a form of 
dwarfism, with limb shortening and craniofacial defects giving rise to a look described as ‘foetal 
face’ due to the similarities with the developing face of a foetus (Brunetti-Pierri, et al., 2008; 
Beiraghi, et al., 2011), due to loss-of-function mutations (Schwabe, et al., 2004; Person, et al., 2010; 
Roifman, et al., 2014; Tamhankar, et al., 2014). Due to the similarities and the known involvement 
of ROR2, Ror2-/- mice have been used to model Robinow Syndrome (Schwabe, et al., 2004). 
Similar to Wnt5a-/- mice, mice overexpressing Wnt5a specifically in cartilage (by driving expression 
from to the Col2a1 promoter), resulted in severe skeletal defects, including shortening of the 
skeletal elements of the limb, despite an overall increase in cartilage thickness, and severe delay in 
hypertrophic differentiation of chondrocytes (Yang, et al., 2003). Overexpression of Wnt5a resulted 
in an increase in p130 expression with a decrease in cyclin D1 expression, causing an expansion of 
zone I chondrocytes, which go on to form the articular cartilage, at the expense of zone II 
chondrocytes which undergo hypertrophy form the growth plate cartilage. In comparison, 
chondrocytes from Wnt5a-/- mice enter zone II prematurely but are prevented from terminal 
differentiation (Yang, et al., 2003). 
Similarly, the effect of WNT5A and its inhibition of hypertrophy has also been seen in vitro in 
micromass cultures (three-dimensional culture, discussed in section 1.4.4) of immortalised mouse 
limb bud cells via nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-dependent 
inhibition of runt-related transcription factor 2 (Runx2), the major transcription factor driving 
hypertrophic differentiation. However, the effect of WNT5A on chondrocyte differentiation was 
shown to be stage dependent – whilst WNT5A inhibited hypertrophic differentiation at later stages 
of chondrogenesis, WNT5A enhanced chondrogenesis at earlier stages via NFAT-dependent 
induction of SOX9, the master transcription factor driving early chondrogenesis (Bradley & Drissi, 
2010). This highlights the deep involvement of WNT5A in cartilage biology. 
1.2.4 WNT signalling and chondrocytes 
In addition to WNT5A, a number of other WNT family members are known for their role in the 
regulation of limb and skeletal development. Transfection with WNT1 in the developing chick limb 
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bud resulted in a truncated radius and ulna. Abnormalities were also revealed by Alcian blue 
staining (which stains the sulphated GAGs attached to proteoglycans) of the cartilaginous elements 
in the beak when WNT1 was ectopically expressed in the craniofacial mesenchyme. Infection of 
micromass cultures with WNT1 virus, which ordinarily undergo chondrogenesis by the act of the 
high density culture alone, failed to undergo chondrogenesis. The same result was also observed 
with WNT7A (Rudnicki & Brown, 1997). These results suggest that WNT1 and WNT7A both have 
inhibitory effects on chondrogenesis. 
Misexpression of WNT3A in the developing chick limb bud resulted in ectopic expression of apical 
ectodermal ridge (AER)-specific genes, a region that induces limb development, such as BMP-2, 
known to induce chondrogenesis (Kengaku, et al., 1998). In a different micromass experiment in a 
murine multipotent cell line (C3H10T1/2), results showed that treatment with BMP-2 to induce 
chondrogenesis increased levels of Wnt3a mRNA during early stages of chondrogenesis and 
decreased levels of Wnt7a mRNA during late stages of chondrogenesis (Fischer, et al., 2002a), in 
agreement with Rudnicki & Brown’s report (2007) regarding the inhibitory effect of WNT7A. The 
same group later found that overexpression of Wnt3a was insufficient to induce chondrogenesis in 
the same cell line, requiring addition of BMP-2, although overexpression of Wnt3a made the cells 
more responsive to chondrogenesis induced by BMP-2 (Fischer, et al., 2002b). Conversely, WNT3A 
has also been shown to inhibit chondrogenesis in micromass cultures of chick limb buds (Hwang, et 
al., 2005), which can be restored by WNT inhibitory factor 1 (WIF1) (Surmann-Schmitt, et al., 2009) 
and has been shown to induce de-differentiation of articular chondrocytes from New Zealand white 
rabbits (Hwang, et al., 2005). 
1.2.5 WNT Signalling in Osteoarthritis 
In addition to their involvement in the cartilage development, various members of the WNT family 
have also been implicated in cartilage pathologies, such as osteoarthritis (OA), characterised by the 
degradation of articular cartilage (discussed in more detail in section 1.3), and matrix turnover. 
WNT3A transfection in articular chondrocytes from rabbit knee and elbow decreased the levels of 
proteoglycans in the ECM. These cells also exhibited increased levels of matrix metalloproteinase 
(MMP)3, MMP13, A Disintegrin And Metalloproteinase with Thrombospondin Motif (ADAMTS)4 
and ADAMTS5, known matrix-degrading enzymes. Additionally, in a Hartley guinea pig model of 
age-dependent OA, nuclear β-catenin staining was more prominent with worsening OA with severe 
cartilage degeneration and thinning, indicating canonical WNT signalling in the involvement of 
cartilage degeneration (Yuasa, et al., 2008). 
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Mutations in Frizzled-related protein (FRZB, also known as “secreted Frizzled-related protein 3” 
[sFRP3]) have been associated with hip OA susceptibility in women (Loughlin, et al., 2004; Lane, et 
al., 2006). FRZB is a glycoprotein antagonist of WNT signalling that resembles the FZD 
transmembrane receptors but lacks the transmembrane domain, therefore competitively inhibiting 
WNT signalling (Jones & Jomary, 2002). Transfection studies in a human embryonic kidney cell line 
(HEK293) revealed that a single nucleotide polymorphism resulting in a R325G mutation in FRZB, 
associated with hip-OA in female patients, had a diminished ability to antagonise WNT signalling, 
as noted by nuclear levels of β-catenin, suggesting an importance of inhibiting WNT signalling to 
maintain the integrity of the cartilage (Loughlin, et al., 2004). 
Mouse models have also demonstrated the significance of WNT signalling in OA development via 
FRZB. Frzb-/- mice, which were macroscopically and histomorphologically indistinguishable from 
wild-type littermates, were more susceptible to cartilage damage via various induced OA models 
with an increase in active WNT signalling. In arthritic Frzb-/- mice, Mmp3 mRNA expression was up-
regulated, with no increase in Mmp9, Mmp13, Adamts4 or Adamts5 detected. Recombinant FRZB 
dose-dependently inhibited recombinant MMP3 activity in a colorimetric in vitro activity assay, 
indicating that inhibition of WNT signalling may impede cartilage damage by inhibiting matrix-
degrading enzyme (Lories, et al., 2007). 
In addition to FRZB, Dickkopf-1 (DKK1), another WNT inhibitor, has also been implicated in 
osteoarthritis, with increased levels of DKK1 protein and mRNA found in human knee OA cartilage 
(Weng, et al., 2009; Oh, et al., 2012) and in experimental mouse OA cartilage (Oh, et al., 2012). 
Treatment of primary human chondrocytes with DKK1 increased the number of observed apoptotic 
cells in a time-dependent manner. Antibody-mediated neutralisation of DKK1 also abrogated 
interleukin (IL)-1β-mediated induction of apoptosis (Weng, et al., 2009). Conversely, cartilage-
specific overexpression of Dkk1 in mice significantly inhibited cartilage damage by destabilisation 
of the medial meniscus (DMM, a commonly used experimental OA model), and pre-exposure of 
primary mouse chondrocyte cultures with DKK1 inhibited WNT3A-mediated up-regulation of 
Mmp13 and Adamts4, two key enzymes in cartilage destruction (discussed in more detail in section 
1.3.2) (Oh, et al., 2012). Additionally, lower levels of circulating DKK1 have been found in the plasma 
from OA patients, negatively correlating with worsening OA (Honsawek, et al., 2010). 
1.2.6 CCN family and osteoarthritis 
The CCN proteins are a family of six cysteine-rich matricellular proteins of the ECM, named after 
the first three founding members: Cysteine-rich Protein 61 (CYR61), Connective Tissue Growth 
Factor (CTGF) and Nephroblastoma Overexpressed (NOV). Three further members were also 
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subsequently discovered – WNT-1-inducible Secreted Protein 1 (WISP1), WISP2 and WISP3 – and 
have since also been referred to as CCN1-6 respectively. These CCN proteins all contain a similar 
modular structure (Figure 1.7), containing four domains: insulin-like growth factor binding protein 
domain (IGFBP), von Williebrand factor type C (VWC) domain, thrombospondin type 1 repeat 
domain (TSP-1) and a c-terminal domain containing a cysteine knot (CT). However, NOV/CCN3 is 
unique in that it lacks the CT domain (Zuo, et al., 2010). 
These CCN proteins have been implicated in a number of biological processes, including cell 
adhesion, migration, differentiation, survival and mitogenesis (Dhar & Ray, 2010). They have also 
been implicated in a number of chondrocytic processes. 
 
 
 
 
 
 
 
 
1.2.6.1 CYR61/CCN1 
CYR61/CCN1, the first founding member of the CCN family, has been shown to be involved in 
mammalian chondrogenesis. Immunohistochemistry of mouse embryos revealed staining for 
CYR61/CCN1 in the maturing cartilage and perichondrium of the forelimb digits; in the skeletal 
anlagen of the forelimb; and in the less mature, condensing mesenchyme of posterior somites, 
indicating a role in chondrogenesis. Antibody neutralisation of CYR61/CCN1 in single-cell suspended 
isolated limb bud mesenchymal cells significantly inhibited the cells’ ability to aggregate, an 
important step in chondrocyte differentiation. Treatment of a micromass culture with CYR61/CCN1 
also significantly increased levels of Col2a1 (Wong, et al., 1997). These results indicate that 
CYR61/CCN1 induce differentiation of MSCs into chondrocytes during chondrogenesis in the mouse. 
On the contrary in human bone marrow-derived mesenchymal stem cells (hBMSCs), mRNA levels 
Figure 1.7 – The modular structure of the CCN Growth Factor family. Each member of the CCN 
family contain a similar modular structure consisting of a signal peptide (SP) necessary for 
secretion from the cell, an insulin-like growth factor binding protein domain (IGFBP), a von 
Williebrand factor type C domain (VWC), a thrombospondin type 1 repeat domain (TSP1) 
separated from the VWC domain via a linker bridge, and a c-terminal domain containing a 
cysteine knot (CT), which is absent in CCN5. Figure comprised using information from Brigstock, 
et al. (2003) and Chen and Lau (2009) 
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of CYR61 decreased from high expression prior to differentiation to undetectable levels one week 
after initiation of differentiation (Schütze, et al., 2005). 
CYR61/CCN1 has also been implicated in fracture healing of rat femur, an environment that 
reportedly recapitulates embryonic development, displaying significantly elevated mRNA 
expression and protein levels in proliferating chondrocytes, but not hypertrophic chondrocytes 
(Hadjiargyrou, et al., 2000). Furthermore, CYR61/CCN1 has been shown to be up-regulated in 
response to WNT3A in a mouse pluripotent progenitor cell line (C3H10T1/2). siRNA knockdown of 
Cyr61 also inhibited osteogenic differentiation in WNT3A-overexpressing cells, demonstrating the 
importance of Cyr61 in WNT3A-induced osteogenic differentiation of MSCs (Si, et al., 2006). 
1.2.6.2 CTGF/CCN2 
CTGF/CCN2, the second founding member of the CCN family, has been well documented to be 
involved in chondrocyte hypertrophy, with immunohistochemical analysis showing localisation of 
CTGF/CCN2 expression in the most hypertrophic cells (Huang, et al., 2010). Immortalised 
chondrocytes isolated from a chondrosarcoma from a 72 year Japanese male (Takigawa, et al., 
1989), HCS-2/8 cells, transfected with CTGF resulted in earlier and increased expression of aggrecan 
core protein, a marker of chondrocyte maturation, and earlier and increased expression of type X 
collagen, a marker of chondrocyte hypertrophy (Nakanishi, et al., 2000). These results have also 
been mimicked in rabbit auricular chondrocytes (Fujisawa, et al., 2008), demonstrating the 
importance of CTGF/CCN2 in chondrocyte differentiation and hypertrophy. 
It has been shown that SOX9 represses Ctgf expression in chondroprogenitor cells by binding to a 
TCF/LEF·SOX9 consensus site in the Ctgf promoter. In hypertrophic cells where SOX9 levels are 
decreased, the TCF/LEF consensus site is occupied by β-catenin, leading to increased levels of Ctgf. 
WNT3A stimulation of chondroprogenitor cells also lead to an increase in Ctgf expression, further 
implicating the involvement of WNT signalling in the various stages of chondrogenesis (Huang, et 
al., 2010). 
The importance of CTGF/CCN2 was established in 2003 upon the discovery that Ctgf-/- mice die 
within minutes after birth due to respiratory failure caused by skeletal defects (Ivkovic, et al., 2003). 
These mice exhibited shortened sterna which were bent inwards and had kinked ribs. Mineralised 
cartilage zones were expanded whilst ossification was reduced, suggesting a defective replacement 
of cartilage with bone. The hypertrophic zone in the cartilage of long bones was also disorganised. 
Although growth plate cartilage had normal expression and distribution of type II collagen and type 
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X collagen, expression of aggrecan and link protein were decreased (Ivkovic, et al., 2003). Together, 
this highlights the importance of CTGF/CCN2 in cartilage. 
1.2.6.3 NOV/CCN3 
NOV/CCN3, the third founding member of the CCN family, has also been implicated in chondrocyte 
hypertrophy. Immunohistochemistry and semi-quantitative RT-PCR revealed NOV/CCN3 
expression in the pre-hypertrophic and hypertrophic zones of the embryonic murine growth plate. 
Treatment with parathyroid hormone-related protein (PTHrP), known to delay terminal 
differentiation, resulted in a decrease of type X collagen in murine explant cultures and decrease 
of NOV/CCN3 mRNA and protein, indicating NOV/CCN3’s involvement in chondrocyte hypertrophy 
(Yu, et al., 2003). This has also been shown by siRNA knockdown (Lafont, et al., 2005a). Furthermore, 
the same group also demonstrated that NOV/CCN3 up-regulates transforming growth factor (TGF)-
β2, implicating NOV/CCN3 in two stages of chondrogenesis: condensation (TGFβ2 increase) and 
hypertrophy (type X collagen increase). Additionally, deletion of Ctgf in mouse chondrocytes has 
been shown to increase levels of Nov, and stimulation of wild-type chondrocytes with recombinant 
NOV/CCN3 decreased expression of Ctgf, suggesting regulation of the CCN family by itself (Kawaki, 
et al., 2008). 
1.2.6.4 WISP1/CCN4 
WISP1/CCN4 is the first member of the WNT1-inducible secreted proteins and the fourth member 
of the CCN family, and has been implicated in OA directly. WISP1/CCN4 protein has been shown to 
be increased in murine OA knee joints up to day 21 after OA induction by collagenase, after which 
WISP1/CCN4 levels decreased with decreasing chondrocytes in the cartilage. Additionally, 
immunohistochemistry revealed strong WISP1/CCN4 staining at the cell surface and ECM in human 
knee and hip OA cartilage, especially in the midzone and chondrocyte clusters (Blom, et al., 2009). 
WISP1/CCN4 expression has also been shown in hypertrophic zone of the developing tibia in murine 
embryos in a non-OA model (Yanagita, et al., 2007). 
Dose-dependent induction of Adamts4, Mmp3, Mmp9 and Mmp13 was observed by WISP1/CCN4 
treatment in the murine RAW 264.7 macrophage cell line, and MMP3 and MMP9 in both primary 
human synovial cells and primary human chondrocytes (Blom, et al., 2009), all known matrix-
degrading enzymes, further implicating the involvement of WISP1/CCN4 in the progression of OA. 
Furthermore, overexpression of WISP1/CCN4 in HCS-2/8 cells did not regulate expression of Col2a1 
and aggrecan (Acan), but did significantly increase expression of ALPL, and may therefore be 
important in chondrocyte differentiation in endochondral ossification (Yanagita, et al., 2007). 
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1.2.6.5 WISP2/CCN5 
WISP2/CCN5 is unique amongst the CCN family as it lacks the CT domain that is present in the 
remaining five members (Wei, et al., 2009). In situ hybridisation revealed localised strong 
expression of Wisp2 mRNA in osteoblasts of calcified cartilage in human foetal femur with weaker 
expression in chondrocytes and osteoclasts (Kumar, et al., 1999). RT-PCR has also shown WISP2 to 
be expressed in BMSCs from human femoral heads and is expressed prior to initiation, and in the 
initial stages, of adipogenesis. However no differences were found during chondrogenic 
differentiation of MSCs (Schütze, et al., 2005). WISP2 has also been detected by RT-PCR 
preferentially in the synovium of rheumatoid arthritis (RA) patients compared to that of OA patients, 
and shown via immunohistochemistry to be restricted to fibroblast cells in extensive fibrotic tissue 
in RA patients (Tanaka, et al., 2005). These findings suggest that WISP2/CCN5 may therefore be 
preferentially implicated in RA and pathologies involving the bone rather than OA. 
1.2.6.6 WISP3/CCN6 
WISP3/CCN6 is the final member of the WISP and CCN families and has been implicated in a number 
of diseases, such as breast cancer (Marrakchi, et al., 2010) and is mutated in progressive 
pseudorheumatoid dysplasia (PPRD) (Hurvitz, et al., 1999; Zhou, et al., 2007; Ye, et al., 2010). PPRD 
is a disease affecting articular cartilage of multiple joints, most commonly the interphalangeal joints 
of the hands and then hips and elbows, leading to restricted mobility, osseous swelling and 
progressive reduction of cartilage starting from the age of about 3-4, resulting in severe joint 
degeneration as the patient ages (Wynne-Davies, et al., 1982; Mampaey, et al., 2000). 
Wisp3 mRNA has been observed via RT-PCR in human synoviocytes, articular cartilage chondrocytes 
and BMSCs induced to undergo chondrogenesis in vitro (Hurvitz, et al., 1999). It has been suggested 
that WISP3/CCN6 has a role in post-natal skeletal and cartilage homeostasis, due to the lack of 
extraskeletal abnormalities and prominence of degenerated cartilage in patients with PPRD (Hurvitz, 
et al., 1999; Sen, et al., 2004). This role in cartilage homeostasis is further backed by the localisation 
of WISP3/CCN6 in clusters of proliferating chondrocytes in human OA cartilage, in midzone 
chondrocytes in normal cartilage and in areas of chondrocyte proliferation in foetal cartilage growth 
plates with reduced expression in the hypertrophic zone (Sen, et al., 2004). Furthermore, studies 
have shown down-regulation of MMP1, MMP3 and MMP13 in PPRD articular chondrocytes (Zhou, 
et al., 2007) and up-regulation of COL2A1, ACAN (aggrecan) and SOX9 in WISP3-transfected 
immortalised chondrocyte cell line (C-28/I2) (Sen, et al., 2004) implicating a chondroprotective role 
of WISP3/CCN6. 
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It has been proposed that WISP3/CCN6 inhibits the action of insulin-like growth factor (IGF)-1, 
which has been shown to enhance chondrocyte hypertrophy, by its IGFBP domain, and thus 
stabilises the chondrocyte phenotype. Loss of WISP3/CCN6 function, via mutations, may therefore 
promote chondrocyte hypertrophy by increasing sensitivity to IGF1 (Yang & Liao, 2007). 
Consequently, mutations have been found in WISP3/CCN6 in PPRD families (Hurvitz, et al., 1999; 
Zhou, et al., 2007). To further back this, a C78R mutation of a conserved cysteine residue in the 
IGFBP motif of WISP3 failed to up-regulate COL2A1 and ACAN (aggrecan) mRNA or type II collagen 
protein when transfected in an immortalised human chondrocyte cell line (C28/I2) cells unlike 
transfection with wild-type WISP3 (Sen, et al., 2004). 
Previous work in the Gavrilović group has demonstrated the ability of WISP-3/CCN6 to also regulate 
metalloproteinase expression (Baker, et al., 2012). In WISP3/CCN6 overexpressing C28/I2 cells, 
MMP10 was upregulated 14-fold at the message level, whilst ADAMTS5 was down-regulated five-
fold. Pharmacological inhibition of MEK1/2, p38 MAPK and IKK each partially suppressed MMP10 
up-regulation, whereas only IKK inhibition further reduced ADAMTS5 expression. Stimulation of β- 
catenin also partially reversed the suppression of ADAMTS5 and further enhanced MMP10 
expression in these WISP3/CCN6 overexpressing cells, implicating a number of potential signalling 
pathways involved in WISP3/CCN6-mediated metalloproteinase regulation (Baker, et al., 2012). 
Baker, et al. showed that WISP3 was up-regulated at the mRNA level of cartilage. By 
immunohistochemistry, it was demonstrated that WISP3/CCN6 was detected in osteoarthritic 
cartilage samples, mainly localised to the pericellular regions, in sites of cartilage damage. Similarly, 
WISP3/CCN6 was also detected in patients with no clinical history of osteoarthritis, but exhibited 
cartilage damage, localised to these damaged regions. 
In addition to its role in cartilage homeostasis, WISP3/CCN6 has also been implicated in the 
regulation of BMSCs. RT-PCR revealed high expression of WISP3 in undifferentiated primary human 
chondrocytes from the femoral head of patients undergoing total hip replacement arthroplasty. 
During high-density pellet chondrogenic differentiation, mRNA levels decreased 5.5-fold (Schütze, 
et al., 2005). The same group then later showed that WISP3/CCN6 and CYR61/CCN1 can stimulate 
migration of hBMSCs dose-dependently across gelatin-coated chemotaxis filters and that 
WISP3/CCN6-mediated migration, and not CYR61/CCN1, was mediated by integrin αvβ5, shown by 
antibody-blocking (Schütze, et al., 2007). Furthermore, WISP3/CCN6 has also been shown to 
increase migration across a matrigel-coated porous transwell in the chondrosarcoma cell line JJ012, 
through up-regulation of intercellular adhesion molecule (ICAM)-1 (Fong, et al., 2011). 
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Taking these findings together, it is possible to envisage that WISP3/CCN6 has a 
protective/reparative role in cartilage, up-regulating expression of cartilaginous genes and 
remodelling the matrix which could theoretically allow for the chemoattractive invasion of 
progenitor cells to help repair cartilage damage by undergoing chondrogenesis. 
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1.3 Osteoarthritis 
Osteoarthritis is the most common form of arthritis (CDC, 2010), affecting up to 8 million people in 
the UK alone (Arthritis Research UK, 2011). It is a painful disease characterised by the degradation 
of articular cartilage, with changes in the underlying subchondral bone, along with limited intra-
articular inflammation (Poole, 1999), outlined in Figure 1.8. Rheumatoid arthritis (RA), on the other 
hand, involves persistent synovitis, systemic inflammation and generation of auto-antibodies (Scott, 
et al., 2010). Current treatment for OA primarily focuses on temporary pain relief and anti-
inflammatories, with no effective drugs on the market to combat the underlying causes (Poole, et 
al., 2002; Seed, et al., 2009; Arthritis Research UK, 2011). Joint replacement surgery is the only 
effective option, although these need to be replaced after a certain number of years. Research into 
OA, its biological causes and the molecular pathways involved is therefore of big interest in order 
to develop potential effective future therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 – Simplified comparison between a healthy joint and an osteoarthritic joint. In 
osteoarthritis, cartilage is degraded. This increases the friction when moving the joint, leading 
to pain and stiffness. Wearing away of this cartilage may therefore lead to the two bones of the 
joint rubbing against each other, causing further pain and stiffness. Other symptoms of OA 
include joint swelling and changes in the subchondral bone, such as bone thickening and 
outgrowths (osteophytes). 
 
23 
 
1.3.1 Cartilage changes in OA 
OA is commonly described as the result of one of two routes: abnormal loading on normal cartilage, 
or normal loading on abnormal cartilage, with the former normally resulting from some sort of 
mechanical stress possibly due to injury and the latter normally being an idiopathic form of OA that 
develops over long periods of time (Sandell & Aigner, 2001; Poole, et al., 2002; Horton Jr, et al., 
2006). 
At the macroscopic level, the first indicators of OA are fibrillation at the surface of articular cartilage 
as the collagen fibrils are damaged, softening of the cartilage (chondromalacia) and ulceration of 
the cartilage (Poole, et al., 2002; Horton Jr, et al., 2006). 
1.3.1.1 Catabolic changes in OA 
Osteoarthritis results in a number of catabolic changes leading to the destruction of cartilage. In 
addition to the enzymatic destruction of cartilage matrix components, discussed in section 1.3.2, 
osteoarthritis also results in the activation of other functional catabolic pathways, including 
chondrocyte apoptosis and changes in the retention of water due to the loss of aggregating 
aggrecan attached to hyaluronan. Despite an overall increase in water content in OA joints resulting 
in swelling, hydrostatic pressure of the joint is decreased as the water is not fixed to the GAG side 
chains of the aggrecan (Horton Jr, et al., 2006), thereby diminished the resistance to compressive 
forces that aggrecan normally protects against. 
Studies have investigated apoptosis of chondrocytes both in vivo and in vitro. In vitro studies have 
shown that primary human articular chondrocytes from non-OA donors, treated with IL-1β, an 
inflammatory cytokine up-regulated in OA tissue, in the presence of oxygen radical scavengers, can 
induce cell death by the interaction of oxygen radicals with nitric oxide (Blanco, et al., 1995). An 
association has also been reported between low production of endogenous IL-1β with higher 
frequencies of absence of hip-OA in volunteers aged over 85 (Goekoop, et al., 2010). Furthermore, 
it has been shown by immunohistochemistry of mice and rat knee cartilage that chondrocyte 
apoptosis increases with age (Adams & Horton Jr, 1998). However, the impact of chondrocyte 
apoptosis in the development of OA has been under scrutiny (Sandell & Aigner, 2001). 
1.3.1.2 Anabolic changes in OA 
In addition to the catabolic changes found during the progression of OA, it is known that OA 
cartilage also induces anabolic activity, eliciting a repair response to repair the damaged cartilage. 
Therefore degeneration of cartilage is as a result of increased net catabolic activity and not due to 
the lack of synthesis, since chondrocytes in OA cartilage are anabolically hyperactive. 
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To observe the synthesis of new type II collagen, studies have observed the release of CPII, the C-
propeptide of type II procollagen, from both human articular cartilage explants (Nelson, et al., 1998; 
Hermansson, et al., 2004) and porcine articular cartilage explants (Hermansson, et al., 2004). 
Additionally, it has been reported that OA cartilage samples revealed increased expression of two 
prolyl-4-hydroxylase subunits (P4HA2 and P4HB), a key enzyme in type II collagen synthesis, along 
with increases in COL2A1 itself (Grimmer, et al., 2006). 
Aggrecan synthesis has also been shown to be increased in OA cartilage compared to non-OA 
cartilage. This has been achieved in one study by observing the presence of epitope 846, an epitope 
present on large aggrecan that has been newly synthesised, analogous to the use of observing CPII 
for type II collagen synthesis. The study showed an increase in the presence of epitope 846 in OA 
human knee cartilage compared to non-OA knee cartilage. This increase in presence was also more 
profound in late-stage OA compared to early-stage OA (Lohmander, et al., 1999). 
However, studies on the increase of cartilage matrix components have tended to examine the 
cartilage as a whole, disregarding the different zones present in cartilage. Immunostaining against 
CPII showed that type II collagen synthesis was restricted to the mid and deep zones of the cartilage 
and was absent from natural and new articular surface (Nelson, et al., 1998). This has also been 
shown in a separate experiment for proteoglycans, with hyper-anabolic activity of chondrocytes 
being restricted to the middle and deeper zones of OA cartilage. Chondrocytes in the upper zone, 
which does not relate to the superficial zone due to erosion, showed no expression of type II 
collagen or aggrecan (Aigner & Dudhia, 1997). 
1.3.2 Enzymes in cartilage degradation 
The catabolic activities involved during osteoarthritis are primarily mediated by a family of enzymes 
known as the metalloproteinases, which encompasses the matrix metalloproteinases (MMPs), a 
disintegrin and metalloproteinases (ADAMs) and ADAM with thrombospondin motifs (ADAMTSs), 
all part of the metzincin superfamily of zinc-based enzymes. 
1.3.2.1 MMPs 
The MMP family, which together can degrade all components of the ECM, can be further subdivided 
into different groups, based upon their substrate specificity, primary structure or cellular location. 
Of note in cartilage remodelling and degradation are the collagenases (MMP1, MMP8 and MMP13) 
that are able to cleave triple-helical, fibrillar collagens into the characteristic three-quarter and one-
quarter fragments; and the gelatinases (MMP2 and MMP9) (Murphy, et al., 2002),  which are then 
able to degrade the collagen fragments further (Burrage, et al., 2006). While all three collagenases 
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have been shown to degrade type II collagen in vitro, MMP13 has the most catalytic activity, with 
MMP8 having the least (Billinghurst, et al., 1997). 
1.3.2.2 ADAMTSs 
Although various MMPs can also degrade aggrecan in vitro (Fosang, et al., 1993; Murphy, et al., 
2002), it is now known that the principle enzymes involved in aggrecan degradation are the 
aggrecanases, ADAMTS4 and ADAMTS5 (Huang & Wu, 2008). Other members of the ADAMTS family 
have also been shown to have aggrecanase activity (ADAMTS1, -8, -9, -15, -16 and -18), with 
ADAMTS5 being the most active, with aggrecanase activity 1000-fold greater than ADAMTS4 
(Gendron, et al., 2007). Despite both MMPs and ADAMTSs degrading aggrecan, it has been shown 
that they exert their activity at different preferential sites, with MMPs primarily cleaving aggrecan 
at Asn341–Phe342, while the ADAMTSs preferentially cleave at Glu373–Ala374 (Porter, et al., 2005). 
These cleavage sites occur within the IGD of aggrecan, thereby releasing the GAG-rich portion of 
aggrecan, which provides aggrecan with its vital function of retaining water, which is then free to 
leave the ECM, devoiding the cartilage of its resistance to compressive forces (Huang & Wu, 2008). 
1.3.2.3 Enzyme dysregulation 
While metalloproteinases are required by the body for remodelling of the ECM, dysregulation of 
their activities can lead to a net increase of cartilage degradation, potentially aiding the onset of 
idiopathic OA. This dysregulation has been shown in early work on tissue inhibitors of 
metalloproteinases (TIMPs), which as the name suggests, inhibit MMPs. It was shown that in non-
arthritic human cartilage, there is a small excess of TIMP over MMPs present. In OA cartilage, levels 
of both TIMP and MMPs were increased, however, the increase of MMPs were proportionally 
higher than that of TIMP, suggesting a net increase of MMP activity and decrease in TIMP activity, 
implicating the role of dysregulation of MMPs in OA (Dean, et al., 1989). 
MMP13, which has the highest catalytic activity against type II collagen, has been shown to be 
dysregulated in OA, such that inhibition of MMP13 abrogates the release of a collagenase-derived 
neo-epitope in human OA articular cartilage explants (Billinghurst, et al., 1997); knockout of Mmp13 
in mice provides resistance to structural cartilage damage in an induced-OA model compared to 
wild-type mice (Little, et al., 2009); and RT-PCR has shown MMP13 to be significantly up-regulated 
in late-stage OA (Bau, et al., 2002; Davidson, et al., 2006). This expression of MMP13 has been 
shown to be mediated by the inflammatory cytokines IL-1β and tumour necrosis factor (TNF)-α, 
regulated via activation of various mitogen-activated protein (MAP) kinases (Bau, et al., 2002; 
Liacini, et al., 2003; Burrage, et al., 2006). 
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In addition to MMPs, the dysregulation of the ADAMTSs have also been implicated in OA. While 
many ADAMTSs are able to cleave aggrecan, specifically ADAMTS4 and ADAMTS5, with their higher 
aggrecanase activity, are the likeliest candidates for involvement in OA pathology (Huang & Wu, 
2008). The involvement of ADAMTSs and not MMPs in aggrecan degradation in OA cartilage has 
been shown by dose-dependent inhibition of GAG release into culture media, which correlated with 
the 374ARGS neo-epitope produced by ADAMTS cleavage of aggrecan and not MMP cleavage 
(Malfait, et al., 2002). Both ADAMTS4 and ADAMTS5 were detected at the mRNA and protein levels 
in OA cartilage, however, only ADAMTS5 was detected in healthy cartilage (Malfait, et al., 2002). 
However, by qRT-PCR, another report has detected both ADAMTS4 and ADAMTS5 expression in 
healthy human cartilage, with up-regulation of both in OA cartilage, with ADAMTS4 levels elevated 
to a higher fold compared to ADAMTS5 (Song, et al., 2007b). 
The contribution of both ADAMTS4 and ADAMTS5 have been affirmed by further inhibition studies 
using siRNA knockdown of both genes, which significantly reduced the amount of GAGs released 
into the culture medium from OA cartilage explants and normal cartilage with cytokine-induced 
catabolic activity, representing a reduction in the cleavage of aggrecan (Song, et al., 2007b). These 
results suggest that both ADAMTS4 and ADAMTS5 are involved in the pathology of OA. 
1.3.2.4 ADAMTS knockout studies 
However, perhaps the biggest discovery regarding ADAMTS4 and ADAMTS5 came in 2005 when 
two groups,  Glasson et al., and  Stanton et al., published their findings concurrently in Nature. Both 
teams used cre-loxP transgenics to excise the catalytic domains in the ADAMTS genes (exon 4 in 
Adamts4 and exon 3 in Adamts5) to create functional knockout mice. Antibodies raised against the 
aggrecan neo-epitope TEGE373, a new epitope present in tissue extracts as a result of ADAMTS-
cleavage of aggrecan, were used in both studies and demonstrated a substantial reduction of the 
neo-epitope in Adamts4 knockout cartilage compared to wild-type and Adamts5 knockout cartilage, 
with Glasson, et al., reporting negligible staining of the proximal tibial growth plate in Adamts4 
knockout mice, implicating ADAMTS4 as the enzyme responsible for normal aggrecanase-mediated 
aggrecan turnover of the murine growth plate. In a surgically-induced model of cartilage 
degradation, Glasson, et al., reported markedly reduced staining for the TEGE373 neo-epitope in the 
Adamts5 knockout cartilage, implicating ADAMTS5 in the early phase of degradation. Adamts4 
knockout mice showed no protection of cartilage. 
Inflammatory modulators (IL-1α in Stanton, et al., and IL-1α in combination with retinoic acid in 
Glasson, et al.) to induce ‘degradative enzyme activity’ resulted in no proteoglycan release in 
Adamts5 knockout cartilage compared to a significant increase in wild-type (Glasson, et al., 2005) 
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and Adamts4 knockout cartilage (Glasson, et al., 2005; Stanton, et al., 2005), suggesting ADAMTS5 
is responsible for the proteoglycan release. IL-1α was also seen to increase Adamts5 mRNA 
expression 18-fold compared to Adamts4 by 3-fold (Stanton, et al., 2005). Stanton, et al., also 
investigated the ALGSV neo-epitope, the other neo-epitope formed from the Glu373/Ala374 cleavage, 
which is released into the medium, as well as investigating the AGEG C-terminal neo-epitope 
formed from ADAMTS cleavage of Glu1572/Ala1573. The report found all three neo-epitopes (TEGE, 
ALGSV and AGEG) were absent from the cartilage or media of Adamts5 knockout samples in 
response to IL-1α stimulation, similar to unstimulated controls, compared to stimulation of 
Adamts4 knockout and wild-type samples. Toluidine blue staining of the tibiofemoral joint after 
injection with methylated bovine serum albumin (BSA), to induce monoarticular arthritis, revealed 
significantly less aggrecan loss in Adamts5 knockout mice compared to controls. Furthermore, only 
7% of Adamts5 knockout joints showed cartilage erosion compared to 36% of joints from control 
mice (Stanton, et al., 2005), suggesting that loss of ADAMTS5 activity in mice is sufficient to protect 
against aggrecan loss and cartilage erosion in a model of inflammatory arthritis. Put together, these 
results from the Glasson and Stanton studies show that ADAMTS5, and not ADAMTS4, is the key 
aggrecanase in mice involved in cartilage degradation. 
1.3.3 Stem cell repair 
Currently, the only effective treatment for patients with osteoarthritis is joint replacement surgery 
for end-stage cases in load-bearing joints, with no effective drugs on the market to reverse the 
damage caused by the disease. This therefore does not benefit patients with osteoarthritis in non-
load-bearing joints such as the joints in the hands, or those with early-stage disease who must first 
endure the painful progression through the disease to be eligible for surgery. This makes 
investigation into the disease to find therapeutic targets a huge area of scientific and 
pharmaceutical interest. 
One area of interest lies in a treatment known as autologous chondrocyte implantation (ACI). This 
is the process of taking a cartilage biopsy, extracting the chondrocytes, expanding them in culture 
and implanting them into the site of cartilage damage in the osteoarthritic joint (Giannini, et al., 
2010; Akgun, et al., 2015; Buda, et al., 2015). However, obvious complications arise; in order to 
obtain the chondrocytes, damage has to be inflicted to another area of (non-load-bearing) cartilage. 
Furthermore, due to the small proportion of chondrocytes in cartilage, expansion in culture is a 
necessary step in order to generate enough cartilage for implantation, which risks dedifferentiation 
of the cells, as discussed in section 1.4. 
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Stem cells, derived from the bone marrow, are therefore an attractive alternative to overcome 
these problems, eliminating the need for further cartilage damage and cell culture. Furthermore, 
use of BMSCs has the potential to reduce the number of hospitalisations from two visits with ACI 
down to one visit (Giannini, et al., 2010; Buda, et al., 2015). Both techniques have resulted in 
improved patient outcome with the use of BMSCs sometimes achieving slightly better results based 
on various clinical scores of cartilage damage and osteoarthritis stage (Akgun, et al., 2015; Buda, et 
al., 2015) as well as rate of return to sporting activity (Buda, et al., 2015). 
Nevertheless, both techniques require surgery and a more favourable approach would be to avoid 
the complications of surgery all together by having the body repair the cartilage itself. Therefore 
work continues to identify a suitable therapeutic target to pursue via drugs to prevent the need for 
surgery and benefit patients of all stages and forms of OA. 
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1.4 Maintaining the chondrocytic phenotype 
Isolated primary chondrocytes are typically expanded in two-dimensional monolayer culture to 
increase their number, since chondrocytes present in cartilage are limited in number. However, 
chondrocytes grown in 2D are known to rapidly de-differentiate, reducing expression of 
chondrocytic genes, such as COL2A1, losing their chondrocytic phenotype and gaining a more 
fibroblast-like phenotype with the up-regulation of fibroblastic genes, such as for type I collagen 
(COL1A1, COL1A2) (Stokes, et al., 2001; Francioli, et al., 2010). Three-dimensional culture is 
therefore preferred to maintain the chondrocytic phenotype, mimicking the in vivo 
microenvironment in a number of ways. 
1.4.1 Suspension culture 
One way of culturing chondrocytes in suspension is via the use of poly-2-hydroxyethyl methacrylate 
(polyHEMA), coated onto culture surfaces to prevent cell adhesion to the substratum. Cells plated 
onto polyHEMA therefore remain in suspension, allowing chondrocytes to regain their spherical 
shape and re-establish their cell-cell and cell-matrix contacts in all three dimensions (Stokes, et al., 
2001). 
Stokes, et al. (2001) demonstrated the recovery of the chondrocytic phenotype. By RT-PCR, they 
reported that isolated primary chondrocytes lost expression of COL11A2 (encoding the α2 chain of 
type XI collagen) by passage (P)3, lost expression of ACAN (aggrecan) by P2 and diminished 
expression of COL2A1 by P1 compared to P0. Transfer to polyHEMA returned expression of 
COL11A2 and ACAN back to P0 levels. De-differentiation was attributed to diminished binding of 
SOX9 to the promoter region of COL2A1 (Stokes, et al., 2001). 
1.4.2 Encapsulation 
An alternative method of culturing chondrocytes in 3D involves encapsulation, for example, by 
using alginate beads, a linear co-polymer of D-mannuronic acid and L-guluronic acid (Bonaventure, 
et al., 1994). Previous studies have directly compared culture in alginate beads compared to 2D 
monolayer. It was found that in 2D, α1(I), α2(I) and α1(III) chains, abundantly present in de-
differentiated chondrocytes, represented 90% of the total collagen, indicating a high amount of 
type I collagen and type III collagen. These chains were almost undetectable in the alginate culture 
system (Bonaventure, et al., 1994). Seeding at high density is also known to preserve the 
chondrocytic phenotype with up-regulation of COL2A1 mRNA, however, chondrocytes isolated 
from cartilage biopsies do not allow this due to the limited amount present in cartilage. However, 
alginate culture was able to re-differentiate chondrocytes that had been isolated and expanded in 
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monolayer culture to overcome this problem, with a high detection of COL2A1 and no detection of 
COL1A1 (type I collagen)(Bonaventure, et al., 1994). 
However, seeding at a high density into alginate may not be necessary. It has been shown that 
seeding at a low density (1 x 104 cells/ml alginate) resulted in higher expression of COL2A1 (up to 
26-fold higher) and sulphated GAG deposition compared to high density cultures (1 x 106 cells/ml 
alginate). The rate of proliferation was also observed to be higher in the low density culture than 
the high density culture. Thin fibrils, similar in size to type II collagen, were also observed 
throughout the matrix in low density cultures via scanning electron microscopy, but not in high 
density cultures. This ability of increased proliferation and re-differentiation of chondrocytes in a 
low density culture was seen to be dependent on the formation of clonal populations not observed 
in the high density cultures (Gagne, et al., 2000). 
1.4.3 Pellet Culture 
An alternative method of three-dimensional culture is pellet culture. Essentially, cells are pelleted 
by centrifugation and the pellet incubated. In time, the chondrocytes lay down an ECM typical of a 
cartilage biopsy, displaying typical physeal patterning with the hypertrophic zone at the top, 
proliferative zone in the middle and the resting zone at the bottom (Cheung, et al., 2008).  
One report has suggested that pellet culture “elicits superior chondrogenic re-differentiation” 
compared to culturing in alginate beads (Bernstein, et al., 2009). Immunohistological staining 
showed high accumulation of type II collagen in the pellet cultures with very little in the alginate 
beads. qRT-PCR showed consistently high levels of SOX9 expression, similar to native cartilage, 
compared to low levels in monolayer and variable expression in alginate-based encapsulated 
chondrocytes. Type II collagen levels were also significantly increased in pellet cultures compared 
to alginate. Type I collagen levels on the other hand were decreased in both pellet culture and 
alginate-based cultures compared to monolayer (Bernstein, et al., 2009). 
Another paper compared pellet culture directly to hyaline cartilage explants from chicks, with 
results revealing that after 1-2 weeks, neo-cartilage from the pellet cultures shared many 
similarities with cartilage explants. For example, immunohistochemical staining showed similar 
staining patterns for aggrecan and type IX collagen; type I collagen was only seen at the edge of 
some of the pellet and explant; no type X collagen was observed in either; chondrocytes were 
spherical in both pellet and explant, and were observed to look healthy and active; and collagen 
fibrils were observed in both. However, these collagen fibrils appeared to be disorganised in the 
pellet compared to the explant. Staining of type II collagen was also different, with staining in the 
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pericellular matrix (PCM) of the chondrocytes in the explant compared to more ECM-located 
staining in the pellet culture (Zhang, et al., 2004). 
1.4.4 High density micromass culture 
High density micromass culture (not to be confused with the pellet culture system described in 
1.4.3 which is also sometimes referred to as a micromass) was established by Ahrens, et al. (1977) 
for the in vitro chondrogenic differentiation of cells isolated from the chick wing bud. It is a culture 
system whereby a high density of cells that is spotted onto a plate and is allowed to adhere to the 
plate before flooding with media (Figure 1.9). This ensures that cells grow as a central spot growing 
in three dimensions, increasing their cell-cell contacts, and secreting their own extensive matrix 
and thus increases their cell-matrix contacts in all three dimensions. 
 
 
 
 
 
 
 
 
 
 
 
This system has been shown to give increased expression of chondrocytic genes, such as COL2A1, 
compared to other three-dimensional culture systems, such as growth in alginate (Tanaka, et al., 
2004). Compared to pellet culture, micromass culture has been shown by immunohistochemistry 
to increase deposition of type II collagen and decrease deposition of fibroblastic type I collagen and 
hypertrophic type X collagen (Zhang, et al., 2010). 
There are many variations of micromass culture to enhance the culture of chondrocytes. One such 
example is to enhance chondrogenesis from chondrocyte precursors, MSCs. It has become a widely 
established culture system for inducing chondrogenesis, utilising many types of cells to undergo 
chondrogenesis, such as primary BMSCs (Tropel, et al., 2004; Taipaleenmaki, et al., 2008; Markway, 
Figure 1.9 – Setting up a micromass culture. Cells are plated in a high-density, low volume 
(typically around 10 µl) spot into a culture well and allowed to adhere in the incubator for two 
hours. The wells are then flooded with the desired media, with the cells remaining as a spot. 
The micromass is then allowed to differentiate and/or grow for the desired period of time. 
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et al., 2010; Zhang, et al., 2010), primary adipose-derived mesenchymal stem cells (AMCs) (Malladi, 
et al., 2006; Xu, et al., 2007b), primary embryonic limb bud mesenchyme (Yoon, et al., 2000; Matta, 
et al., 2011), and various cell lines (Denker, et al., 1999; Kipnes, et al., 2003; Seriwatanachai, et al., 
2012). 
Additionally, micromass culture has also been used in conjunction with hypoxia culture (Egli, et al., 
2008; Ströbel, et al., 2010), discussed in section 1.4.6, to further enhance differentiation and re-
differentiation. The smaller culturing vessels needed for micromass culture (e.g. 24-well plate) 
makes this an attractive culturing model to use compared to other cultures such as pellet cultures, 
which are normally cultured in 15 ml tubes, making micromass cultures more practical than pellet 
cultures, which may need larger hypoxia chambers or require a larger incubator space for the same 
number of samples. 
1.4.5 Mesenchymal Stem Cell Differentiation 
‘Healthy’, non-OA primary chondrocytes are normally obtained post mortem. Although these 
donors may not have had a clinical history of OA, it cannot be ruled out that there may be some 
degree of the disease that has gone unnoticed. Furthermore, obtaining these ‘healthy’ primary 
chondrocytes is infrequent, dependent on consenting patients undergoing joint replacement 
surgery locally and only a limited number of chondrocytes are present within cartilage explants. 
Since the initial steps of chondrogenesis involve condensation of MSCs and their subsequent 
differentiation into chondrocytes, MSCs are therefore an attractive, alternative and plentiful source 
of chondrocytes, overcoming the difficulty of obtaining ‘healthy’, non-OA primary chondrocytes, 
and eliminating the need to use 2D monolayer expansion of primary chondrocytes which would 
otherwise result in de-differentiation prior to re-differentiation. 
It has been suggested that 3D culture of MSCs enables cell-cell contact, reminiscent of the in vivo 
situation when MSCs condense as one of the initial steps of chondrogenesis (Wang, et al., 2005). It 
has previously been reported that N-cadherin is required for in vitro chondrogenesis whereby 
antibody blocking of the adhesion molecule inhibited chondrogenesis in micromass cultures of 
embryonic chick limb MSCs (Oberlender & Tuan, 1994). However, chondrogenesis has also been 
observed in 3D scaffold cultures (Nam, et al., 2010), which limits cell-cell contact. Furthermore, 
paraformaldehyde inactivation of MSCs, which keeps transmembrane signalling molecules intact 
on the cell surface, has been shown to inhibit chondrogenesis, indicating that cell-cell contact alone 
is not enough to initiate chondrogenesis and that various signalling is required (Liu, et al., 2010).  
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In addition to differentiating MSCs into chondrocytes in the various three-dimensional culture 
systems outlined previously, some studies have demonstrated the additional benefits of co-
culturing MSCs with mature articular chondrocytes. Equine MSCs isolated from the marrow of the 
sternebra, when co-cultured with equine articular chondrocytes isolated from the femoropatellar 
joint, produced higher levels of COL2A1 and SOX9 mRNA, and stronger, more homogeneous Alcian 
blue staining (indicating proteoglycan deposition) compared to separate MSC and chondrocyte 
cultures with and without stimulation via TGFβ1 (Lettry, et al., 2010). 
It has also been shown that co-culture of MSCs with articular chondrocytes reduces markers of 
chondrocyte hypertrophy, a fate spared from articular cartilage and reportedly to occur 
prematurely in differentiating MSC micromass cultures (Pelttari, et al., 2006). A report by Fischer, 
et al., (2010) revealed a decrease in mRNA levels of ALPL, which encodes the enzyme alkaline 
phosphatase produced by hypertrophic chondrocytes responsible for matrix mineralisation during 
endochondral ossification, in human articular chondrocyte-conditioned MSC pellets. 
Supplementation of unconditioned media with PTHrP (parathyroid hormone-related protein), 
previously detected in culture supernatants, strongly reduced alkaline phosphatase activity in MSC 
pellets and significantly decreased COL10A1 and Indian hedgehog (IHH) mRNA levels (Fischer, et al., 
2010) suggesting PTHrP may be one soluble factor secreted by chondrocytes to repress hypertrophy 
and may therefore be added to MSC-derived chondrocytes to prevent them from going down the 
hypertrophic pathway to maintain the articular chondrocyte phenotype. 
1.4.6 Hypoxia 
Articular cartilage is an avascular, aneural, alymphatic connective tissue. As such, cartilage is subject 
to a low oxygen tension and therefore the chondrocytes live in a hypoxic environment with oxygen 
tension varying from 1 - 7 % O2 in humans, depending on how deep the cartilage zone is from the 
articular surface, in comparison to arterial blood ranging from 11 - 14 % O2 (Grimshaw & Mason, 
2000; Murphy & Polak, 2004). Culturing cells under normoxic conditions (20 % O2) is therefore 
unphysiological and not suitable for the in vitro culture of chondrocytes. Many studies have shown 
the benefits of culturing chondrocytes under hypoxic conditions, in conjunction with a three-
dimensional environment, to closely mimic more realistic in vivo conditions. 
One study observed the effects of encapsulation of human hip articular chondrocytes in alginate 
beads at 20 % O2 and 5 % O2, in comparison to P0 isolated chondrocytes. qRT-PCR revealed strong 
decreases in COL2A1, ACAN (aggrecan) and SOX9 expression following monolayer subculture of 
chondrocytes (P3). Encapsulation of P3 chondrocytes slowly increased expression, but after 28 days 
at 20 % O2, expression was still lower than that of encapsulated P0 chondrocytes. In comparison, 
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encapsulated P3 chondrocytes restored expression of COL2A1, ACAN and SOX9 by 28, 14 and 7 days 
respectively when cultured at 5 % O2 (Murphy & Polak, 2004). These results show that although 3D 
culture up-regulates chondrocytic genes, the effects can be significantly enhanced by reducing the 
oxygen tension to a more physiologically-relevant level. 
Another study also observed the effects of hypoxic culture using pellet culture on the anabolic and 
catabolic activities of non-OA human knee articular chondrocytes. Results showed that, in addition 
to increases in type II collagen and aggrecan, culture of chondrocytes at 5 % O2 also decreased 
expression of MMP1 and MMP13. Switching to 19 % O2 after this initial 5 % O2 phase resulted in 
increased release of MMP1 and MMP13 as well as collagen fibrils with a decrease in persistence 
length and bending ratio seen by scanning electron microscopy, similar to OA cartilage, indicative 
of softening of the cartilage (Ströbel, et al., 2010). Decreasing oxygen tension therefore improves 
the structure, reduces catabolic activities and enhances anabolic activities. 
However, hypoxia also has been reported to exert catabolic effects. The murine chondroprogenitor 
cell line, ATDC5 (described in more detail in Chapter 3), readily undergoes chondrogenesis with 
insulin stimulation at normal oxygen levels. However, upon hypoxic stimulation at 1 % O2, insulin-
induced chondrogenesis was inhibited, resulting in decreased expression of Col2a1, Acan 
(aggrecan), Col10a1, as well as decreased proteoglycan deposition as seen by Alcian blue staining 
(Chen, et al., 2006). Similar results were also seen in chondrogenically differentiating murine AMCs 
in micromass, with decreased expression of type II collagen protein and sulphated GAG content 
(Malladi, et al., 2006). Additionally, hypoxia inducible factor (HIF)-2α, a member of the HIF 
transcription factor family responsible for the regulation of genes under hypoxia, has been shown 
to increase expression of MMP3 and MMP13 in mice via the inflammatory cytokine, IL-6, in mouse 
cartilage (Ryu, et al., 2011). Conversely, HIF-2α has been reported to be responsible for the hypoxic 
induction of COL2A1 and SOX9 in human articular chondrocytes (Lafont, et al., 2007). This highlights 
the complexity of hypoxia and its importance in cartilage, and additionally, consideration may need 
to be taken regarding cell source as mice have thinner cartilage than larger mammals and as a result 
may be subject to different oxygen tensions in vivo (Murphy, et al., 2009). 
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1.5 Summary 
Osteoarthritis is a painful and debilitating disease with no disease-modifying drugs available on the 
market. A number of signalling pathways have been implicated in the progression of osteoarthritis, 
including the WNT signalling pathway and the CCN growth factor family. Although these two 
families are known to be tightly linked, the extent of their relationship and the mechanisms behind 
their involvement in the progression of osteoarthritis are not fully understood. 
Additionally, cartilage is now known to be a complex tissue consisting of many layers which all 
regulate different sets of genes, and different cartilages in the body have unique functions 
depending on its location. Previously, little regard has been taken as to the phenotype of cartilage-
like tissue produced from the culture of chondrocytes and chondrogenically differentiating MSCs. 
1.6 General Hypothesis 
It was therefore hypothesised that WNT and CCN signalling may be implicated in the destruction of 
cartilage and may therefore be implicated directly or indirectly in inflammatory cytokine and 
metalloproteinase signalling in chondrocytes and chondroprogenitor cells.  
As mentioned before, chondrocytes and their progenitors are the only cells present in cartilage. 
Given that WNT signalling has been implicated in both the differentiation of chondrocytes and the 
migration of other cells in both a positive and negative manner, it was also therefore hypothesised 
that WNT signalling may be involved in the modulation of the migration of the cells in response to 
cartilage damage to either promote or impede repair. 
1.7 Aims 
To investigate these hypotheses with physiological relevance, this thesis therefore aimed to: 
1. Establish a culturing model of physiological relevance to model articular cartilage and the 
changes that occur during osteoarthritis 
a. Identify the phenotype of the cartilage model to ascertain its biological relevance 
by examining regulation of known cartilage phenotypic genes 
b. Investigate the gene expression changes of the WNT and CCN signalling families 
during chondrogenesis using the above model 
2. Investigate the impact of WNT signalling in an osteoarthritic-like setting via examining gene 
and protein regulation 
3. Investigate the functional outcomes of WNT signalling via migration and invasion studies 
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Chapter 2 
Materials and Methods 
Chapter 2 – Materials and Methods 
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2.1 ATDC5 Cell Culture 
2.1.1 Maintenance 
ATDC5 cells, originally cloned from the AT805 mouse embryonic teratocarcinoma cell line (Atsumi, 
et al., 1990), were obtained from Dr. Tracey Swingler (University of East Anglia). Undifferentiated 
ATDC5 cells were maintained in a culture medium consisting of DMEM:F12 (Invitrogen) containing 
5% (v/v) foetal calf serum (FCS), 1% (v/v) L-glutamine and 1% (v/v) penicillin/streptomycin 
(Invitrogen) supplemented with 10 μg/ml transferrin (Sigma-Aldrich) and 30 nM sodium selenite 
(Sigma-Aldrich), referred to as maintenance medium. Medium not supplemented with transferrin 
or sodium selenite was referred to as basal medium. Cells were maintained in a humidified 
incubator at 37 °C with 5% CO2. Undifferentiated cells doubled every day and were passaged using 
0.05% Trypsin/EDTA (Invitrogen) roughly twice weekly at 1:8 or 1:16 in maintenance medium in 
filter-capped tissue culture flasks (Nunc). 
2.1.2 Experimental Culture 
For experiments, ATDC5 cells were grown in several different culture models. 
2.1.2.1 Monolayer Culture 
Monolayer cultures of ATDC5 cells were plated at a density of 6 x 103 cells/cm2 into a 24-well tissue 
culture plate (Nunc) in 500 µl maintenance medium, and allowed to grow for 2 days until just sub-
confluent, unless stated otherwise. After two days, medium was refreshed or switched to the stated 
condition and this time point is referred to as Day 0. 
2.1.2.2 High Density Micromass Culture 
High density micromass cultures of ATDC5 cells were established essentially as described previously 
(Ahrens, et al., 1977). Briefly, ATDC5 cells were plated in 10 µl droplets in maintenance medium at 
a density of 2 x 107 cells/ml into a 24-well tissue culture plate, unless stated otherwise, and allowed 
to adhere for 2 h in a humidified incubator at 37 °C, 5% CO2 before flooding wells with 500 μl of the 
appropriate medium according to the experiment. This time point was referred to as Day 0. 
2.1.2.3 ATDC5 Chondrogenic Induction with Insulin 
Insulin was used to induce differentiation of ATDC5 cells essentially as described previously (Atsumi, 
et al., 1990), by supplementing basal medium with an insulin, transferrin and sodium selenite (ITS) 
premix (Invitrogen), giving final concentrations of 10 µg/ml insulin, 5.5 µg/ml transferrin and 38.73 
nM sodium selenite. Differentiating medium was added at Day 0 and refreshed every 2-3 days for 
14 days. For the time course analysis, cells were differentiated for 7, 14 and 21 days. 
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Undifferentiated (non-induced) ATDC5 cells in maintenance medium were used as controls for 
differentiated ATDC5 cells and maintained for the same time period. 
2.1.2.4 Stimulation with Ascorbic Acid 
In some experiments, maintenance or differentiation media were also supplemented with 50 μg/ml 
L-ascorbic acid sodium salt (hereafter “ascorbic acid”) (Sigma-Aldrich), as previously established in 
chondrogenic culture (Spagnoli, et al., 2005; Taipaleenmaki, et al., 2008; Temu, et al., 2010). Media 
were then refreshed every 2-3 days. 
2.1.2.5 ECM Components 
Where indicated, culture wells or 13 mm sterilised glass coverslips (VWR International) were coated 
with either Type II Collagen (from chick sternal cartilage, Sigma-Aldrich), or Fibronectin (from 
human plasma, Sigma-Aldrich) at the desired concentration and incubated overnight at 4 °C. Excess 
liquid was removed, the plates and coverslips washed with PBS and allowed to air dry under sterile 
conditions. 
2.2 Gene Transcription Analysis by qRT-PCR 
2.2.1 RNA Extraction using RNEasy Mini/Micro Plus kits from QIAGEN 
Total RNA was extracted using RNEasy Mini Plus or RNEasy Micro Plus kits from QIAGEN, according 
to the manufacturer’s instructions. Briefly, cells were washed with PBS and lysed in RLT+ lysis buffer 
containing guanidine thiocyanate, supplemented with β-mecaptoethanol (to a final concentration 
of 143 mM). Cell lysates were homogenised by repeatedly pipetting up and down before being 
transferred to gDNA eliminator columns. Micromass cultures that had been induced with insulin 
were further homogenised using a TissueLyser (QIAGEN) by vigorous shaking with a sterile ball-
bearing in a 2 ml safety-lock tube (Eppendorf) at 30 Hz for 30 s before being transferred to a gDNA 
eliminator column due to the ECM produced in micromass cultures that may otherwise prevent 
complete homogenisation. After centrifugation, flow-through was precipitated with equal volumes 
of 70 % ethanol before being transferred to the RNA spin columns and centrifuged again. RNA was 
trapped on the silicone membrane and a series of washes with high-salt buffers further purified the 
RNA before elution in RNAse-free water. Eluted RNA was stored at -20 °C. 
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2.2.2 RNA quality/quantity analysis with NanoDrop 
RNA quality and quantity was analysed using the NanoDrop 2000 spectrophotometer (Thermo 
Scientific) at wavelengths of 230, 260 and 280 nm. RNA concentration was measured at 260 nm. 
Ratios of 260/280 and 260/230 were used to analyse the quality of the RNA for protein 
contamination and guanidine contamination respectively. Samples with ratios above 1.8 were 
deemed as high quality with respect to contaminants. 
2.2.3 Two-step reverse transcription to cDNA using M-MLV 
RNA was reverse transcribed to cDNA in a two-step process. Random primers (0.5 µg/µg RNA) 
(Invitrogen) were annealed to RNA by heating to 70 °C for 10 min then immediately plunged into 
ice to prevent restoration of secondary structures. Primed RNA was reverse transcribed using M-
MLV (200 u/µg RNA) (Promega) with 0.2 mM dNTP mix (Bioline) by heating to 42 °C for 60 min to 
allow primer extension. Enzyme activity was destroyed by heating to 70 °C for 10 min, and samples 
stored at -20 °C until use. 
2.2.4 Identification of suitable housekeeping gene using geNorm from PrimerDesign  
To identify a suitable housekeeping gene for experimental analysis, a geNorm reference analysis 
was carried out using a 12 gene geNorm gene selection kit (PrimerDesign) using PerfectProbe 
technology with a 6-carboxyfluorescein (FAM) reporter, according to manufacturer’s instructions. 
Briefly, 5 ng cDNA from different conditions were loaded onto a qPCR plate (Applied Biosystems) 
along with a mixture containing 2x qPCR MasterMix (Applied Biosystems) and selected 
primer/probe mixes at 300 nM. The loaded plate was sealed and loaded into a 7500/7500 Fast Real-
Time PCR System (Applied Biosystems) and subjected to the following cycling conditions detailed 
in Table 2.1. 
Table 2.1 – PCR cycling conditions for geNorm analysis using PerfectProbe Technology 
 Step Time (min:sec) Temperature (°C) 
 Enzyme Activation 10:00 95 
Cycling x50 
Denaturation 00:15 95 
Data Collection 00:30 50 
Extension 00:15 72 
 
CTs were analysed using qbasePLUS (Biogazelle) and subjected to geNorm analysis (Vandesompele, 
et al., 2002). Reference genes were ranked using a geNorm M value from worst (higher value) to 
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best (lower value). A geNorm M value below 0.5 was considered acceptable for use as a reference 
gene. A list of genes used in the geNorm analysis can be found in Table 2.2. 
Table 2.2 – Genes analysed using the geNorm gene selection kit. Full gene names taken from 
National Centre for Biotechnology Information (NCBI). 
Symbol Name 
18s 18S ribosomal RNA 
Actb Actin, beta 
Atp5b ATP synthase, H+ 
transporting mitochondrial 
F1 complex, beta subunit 
B2m Beta-2 microglobulin 
Canx Calnexin 
Cyc1 Cytochrome c-1 
Eif4a2 eukaryotic translation 
initiation factor 4A2 
Gapdh Glyceraldehyde-3-phosphate 
dehydrogenase 
Rpl13a Ribosomal protein L13A 
Sdha Succinate dehydrogenase 
complex, subunit A, 
flavoprotein (Fp) 
Ubc Ubiquitin C 
Ywhaz Tyrosine 3-
monooxygenase/tryptophan 
5-monooxygenase activation 
protein, zeta polypeptide 
 
2.2.5 Generation of custom assays using the Universal ProbeLibrary 
Custom-made primer/prone sets (hereafter referred to as assays) for use with the Universal 
ProbeLibrary (UPL)(Roche) for use in qRT-PCR were designed using the UPL assay design centre 
using the ProbeFinder database. Assays were designed to be intron-spanning to eliminate PCR 
amplification of any potential, residual, contaminating gDNA. Designed DNA primers were 
synthesised and purchased from Sigma-Aldrich and used in combination with the relevant LNA UPL 
probe (8-9 mers), purchased from Roche, labelled with FAM (5’) and a dark quencher dye (3’). The 
use of LNA, DNA analogues which incorporate a methylene bridge between the 2’-O atom and 4’-C 
atom to “lock” the ribose ring, in the UPL probes gives increased thermal stability with a greater 
ΔTm between perfectly matched and mismatched pairing, and thus allows for more sensitive 
discrimination of mismatches in base-pairing (Roche Applied Science, 2009). In qRT-PCR reactions 
using the UPL, primers and probes were used at 250 nM and 125 nM respectively and used under 
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standard TaqMan cycling conditions (Table 2.4).  Primer sequences and UPL probe numbers can be 
found in Table 2.3 
2.2.6 Generation of custom assays from PrimerDesign 
For assays that were not able to be designed through the UPL, either due to a lack of intron-
spanning assays available or lack of specificity, custom assays, using primer and double-dye 
(TaqMan-style) technology, were designed by PrimerDesign (Southampton, UK). Custom assays 
were designed and checked for efficiency and specificity by PrimerDesign, and supplied as a 
primer/probe mix used at a final concentration of 300 nM per reaction. PrimerDesign assays were 
used under standard TaqMan cycling conditions (Table 2.4) with sequences detailed in Table 2.3. 
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Table 2.3 – Primer/Probe sequences for murine assays for use with qRT-PCR. Where more than one accession number is given, the primer/probes are 
designed as a common assay that detects all variants listed. Exact probe sequences for assays designed by the UPL and primer/probe sequences for 
housekeeping genes designed by PrimerDesign are property of, and withheld by, the respective companies. All given probes are labelled with FAM (5’) and 
tetramethylrhodamine (TAMRA) (3’). 
  
Official 
Gene 
Symbol 
Other Names 
Accession 
Number(s) 
Design Source   Sequence (5'-3') 
H
o
u
se
ke
e
p
in
g 
G
e
n
e
s 
18S 18S rRNA M10098 Corps, et al., (2006) 
Forward Primer: GCCGCTAGAGGTGAAATTCTTG 
Reverse Primer: CATTCTTGGCAAATGCTTTCG 
Probe: ACCGGCGCAAGACGGACCAG 
Ywhaz 
Tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein, zeta polypeptide 
NM_001253805.1 
PrimerDesign 
Forward Primer: Property of PrimerDesign 
NM_001253806.1 Reverse Primer: Property of PrimerDesign 
NM_001253807.1 Probe: Property of PrimerDesign 
NM_011740.3     
M
e
ta
llo
p
ro
te
in
as
es
 Adamts4 Aggrecanase 1 NM_172845.2 
Folgueras, et al., 
(2008) 
Forward Primer: TCAACACCCCTAACGACTCAGA 
Reverse Primer: CAGCTCCTAGCTGGATCACACA 
Probe: CTGACCACTTTGACACAGCCATTCTGTTCA 
Adamts5 Aggrecanase 2 NM_011782.2 UPL  
Forward Primer: CCTGGATGATGGTCATGGTA 
Reverse Primer: AGTTCCTCGGGACCCAAA 
Probe: UPL Probe #38 
Mmp13 Collagenase 3 NM_008607.2  UPL 
Forward Primer: CTTTTCCTCCTGGACCAAACT 
Reverse Primer: TCATGGGCAGCAACAATAAA 
Probe: UPL Probe #105 
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C
C
N
 G
ro
w
th
 F
ac
to
rs
 
Cyr61 
CCN1; 
NM_010516.2 UPL  
Forward Primer: GGATCTGTGAAGTGCGTCCT 
Cysteine rich protein 61 Reverse Primer: CTGCATTTCTTGCCCTTTTT 
  Probe: UPL Probe #66 
Ctgf 
CCN2; 
NM_010217.2 UPL  
Forward Primer: TGACCTGGAGGAAAACATTAAGA 
Connective tissue growth factor Reverse Primer: AGCCCTGTATGTCTTCACACTG 
  Probe: UPL Probe #71 
Nov 
CCN3; 
NM_010930.4 UPL  
Forward Primer: AGTGGACCTGTGGCTCAGA 
Nephroblastoma overexpressed Reverse Primer: TCAACTCCTACGGTGGCTTC 
  Probe: UPL Probe #11 
Wisp1 
CCN4; 
WNT1 inducible signaling 
pathway protein 1 
  
NM_018865 PrimerDesign 
Forward Primer: TTATCCCCTGTGGCTCCTC 
Reverse Primer: CCATTTATGAGTGTGTGTATAGTTCT 
Probe: ATGATGATTCAGTTTGCCCCACACCATACA 
Wisp2 
CCN5; 
WNT1 inducible signaling 
pathway protein 2 
  
NM_016873.2 UPL  
Forward Primer: TCCTCTGCATTCTCTCAATGG 
Reverse Primer: GTGTCCAAGGACAGGCACA 
Probe: UPL Probe #104 
Wisp3 
CCN6; 
WNT1 inducible signaling 
pathway protein 3 
  
NM_001127376 PrimerDesign 
Forward Primer: GCAAGCAACCAAGTGGACTC 
Reverse Primer: CAGCCTCCTCTCCTTTCTCAT 
Probe: CGGGTAACCAACGATAACGCCAACTGTGA 
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C
o
lla
ge
n
s 
Col1a1 Collagen, type I, alpha 1 NM_007742.3 UPL  
Forward Primer: CATGTTCAGCTTTGTGGACCT 
Reverse Primer: GCAGCTGACTTCAGGGATGT 
Probe: UPL Probe #15 
Col1a2 Collagen, type I, alpha 2 NM_007743.2 UPL  
Forward Primer: GCAGGTTCACCTACTCTGTCCT 
Reverse Primer: CTTGCCCCATTCATTTGTCT 
Probe: UPL Probe #46 
Col2a1 Collagen, type 2, alpha 1 
NM_001113515.2 
UPL  
Forward Primer: ACCCCCAGGTGCTAATGG 
NM_031163.3 Reverse Primer: AACACCTTTGGGACCATCTTT 
  Probe: UPL Probe #18 
Col9a1 Collagen, type 9, alpha 1 NM_007740.3 UPL  
Forward Primer: CCTGGGTATCCGCAACTCT 
Reverse Primer: CCTGATCTTGGGACACAGTTC 
Probe: UPL Probe #31 
Col10a1 Collagen, type 10, alpha 1 NM_009925.4 UPL  
Forward Primer: GCATCTCCCAGCACCAGA 
Reverse Primer: CCATGAACCAGGGTCAAGAA 
Probe: UPL Probe #84 
N
o
n
-c
o
lla
ge
n
o
u
s 
EC
M
 
C
o
m
p
o
n
e
n
ts
 
Acan Aggrecan NM_007424.2 UPL  
Forward Primer: CCAGCCTACACCCCAGTG 
Reverse Primer: GAGGGTGGGAAGCCATGT 
Probe: UPL Probe #76 
Matn3 Matrilin 3 NM_010770.4 UPL  
Forward Primer: GCTATGGAGGTTACGCCTTG 
Reverse Primer: GTACCAGAGGCGCATTTGTC 
Probe: UPL Probe #2 
Prg4 Proteoglycan 4 (Lubricin) NM_021400.3 UPL  
Forward Primer: GGCAAGTGCTGTGCAGATTA 
Reverse Primer: AGGCGGAGGTGCAGTCTT 
Probe: UPL Probe #9 
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W
N
T
 S
ig
n
al
lin
g 
Dkk1 Dickkopf homolog 1 NM_010051.3 UPL  
Forward Primer: CCGGGAACTACTGCAAAAAT 
Reverse Primer: CCAAGGTTTTCAATGATGCTT 
Probe: UPL Probe #76 
Dkk3 Dickkopf homolog 3 NM_015814.2 UPL  
Forward Primer: TCGTGACCAGATCCAGCTT 
Reverse Primer: AGCCGCTGCATGTTTGTT 
Probe: UPL Probe #70 
Frzb 
Frizzled-related protein; 
NM_011356.4 UPL  
Forward Primer: CACCGTCAATCTTTATACCACCT 
Secreted frizzled-related 
protein 3 (Sfrp3) 
Reverse Primer: GAGCCTTCTACCAAGAGTAACCTG 
  Probe: UPL Probe #34 
Grem1 Gremlin 1 NM_011824.4 UPL  
Forward Primer: GACCCACGGAAGTGACAGA 
Reverse Primer: CCCTCAGCTGTTGGCAGTAG 
Probe: UPL Probe #63 
Ror2 
Receptor tyrosine kinase-like 
orphan receptor 2 
NM_013846.3 UPL  
Forward Primer: TCATCAGCCAGCACAAACA 
Reverse Primer: GTGGCCTTTGTAGACCTTGC 
Probe: UPL Probe #25 
Wnt3a 
Wingless-related MMTV 
integration site 3A 
NM_009522.2 UPL  
Forward Primer: CTTAGTGCTCTGCAGCCTGA 
Reverse Primer: GAGTGCTCAGAGAGGAGTACTGG 
Probe: UPL Probe #76 
Wnt5a 
Wingless-related MMTV 
integration site 5A 
NM_009524.2 UPL  
Forward Primer: ACGCTTCGCTTGAATTCCT 
Reverse Primer: CCCGGGCTTAATATTCCAA 
Probe: UPL Probe #55 
P
h
o
sp
h
-
at
as
e
s 
Alpl 
Alkaline phosphatase, 
liver/bone/kidney 
NM_007431.2 UPL  
Forward Primer: CGGATCCTGACCAAAAACC 
Reverse Primer: TCATGATGTCCGTGGTCAAT 
Probe: UPL Probe #12 
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EC
M
 R
ec
e
p
to
rs
 
Ddr1 Discoidin domain receptor 1 
NM_007584.2 
UPL  
Forward Primer: TGTGCCTAGGGAGACTGAAAC 
NM_172962.1 Reverse Primer: TCCCTCTGGTCTATGGAGGA 
  Probe: UPL Probe #56 
Ddr2 Discoidin domain receptor 1 NM_022563.2 UPL  
Forward Primer: CGAAAGCTTCCAGAGTTTGC 
Reverse Primer: GCTTCACAACACCACTGCAC 
Probe: UPL Probe #55 
TG
Fβ
 F
am
ily
 
Tgfb1 
Transforming growth factor, 
beta 1 
NM_011577.1 UPL  
Forward Primer: TGGAGCAACATGTGGAACTC 
Reverse Primer: CAGCAGCCGGTTACCAAG 
Probe: UPL Probe #72 
Tgfb2 
Transforming growth factor, 
beta 2 
NM_009367.3 UPL  
Forward Primer: TGGAGTTCAGACACTCAACACA 
Reverse Primer: AAGCTTCGGGATTTATGGTGT 
Probe: UPL Probe #73 
Tgfb3 
Transforming growth factor, 
beta 3 
NM_009368.3 UPL  
Forward Primer: TGGCTGTCTTTCGATGTCAC 
Reverse Primer: GCTGATTTCCAGACCCAAGT 
Probe: UPL Probe #91 
Tr
an
sc
ri
p
ti
o
n
 
Fa
ct
o
rs
 Runx2 
Runt related transcription 
factor 2 
NM_001146038.1 
UPL  
Forward Primer: GATGATGACACTGCCACCTCT 
NM_009820.4 Reverse Primer: AAAAGGGCCCAGTTCTGAAG 
NM_001145920.1 Probe: UPL Probe #34 
Sox9 SRY-box containing gene 9 NM_011448.4 UPL  
Forward Primer: CAGCAAGACTCTGGGCAAG 
Reverse Primer: TCCACGAAGGGTCTCTTCTC 
Probe: UPL Probe #66 
     Forward Primer: CTTTGCCAAGCCATCCTG 
Others Anxa1 Annexin A1 NM_010730.2 UPL Reverse Primer: TGGGATGTCTAGTTTCCACCA 
     Probe: UPL Probe #66 
 
47 
 
2.2.7 qRT-PCR analysis using double-dye hydrolysis probe technology 
Five nanograms of cDNA were used for gene expression analysis using the 7500/7500 Fast Real-
Time PCR System (Applied Biosystems) with 2x qPCR MasterMix (Applied Biosystems) and selected 
primer/probe combinations at the relevant concentrations described above. For qRT-PCR analysis 
using double-dye hydrolysis probes, standard TaqMan cycling conditions were used (Table 2.4). 
Gene expression was normalised using the relative standard curve method against expression of 
the housekeeping genes, 18S or Ywhaz. 
Table 2.4 – Standard TaqMan cycling conditions for qRT-PCR using double-dye hydrolysis probes. 
Data collection was under the FAM channel. 
 Step Time (min:sec) Temperature (°C) 
 Enzyme Activation 10:00 95 
Cycling x40 
Denaturation 00:15 95 
Data Collection 01:00 60 
 
2.3 Histological Staining 
2.3.1 Detection of proteoglycans/GAGs with Alcian Blue 
Proteoglycans/GAGs were detected by Alcian blue staining using a modified protocol from Kawai, 
et al., (2012) and Cha, et al., (2013). Briefly, cells cultured directly on 24-well plates were washed 
twice with PBS and fixed with ice-cold methanol at -20 °C for 5 min. Methanol was then immediately 
replaced with an equal amount of Alcian Blue 8GX (0.1 % w/v in 0.1 M HCl) (Sigma-Aldrich Aldrich) 
and left at room temperature overnight. Cells were repeatedly washed with water until the water 
pipetted off was clear, then cells were left in fresh water for imaging. Cells were imaged using a 
Zeiss SV11 stereo widefield microscope (Zeiss) with a colour AxioCam HRc camera (Zeiss) using 
AxioVision software (Zeiss). 
The amount of Alcian blue staining was quantified using a modified protocol based on Frazier,  et 
al., (2008). Briefly, Alcian blue staining was removed from cultures and solubilised with 8 M 
guanidine hydrochloride for 6 h with gentle shaking at room temperature. One hundred microlitres 
was then removed and placed into a 96-well plate (Nunc) and absorbance read at 630 nm. The 
absorbance of unused 8 M guanidine hydrochloride was subtracted from all absorbance readings 
before data analysis. 
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2.3.2 Immunofluorescence 
To ensure adequate antibody penetration in cultures which have been induced to differentiate, due 
to the thickness of the developed micromass and the three-dimensional cartilaginous nodules in 
monolayer cultures, immunofluorescence was carried out using a modified protocol based on Bader, 
et al., (1998). 
Cells were seeded, according to the experiment, onto sterile 13 mm glass coverslips (VWR 
International) in a 24-well plate. For immunofluorescent detection of ECM components, cells were 
washed in PBS and fixed in ice cold acetone for 5 min at -20 °C. Cells were rehydrated to PBS in 
stepwise 10 min incubations from 80, 50 and 20 % acetone/PBS to 100 % PBS at room temperature. 
Non-specific sites in the ECM were then blocked in either 10 % normal goat serum + 5 % BSA in PBS 
or 10% normal donkey serum (Sigma-Aldrich) + 5% BSA in PBS, depending on the antibody for 2 x 
60 min incubations at room temperature. Coverslips were then inverted onto a 50 µl droplet 
containing the primary antibody diluted in the blocking buffer on parafilm (Bemis Company, Inc) 
overnight at 4 °C in a humidified chamber. Cells were then placed cell-side up back into the 24-well 
plate and washed seven times for 60 min each in TBS. The same process was then used to incubate 
with the secondary antibody overnight before seven more washes in TBS to remove residual 
unbound antibody. The fifth wash also contained 1 µg/ml 4',6-diamidino-2-phenylindole (DAPI) to 
stain for nuclear content. Coverslips were then mounted onto a glass slide using Hydromount 
(National Diagnostics) and kept in the dark at 4 °C until imaging. 
Cells were imaged using either a Zeiss LSM510 META confocal micropscope with an inverted 
Axiovert 200M stand or a Leica TCS SP2 UV confocal microscope with an inverted Leica DM IRE2 
stand. Z stacks were taken at 2 µm steps through and beyond positively DAPI-stained areas at a 
resolution of 2048 x 2048 pixels per slice. Images were then processed using Volocity software 
(PerkinElmer, Waltham, MA). Fluorescence intensity was calculated using ImageJ per slice and the 
results per slice added together and divided by the number of slices. Total intensity was then 
normalised to the no primary controls by subtracting the total intensity for the no primary 
conditions. 
A full list of primary and secondary antibodies can be found in Table 2.5 and Table 2.6 respectively. 
2.3.3 Protein Detection by Western Blotting 
Western blotting was performed essentially as described in Baker, et al., (2012), detailed below. 
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2.3.3.1 Preparation of cell lysates 
Cell cultures were washed twice in ice cold PBS and lysed in either RIPA buffer (50 mM Tris HCl pH 
8, 150 mM NaCl, 1 % Triton X100, 0.5 % Sodium Deoxycholate, 0.1 % SDS) (recipe from Abcam, 
Cambridge, UK) or Urea/Thiourea buffer (7 M urea, 2 M thiourea, 4 % CHAPS, 30 mM Tris HCl pH 
8.5, 1 mM DTT) (recipe based on Ngoka (2008) and Peach, et al. (2012)) containing Halt™ Protease 
and Phosphatase Inhibitor Cocktail (Pierce). RIPA extraction was carried out on ice for at least 30 
min with occasional scraping. Urea/thiourea extraction was carried out at room temperature for 15 
min. For further homogenisation, if needed, lysate was transferred to a 2 ml safety-lock tube 
(Eppendorf) with a sterile ball bearing, and homogenised using a pre-cooled TissueLyser (QIAGEN) 
machine by vigorous shaking at 30 Hz for 30 s. Some RIPA samples were cleared of insoluble 
material by centrifugation at 4 °C at 13 000 RPM for 10 min and any insoluble material discarded 
by placing supernatant in a fresh tube, stored at -20 °C until use. 
For SDS-PAGE, prepared protein lysates at the desired concentration were mixed with either 5x 
reducing or non-reducing sample buffer (625 mM Tris pH 6.8, 2 % SDS, 10 % glycerol, bromophenol 
blue ± 12.5 % β-mercaptoethanol). RIPA-extracted samples were denatured by incubating at 95 °C 
for 5 min. Urea/thiourea-extracted samples were not boiled to prevent carbamoylation of samples. 
2.3.3.2 Protein quantification by Pierce BCA Protein Assay (RIPA-extracted samples) 
Protein concentration of RIPA-extracted samples was quantified using a Pierce Bicinchoninic Acid 
(BCA) Protein Assay kit, following manufacturer’s instructions. 
Briefly, protein standards of known concentrations of BSA were prepared and 25 µl plated in 
duplicate, ranging from 0 – 2000 µg/ml. The same volume of unknown protein samples were also 
plated in duplicate. Two hundred microlitres of working reagent at 50:1 Reagent A:Reagent B  were 
added to each standard/unknown sample and incubated at 37 °C for 30 min. Absorbance was then 
read at 562 nm in a spectrophotometer plate reader. 
For calculation of protein concentration in unknown samples, the absorbance reading from the 
control (0 µg/ml BSA) was subtracted from all standards/samples. A standard curve was prepared 
from the average values of the known BSA standards and the equation of the trendline used to 
calculate the concentration of the unknown samples via interpolation. 
2.3.3.3 Protein quantification by Pierce 660 nm assay (Urea/thiourea-extracted samples) 
Due to incompatibility of thiourea with the BCA protein assay, protein concentration of 
urea/thiourea-extracted samples was determined using the Pierce 660 nm assay following 
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manufacturer’s instructions. Briefly, 10 µl protein standards of known concentrations of BSA were 
plated in duplicate from 50 – 2000 µg/ml in a 96-well plate. The same volume of unknown protein 
samples were also plated in duplicate before adding 150 µl of protein assay reagent to each well 
containing either known or unknown samples. Samples were incubated for 5 min before reading 
absorbance at 660 nm in a spectrophotometer plate reader. Calculation of protein concentration 
in unknown samples were then carried out as in the BCA protein assay. 
2.3.3.4 Preparation of conditioned media for Western Blotting 
Cell cultures were washed twice with PBS and media replaced with serum-free medium or medium 
containing 0.2 % FCS. Media samples were collected after 24 h, unless otherwise stated, and were 
centrifuged to remove cell debris and stored at -20 °C until required. 
2.3.3.5 TCA precipitation of conditioned media 
To concentrate protein content of conditioned media samples, trichloroacetic acid (TCA) was added 
to collected samples to 5 % and left to incubate overnight at 4 °C. Samples were centrifuged at 6000 
g for 10 min at 4 °C. Supernatant was discarded and pellets transferred to microcentrifuge tubes 
and were washed twice in ice cold acetone with centrifugation at 13 000 g. Acetone was removed 
and pellets allowed to air dry before reconstituting in 1 x reducing sample buffer, followed by 
denaturation at 95 °C for 5 min. 
2.3.3.6 Protein resolution by SDS-PAGE 
Proteins were resolved using SDS-PAGE. Typically, 15-30 µg of protein, or total TCA-precipitates of 
conditioned media, were loaded onto polyacrylamide gels, with 8 or 10 % resolving gels and 5 % 
stacking gel. Samples were run alongside a well containing Spectra Multicolor Broad Range Protein 
Ladder (Pierce), a pre-stained molecular weight marker (10 kDa to 260 kDa). Gels were run at a 
constant 30 mA per gel until proteins were adequately resolved based on the protein ladder. 
2.3.3.7 Semi-dry transfer of polyacrylamide gels to PVDF 
Polyvinylidene fluoride (PVDF) membranes (Immun-blot, BIO-RAD) were activated by incubation in 
methanol for 5 min. Activated PVDF, thick filter paper (BIO-RAD) and resolving polyacrylamide gels 
were then equilibrated in semi-dry transfer buffer for 5 min before protein transfer at 15 V for 35 
min using a Transblot SD Semi-Dry Transfer Cell (BIO-RAD). 
2.3.3.8 Confirmation of transfer by Ponceau S staining 
Transfer of proteins to the PVDF membrane was confirmed by immediately incubating the PVDF 
membranes in 0.2 % Ponceau S in 5 % TCA for 10 min with rocking. Membranes were repeatedly 
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washed in ddH2O with rocking until excess Ponceau S had been removed, allowing visualisation of 
protein bands. Ponceau S was then removed by repeated washes in TBS-T until clear and then 
proceeded to blocking step. 
2.3.3.9 Immunodetection of proteins 
Depending on the antibody and samples used, membranes were blocked overnight at 4 °C or for 
two hours at room temperature in TBS-T (0.1 % Tween-20) containing either 5 % (dried, skimmed) 
milk, 5 % milk with 3 % bovine serum albumin (BSA) or 5 % BSA. Membranes were incubated with 
primary antibody diluted in blocking buffer for 2 hours at room temperature or overnight at 4 °C 
before being washed for 5 times over 60 min. Membranes were then incubated with the secondary 
antibody conjugated with horse radish peroxidase (HRP) diluted in the blocking buffer for 60 min 
at room temperature and then washed again in TBS-T four times over 30 min. Probed membranes 
were incubated in in-house ECL (0.24 % luminol, 0.0045 % coumaric acid, 0.03 % H2O2, 100 mM Tris 
HCl pH 8.5) for 1 min, which reacts with the HRP enzyme to give chemiluminescence specifically 
where the primary/secondary antibody complex is bound, and exposed to photosensitive film 
(Amersham Hyperfilm ECL, GE Healthcare) before being developed using an autoradiograph film 
processor (Xograph Healthcare). 
A full list of primary and secondary antibodies can be found in Table 2.5 and Table 2.6 respectively. 
2.3.3.10 Stripping membranes 
To re-probe membranes for different proteins, membranes were stripped using ReBlot Plus Strong 
stripping buffer (Millipore) for 15 min before blocking for 2 x 5 min in the desired blocking buffer 
and proceeding to primary antibody incubation.  
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2.3.3.11 Antibodies 
Table 2.5 – Details of primary antibodies; WB = Western Blotting; IF = Immunofluorescence 
Target Supplier 
Product 
Code 
Host Species 
Clonality 
Isotype 
Application 
Concentration
/Dilution 
β-Actin Abcam ab8227 Rabbit 
Polyclonal 
IgG 
WB 1:20000 
β-catenin Abcam ab32572 Rabbit 
Monoclonal 
IgG 
WB 0.2 µg/ml 
DDR2 Abcam ab126773 Rabbit 
Monoclonal 
IgG 
WB 1:500 
FLAG 
(DYKDDDDK) 
Sigma-Aldrich F7425 Rabbit 
Polyclonal 
IgG 
WB 5 µg/ml 
FRZB Abcam ab102811 Rabbit 
Polyclonal 
IgG 
WB 5 µg/ml 
phospho-β-
catenin 
(T41+S45) 
Abcam ab38511 Rabbit 
Polyclonal 
IgG 
WB 2 µg/ml 
RUNX2 Santa Cruz sc-10758 Rabbit 
Polyclonal 
IgG 
WB 2 µg/ml 
Type II 
Collagen 
Millipore AB2031 Rabbit  
Polyclonal 
IgG 
IF 12.5 µg/ml  
Type X 
Collagen 
Santa Cruz sc-323750 Goat  
Polyclonal 
IgG 
IF 4 µg/ml 
 
WNT5A Abcam ab174100 Rabbit 
Polyclonal 
IgG 
WB 1 µg/ml 
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Table 2.6 – Details of secondary antibodies used. Antibody names are designated as host species, 
reactive species, conjugation. The numbers in the antibody name represent the conjugated Alexa-
Fluor® dyes, used in IF. HRP = horse radish peroxidase, used in WB. 
 
2.4 Molecular Cloning 
Molecular cloning was conducted with the kind help of Dr. Tracey Swingler (UEA). 
2.4.1 Generation of competent DH5α cells 
One colony of DH5α Escherichia coli cells (kindly provided by Dr. Tracey Swingler, UEA) was 
inoculated into LB broth grown at 37 °C until an optical density of 0.6 at 600 nm. Cells were chilled 
and pelleted at 4000 rpm at 4 °C and washed and resuspended twice in 0.1 M CaCl2. Resuspended 
cells were left to incubate at 4 °C for 60 min before 400 µl sterile glycerol was added per 1 ml 
aliquotted cells. Aliquots were kept at -80 °C. 
2.4.2 Transformation of DH5α cells 
One hundred nanograms of plasmid was used to transform 70 µl of competent DH5α cells. 
Plasmid/cell mixtures were incubated on ice for 20 min, heat shocked at 42 °C for 1 min, then 
immediately placed back onto ice for 2 min. Transformed DH5α were allowed to recover in 500 µl 
antibiotic-free LB for 1 h at 37 °C before streaking onto selective LB agar plates containing 50 µg/ml 
kanamycin (Sigma-Aldrich) (for pJ201 plasmids) or 100 µg/ml ampicillin (Sigma-Aldrich) (for 
pcDNA3.1+ and pcDNA4 plasmids) and grown overnight at 37 °C. Single colonies were inoculated 
into 5 ml selective LB and grown overnight at 37 °C with shaking. 
2.4.3 Plasmid isolation from DH5α cells using QIAGEN Miniprep 
Plasmid DNA was isolated from transformed DH5α cells by using the QIAGEN QIAprep Spin 
Miniprep Kit according to manufacturer’s instructions. Briefly, pelleted cells were lysed in an 
alkaline buffer, neutralised and adjusted to a high salt concentration to aid plasmid binding to the 
silica spin column. LyseBlue was added to the lysis buffer as a colour indicator to ensure complete 
buffer mixing. The silica membrane of the spin columns traps the plasmid DNA during centrifugation 
and a series of washes removes endonucleases and reduces the salt concentration, allowing elution 
Antibody Supplier Product Code Concentration 
Donkey anti-goat-488 Molecular Probes A-11055 4 µg/ml 
Donkey anti-rabbit-488 Molecular Probes A-21206 4 µg/ml 
Goat anti-rabbit-488 Molecular Probes A-11008 2 µg/ml 
Goat anti-rabbit-HRP Dako P0448 1:2000 – 1:10000 
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in nuclease-free H2O. Plasmid concentration was determined as previously described using the 
NanoDrop system. 
2.4.4 WNT5A amplification and end modification via PCR 
WNT5A was amplified from its supplied pCMV6-XL4 vector (Origene) using primers designed to add 
HindIII and XhoI restriction sites at the 5’ and 3’ ends, insert a Kozak consensus sequence and 
remove the endogenous WNT5A stop codon (Figure 2.1). 
 
 
 
 
 
Figure 2.1 – Primers to amplify and modify the ends of WNT5A from pCMV5-XL4 highlighting the 
extra sequences upstream and downstream of the WNT5A gene to allow insertion into 
pcDNA4:FLAG, allowing expression of the c-terminal tags. 
PCR was carried out using AccuTaq™ LA DNA Polymerase (Sigma-Aldrich) according to 
manufacturer’s instructions, designed with proof-reading activity, on 100 ng plasmid with PCR 
cycling conditions described in Table 2.7. Various annealing temperatures were initially tested for 
efficiency in PCR amplification, confirmed by gel electrophoresis (data not shown). The PCR product 
was cleaned up using QIAGEN MinElute PCR Purification kit, according to manufacturer’s 
instructions, and then restricted with HindIII and XhoI to reveal sticky ends to enable insertion into 
pcDNA4:FLAG, as described below, after gel purification. 
Table 2.7 – Cycling conditions for WNT5A amplification and end-modification with AccuTaq. 
 Step Temperature (°C) Time (min:sec) 
 Initial Denaturation 95  01:00 
Cycling x35 
Denaturation 95 00:15 
Annealing 60 00:15 
Extension 72 01:00 
 Final Extension 72 07:00 
 Hold 4  
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2.4.5 Plasmid restriction 
Human WNT3A was isolated from its supplied pcDNA3.1+  plasmid (gifted from UCB, Slough) using 
HindIII + XhoI (New England Biolabs) at 37 °C for 15 min follow by 75 °C to inactivate the enzymes. 
The pcDNA4:FLAG expression vector set to receive the inserts was also restricted using the same 
enzymes. pcDNA4:FLAG was kindly provided by Dr. Vera Knäuper (Cardiff University) and is a 
modified version of pcDNA™4 (Invitrogen), replacing the V5 tag with an in-frame FLAG tag. 
Expressed proteins are therefore tagged with both FLAG and 6xHis at the c-terminus (Figure 2.2) 
 
  
Figure 2.2 – pcDNA4:FLAG mammalian expression vector map – a modified version of 
pcDNA™4/V5-His A (Invitrogen) replacing the V5 epitope with an in-frame FLAG (DYKDDDDK) 
tag by Dr. Vera Knäuper (Cardiff University). Inserted genes are expressed under the PCMV 
promoter (Cytomegalovirus promoter) for constitutive expression. Transfected cells can be 
selected for using the Zeocin™ selective antibiotic. Modified from Invitrogen. 
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2.4.6 Fragment isolation by traditional agarose gel electrophoresis 
Restricted samples containing loading buffer were separated using agarose gel electrophoresis on 
a 1 % agarose gel (Lonza SeaKem GTG Agarose) in TBE buffer containing ethidium bromide alongside 
a DNA ladder (1 kb plus, Invitrogen) running at 120 V. 
2.4.7 Recovery of fragments from traditional agarose gel 
Bands were quickly visualised in gels using UV light and excised from the gel. DNA was recovered 
from the gel using the QIAquick Gel Extraction Kit (QIAGEN) according to manufacturer’s 
instructions. Briefly, gel pieces are solubilised in a high salt buffer that allows DNA binding to the 
silica membrane of the spin columns. A series of washes by centrifugation removes impurities such 
as agarose and small DNA fragments. A reduction in salt concentration allows elution of the DNA in 
nuclease-free H2O. DNA recovery was assessed by NanoDrop. 
2.4.8 Ligation of inserts into pcDNA4:FLAG 
Isolated inserts were ligated into the pcDNA4:FLAG mammalian expression vector using T4 DNA 
ligase (Roche), incubating at 14 °C overnight  at a molar ratio of 3:1, 1:1 and 1:3 of insert:vector, 
using 50 ng vector, using the Promega BioMath equation: 
mass of insert (ng) =  
length of insert (kb)
length of vector (kb)
× mass of vector (ng) 
2.4.9 Screening for successful ligation 
Ligation mixtures were then transformed and cells grown as described previously. Plasmids were 
extracted and tested for the correct insert by observing the correct bands from a restriction digest 
on an agarose gel, as previously described. Plasmid samples from cultures containing the correct 
banding patterns were sequenced at Source Bioscience (Cambridge, UK) using T7 forward and bGH 
reverse primers. Received sequence information was checked by aligning with the predicted 
sequence using the BLASTN sequence alignment tool (NCBI). 
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2.4.10 Site-Directed Mutagenesis (SDM) of pcDNA4:WNT3A with QuikChange 
Lightning 
SDM was performed on pcDNA4:WNT3A using QuikChange Lightning (Agilent Technologies) to 
mutate two stop codons into two leucine residues and to put the c-terminal tags in-frame with the 
ORF (Figure 2.3). Forward and reverse primers were designed by hand, ensuring Tm ≥ 78 °C using 
the following calculation: 
𝑇𝑚 = 81.5 + 0.41(%GC) −
675
𝑁
− %mismatch 
Where Tm is melting temperature (°C), %GC = percentage of G or C bases, and N = primer length in 
bases excluding any insertions or deletions. 
SDM PCR was performed per manufacturer’s instructions, using 50 ng pcDNA4:WNT3A and 125 ng 
forward and reverse primers each (synthesised by Sigma-Aldrich). Cycling conditions (Table 2.8) 
were based on the size of the plasmid (~ 6 kb). 
 
 
 
Figure 2.3 – SDM of WNT3A to mutate two endogenous Stop codons into two leucine residues and 
a two-base insertion to make c-terminal tags in-frame highlighted in bold. Reverse primer is reverse 
complementary to forward primer. 
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Table 2.8 – PCR Cycling conditions for QuikChange Lightning SDM of pcDNA4:WNT3A 
Cycles Temperature (°C) Time (min:sec) 
1 95 02:00 
18 
95 00:20 
60 00:10 
68 06:00 (00:30/kb) 
1 68 05:00 
 
Parental/Non-mutated DNA was removed by restriction with DpnI to target methylated or hemi-
methylated DNA for 5 min at 37 °C. DpnI-treated plasmid was transformed into X40-Gold 
ultracompetent E. coli supplemented with β-mercaptoethanol by incubation on ice for 30 min, 
followed by heatshock at 42 °C for 30 sec before immediately plunging back into ice for 2 min. 
Transformed cells were allowed to recover for 60 min in 500 µl LB at 37 °C before spreading onto 
selective (ampicillin) LB agar plates, incubating overnight at 37 °C. Colonies were picked, grown and 
screened by sequencing as previously described to ensure successful mutation. 
2.5 Transfection in ATDC5 cells 
2.5.1 High quality plasmid purification by QIAGEN HiSpeed Plasmid Midi Kit 
Transfection-quality plasmid was extracted from transformed DH5α cells grown in 50 ml LB using 
the QIAGEN HiSpeed Plasmid Midi Kit per manufacturer’s instructions. Briefly, pelleted cells were 
lysed in an alkaline lysis buffer and neutralised. Complete homogenisation was observed by the 
addition of LyseBlue. Lysed cells are cleared of SDS precipitates by syringe filtration. Plasmid DNA 
was then precipitated by the addition of isopropanol, which allows the plasmid DNA to become 
trapped in the precipitator module and finally eluted in TE buffer. Plasmid quality and quantity was 
assessed by NanoDrop, as previously described. 
2.5.2 Plasmid linearisation and purification 
For stable transfections, plasmids were linearised at a known position to aid stable integration into 
the genome, using BglII (New England Biolabs) for 2 h at 37 °C. Successful linearisation was 
confirmed by agarose gel electrophoresis. Linearised plasmid was then purified by combining with 
equal amounts of phenol chloroform, mixed by vortex and spun down at max speed for 10 min. The 
aqueous phase containing the DNA was then transferred to a new tube before adding 3M sodium 
acetate to 10% v/v. DNA was precipitated via addition of 100% ethanol (2.5x volume), mixed by 
vortex and spun down at max speed for 10 min. Supernatant was discarded, the pellet washed in 
 
59 
 
70% ethanol, before spinning at max speed again for 10 min. Ethanol was then removed and the 
pellet allowed to air dry before reconstitution in nuclease-free water. 
2.5.3 Determination of optimum selective antibiotic concentration 
To determine the optimum concentration of selective antibiotic (Zeocin™, Invivogen), a kill curve 
was performed using 0, 200, 400, 600, 800 and 1000 µg/ml Zeocin. ATDC5 cells were plated at 2 x 
104 cells/well in a 24-well plate with zeocin-containing medium added the following day. Cells were 
then observed via phase-contrast microscopy over the following 14 days for death. The 
concentration giving complete death after 14 days was then selected for use with stable 
transfections (1000 µg/ml). 
2.5.4 Transfection with TurboFect 
Plasmid DNA was transfected into ATDC5 cells grown in monolayer until ~70 % confluent using 
TurboFect (Thermo Scientific), a cationic reagent that forms positively-charged complexes with 
DNA that allows passage through the lipid membrane, according to manufacturer’s instructions. 
Briefly, 1 µg plasmid per 100 µl serum-free DMEM:F12 was used per millilitre of final culture 
medium volume. Plasmid diluted in serum-free medium was incubated with 2 µl TurboFect per 100 
µl DNA for 15 min at room temperature to allow positively-charged complexes to form. 
DNA/Turbofect mixture was then pipetted drop-wise onto the cells and incubated at 37 °C and left 
for up to 3 days, depending on type of transfection, described below. In all cases, transfection with 
pcDNA4:FLAG with no insert (termed “Vector Only”) was used as a control. 
2.5.5 Generation of conditioned media from transiently transfected cells 
For transiently transfected cells, DNA/Turbofect-containing media were removed after five hours, 
cells washed with PBS and replaced with fresh maintenance media containing 0.2 % FCS and 
conditioned for 24 h. Collected media were centrifuged for 5 min at 800 g and filter sterilised with 
0.2 µm pore-sized Minisart filters (Sartorius). Conditioned media were kept at -20 °C until needed. 
Presence or absence of overexpressing protein was confirmed by western blotting for each batch 
of medium. 
2.5.6 Generation of Stable Clones 
For stable transfections, DNA/Turbofect-containing medium was removed after 3 days. Cells were 
washed in PBS, trypsinised, and placed into T75 culture flasks with maintenance medium 
supplemented with 1000 µg/ml Zeocin. Medium was replaced every 2-3 days, killing cells that did 
not take up the plasmid. 
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To obtain a monoclonal population, cells were seeded at 0.5 - 1 cells/well in a 96-well plate format 
and subsequently gradually passaged, with kind help from Mr. Promise Ogor (UEA), into larger 
culture dishes from 24-well plate, to 6-well plate, to T25 and finally T75 culture flasks (Nunc). Cells 
were checked periodically for expression of the transfected gene (or lack thereof in vector only 
clones) via qRT-PCR and western blotting from cell lysates and/or conditioned medium. 
2.5.7 Analysing gene expression in stable clones 
Non-induced stable clones were plated in both monolayer and micromass culture for 4 days before 
RNA extraction to examine gene expression. 
For differentiation, stable clones were plated in monolayer and micromass culture as described for 
naïve ATDC5 cells in the presence or absence of both insulin and ascorbic acid for 14 days. After 14 
days, cells were stimulated with or without 10 ng/ml OSM (R&D) and 5 ng/ml IL-1α (R&D) in 
maintenance media (no insulin or ascorbic acid). 
Due to the length of time needed in some experiments to allow differentiation to occur, all 
experiments using stable clones were conducted in the presence of 1000 µg/ml Zeocin. 
2.6 Conditioned Media Stimulation 
Naïve ATDC5 cells were cultured in monolayer or micromass in the presence or absence of insulin 
and ascorbic acid as before. At day 14, cells were washed and media replaced with neat conditioned 
media generated from transiently transfected cells for 24 h before RNA or protein extraction. In 
some experiments, 10 ng/ml OSM and 5 ng/ml IL-1α were added to the conditioned media, 
stimulating the cells at the exact same time. 
2.6.1 Microarray Analysis 
RNA was extracted from stimulated cells as previously described and checked for quality (OD 
260/280 ratio between 1.68 - 2.08) by Nanodrop before sending 15 µl RNA above a minimum 
concentration of 50 ng/µl to Almac Diagnostics (Craigavon, Northern Ireland) from microarray 
analysis using the Mouse Genome 430 2.0 Affymetrix GeneChip. Each condition consisted of three 
biological replicates. All samples were confirmed to pass QC. 
Microarray results were analysed with Paul Hales at UCB Pharma LTD (Slough, UK). Results were 
normalised using GeneChip Robust Multiarray Averaging (GC-RMA) normalisation and analysed 
using Genedata’s Analyst software. Probes with an expression value of 10 or below were below the 
minimum threshold of background noise and considered to not be expressed and therefore not 
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used for subsequent analysis unless regulated to appreciable levels. Expression levels from probes 
were compared across the conditions and expressed as a fold change. Probes above an arbitrary 
cut off of 1.5 fold change with P < 0.05 by t-test and Q-Value <0.05 by Benjamini-Hochberg analysis 
were considered significant and used for subsequent analysis. Pathway analysis was carried out 
with the significantly regulated genes using the freely available DAVID Bioinformatics Resources 6.7 
(National Institute of Allergy and Infectious Diseases). 
2.7 Cell Adhesion Assay 
Cell adhesion assays were performed using a modified protocol from Messent, et al., (1998). Wells 
of a 96-well plate (Nunc) were coated with 100 μl of the desired matrix component as above, then 
washed with PBS and blocked with 1% heat-denatured BSA (Sigma-Aldrich) in PBS for 1 h at 4 °C. 
The wells were again washed with PBS and ATDC5 cells plated at 6 x 104 cells/well in 100 μl serum-
free maintenance medium. Cells were allowed to adhere for 60 min at 37 °C, then unattached cells 
were flicked off and wells washed with warmed serum-free maintenance medium. Adhered cells 
were fixed in 70% ethanol at room temperature for 10 min and stained with 100 μl 1% methylene 
blue in 0.01M borate buffer (pH 8.5) for 30 min. Excess dye was washed off and adhered cells were 
lysed with EtOH/0.1M HCl (1:1) for 10 min with shaking and absorbance read at 630 nm with a 
multiwell plate-reader. The average absorbance for adhesion to BSA was subtracted from each 
value of adhesion to the matrix components, and these new values were expressed as an average 
per condition, with the amount of absorbance from the released methylene blue being proportional 
to the number of cells that adhered to the matrix substrate. 
2.8 Random Cell Migration Assay 
Random cell migration assays were performed essentially as described in (Murray, et al., 2013). In 
brief, undifferentiated ATDC5 cells were plated at the desired concentration on matrix-coated 
plates in maintenance medium containing 0.2 % FCS and allowed to adhere for three hours in a 
humidified incubator at 37 °C with 5% CO2. Cell stimulated with either neat WNT3A, WNT5A or 
Vector Only conditioned media from transiently-transfected cells, and/or stimulated with cytokines 
(10 ng/ml OSM and 5 ng/ml IL-1α) were done so after these three hours. Plated cells were 
transferred to a motorised stage within a controlled, humidified environment at 37 °C with 5 % CO2. 
Images were taken every 10 min for 17 h with AxioVision software (Zeiss) using a monochrome 
AxioCam MRm camera (Zeiss) attached to a widefield, Axiovert 200M inverted light microscope 
(Zeiss). Cell migration was manually tracked using the ‘Manual Tracking’ plugin (F. Cordelières, 
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Institute Curie, France) for ImageJ (National Institutes of Health), and expressed as the average cell 
speed in µm/h. 
2.9 Micromass Inverted Invasion Assay 
Micromass inverted invasion assays were carried out using a modified protocol from Hennigan, et 
al. (1994). ATDC5 micromass cultures were plated in the standard 10 µl droplets at 2 x 107 cells/ml 
but onto the top of 6.5 mm 8 µm pore transwells placed into 24 well plates (Corning Life Sciences) 
and allowed to adhere for two hours before flooding with 1 ml insulin- and ascorbic acid-containing 
differentiation medium, allowing the differentiation medium to flood both the top chamber and 
the bottom chamber, covering both sides of the transwell membrane. Micromass cultures were 
differentiated for 14 days, carefully replacing the medium every 2-3 days, as before.  
After 14 days, micromass cultures were washed in PBS and stimulated in maintenance medium 
containing 0.2 % FCS with or without the addition of 10 ng/ml OSM and 5 ng/ml IL-1α for 48 h. After 
48 h, micromass cultures were washed in PBS and fixed in ice cold methanol at -20 °C for 5 min. 
Micromass cultures were then washed in PBS and warm 0.2 % FCS-containing maintenance medium 
before inverting the transwells and plating 100 µl non-induced (undifferentiated) ATDC5 cells at 1 
x 106 cells/ml on the underside of the transwell membrane in standard 5 % FCS-containing 
maintenance medium. Cells were allowed to adhere for 3 hours before inverting again to place the 
transwells the right way up and washing the base containing the freshly-adhered live ATDC5 
chondroprogenitor cells in 0.2 % FCS-containing maintenance medium. Transwells were then 
placed into wells containing 1 ml  Vector Only conditioned medium and 200 µl chemoattractant 
(WNT5A conditioned medium) was placed in the top chamber, or control medium (Vector Only 
conditioned medium). In one experiment, 0.2 µg/ml commercial WNT5A (R&D Systems, kind gift 
from Dr. Victoria Sherwood, UEA) was used or carrier control (from 0.1 % BSA stock). Concentration 
of commercial WNT5A used was based on Ekstrom, et al. (2011) which inhibited WNT3A-mediated 
canonical WNT signalling. Cells were allowed to invade for 48 h before culture media were replaced 
with 1 ml 4 μM calcein-AM and 4 μM ethidium homodomer-1 to stain live or dead cells respectively. 
A diagram of this set-up can be found in Figure 2.4. 
Transwells were then imaged using a Leica TCS SP2 UV confocal microscope with an inverted Leica 
DM IRE2 stand taking images every 2 µm to form a Z-stack. The bottom of the transwells were 
wiped after confirming the presence of adhered cells before imaging the Z-stack. The first image 
was taken from the wiped underside and analysis was carried out using images 10 µm from the 
starting position, which equated to the thickness of the membrane. Images were analysed using 
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Volocity (PerkinElmer) and expressed as the average number of invading cells per field of view from 
three fields of view per transwell across two transwells (n=6). 
  A 
B 
C 
Figure 2.4 – Micromass inverted invasion assay schematic. A) ATDC5 micromass cultures are 
plated onto transwell inserts and stimulated with insulin and ascorbic acid to induce 
differentiation for 14 days before media removed and replaced with maintenance media 
supplemented with or without 5 ng/ml IL-1α and 10 ng/ml OSM for 48 hours. B) Micromasses are 
fixed in methanol and live undifferentiated ATDC5 cells plated underneath the transwell. A 
chemoattractive gradient is established by adding the chemoattractant (WNT5A) to the top well 
and the control condition in the bottom well for 48 hours. C) Wells are flooded with calcein AM 
(green) and ethidium homodimer-1 (red) to stain for live and dead cells respectively before 
imaging with a confocal microscope. 
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2.10 Statistical Analysis 
Statistical analysis was performed using either Student’s independent sample t-test, or one-way 
ANOVA with Tukey post-hoc test, unless otherwise stated, using SPSS software (IBM). Unless 
otherwise stated, statistical analyses are only shown between conditions where only one factor has 
changed. All error bars represent standard error of the mean (SEM). The traditional ‘star’ system 
was used to represent statistical significance, depending on P value as shown below: 
*  0.01 < P ≤ 0.05 
**  0.001 < P ≤ 0.01 
***  0.0001 < P ≤ 0.001 
****  P ≤ 0.0001 
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Chapter 3 
Enhancing and Maintaining the Chondrocytic Phenotype in 
ATDC5 cells by Physiologically-Relevant Culturing 
Chapter 3 – Enhancing and Maintaining the Chondrocytic Phenotype in ATDC5 cells by Physiologically-
Relevant Culturing 
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3.1 Introduction 
3.1.1 Mesenchymal Stem Cells and the ATDC5 chondrogenic differentiation model 
Cartilage is a notable tissue for its extensive extracellular matrix. Chondrocytes and their precursors, 
the only cell types resident within cartilage, comprise < 5 % of the total cartilage volume (Poole, et 
al., 2002). Therefore due to the limited number obtainable from cartilage samples, and with 
difficulty in maintaining a differentiated phenotype, MSCs (which have the ability to differentiate 
into chondrocytes as well as other lineages), along with chondrogenic cell lines, are widely used as 
an attractive alternative (Demoor, et al., 2014). 
The ATDC5 chondrogenic cell line, originally described by Atsumi, et al., (1990), is a murine 
chondrogenic precursor derived from the AT805 embryonic teratocarcinoma. ATDC5 cells plated in 
monolayer can readily and reproducibly undergo chondrogenesis with insulin stimulation, 
producing aggregates rich in cartilage-associated matrix proteins, and can be maintained and 
subcultured in its undifferentiated state in the absence of insulin (Atsumi, et al., 1990). ATDC5 cells 
may also be stimulated to undergo hypertrophic differentiation and mineralisation, enabling 
observations over the full spectrum of chondrogenesis from the initial condensation stages and 
chondrocyte maturation, to processes associated with endochondral ossification (Shukunami, et al., 
1997). They have also been shown to be transfectable (Morimoto & Obinata, 2011; Kawai, et al., 
2012; Caron, et al., 2013; Kobayashi, et al., 2013). Taken together, these traits made the ATDC5 cell 
line an attractive cell line to study chondrogenesis, which can be genetically manipulated, and to 
provide a ready source of chondrocytes that can produce extensive extracellular matrix. 
3.1.2 Chondrocytes and physiologically relevant culturing conditions 
It has been long established that primary chondrocytes rapidly de-differentiate upon isolation and 
expansion using traditional in vitro culturing methods, down-regulating chondrocytic genes, such 
as COL2A1 (which encodes type II collagen), and up-regulating more fibroblastic genes, such as 
COL1A1 (which encodes the α1 chain of type I collagen) (Stokes, et al., 2001). Re-differentiation of 
chondrocytes can occur when isolated chondrocytes are grown using physiologically-relevant 
culturing systems that, for example, allow them to regain their spherical shape that occurs naturally 
in vivo and to regain their cell-cell and cell-matrix interactions in all three dimensions. One such 
system is the high-density micromass culture, originally established to induce the chondrogenic 
differentiation of isolated chick limb bud cells (Ahrens, et al., 1977), which has subsequently been 
used extensively and routinely for the chondrogenic differentiation of MSCs (Bobick & Cobb, 2012; 
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Diaz-Mendoza, et al., 2014; Juhasz, et al., 2014) and the re-differentiation of primary chondrocytes 
and chondrocyte cell lines (Schulze-Tanzil, et al., 2002; Banu & Tsuchiya, 2007; Greco, et al., 2011). 
3.1.3 Chondrocytes and Ascorbic Acid 
Ascorbic acid is an essential co-factor in collagen biosynthesis for the prolyl- and lysyl- hydroxylase 
enzymes to produce hydroxyproline and hydroxylysine, stabilising the triple helical collagen 
structure and forming intermolecular cross-links respectively (Murad, et al., 1981; Pinnell, 1985). 
The use of ascorbic acid in the chondrogenic differentiating medium of mesenchymal stem cells is 
well-established (Tropel, et al., 2004; Spagnoli, et al., 2005; Taipaleenmaki, et al., 2008; Markway, 
et al., 2010), and the ability for ascorbic acid to induce chondrogenic differentiation of ATDC5 cells 
in monolayer in the absence of insulin has previously been shown (Temu, et al., 2010). However, it 
remains unknown whether ATDC5 differentiation may be enhanced by the combination of ascorbic 
acid with micromass culture, and this is investigated in this study. 
3.1.4 Cartilage Phenotypes 
Several different types of cartilage exist within the body, with hyaline cartilage produced in 
developing joints. Hyaline cartilage may also be further subdivided depending on its characteristics 
and location with the body, providing different functions depending on the type. At the ends of 
articulating joints, articular cartilage provides joints with near-frictionless movement and cushions 
the joints from impact. Loss of articular cartilage during osteoarthritis increases friction and joint 
stiffness, resulting in pain. Growth plate cartilage on the other hand, undergoes hypertrophic 
differentiation in a process called endochondral ossification, which becomes mineralised and 
replaced with bone to form and elongate the bone. Articular cartilage and growth plate cartilage 
are therefore two different types of hyaline cartilage which serve different functions within the 
joint, whereby different genes are regulated to provide the two different phenotypes. It is therefore 
important to ascertain the type of cartilage produced by in vitro culture. 
3.1.5 Aims 
It was hypothesised that the combined use of ascorbic acid and micromass culture would enhance 
insulin-induced chondrogenic differentiation in ATDC5 cells. Whilst ATDC5 cells have been cultured 
in micromass before, the beneficial effects over monolayer culture were not investigated and so 
comparisons were also made with the use of micromass culture compared to monolayer, as well as 
the addition of ascorbic acid. Further to this, the resulting cartilage phenotypes of differentiated 
ATDC5 cells under these conditions were also investigated to ascertain the biological relevance for 
future studies. 
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3.2 Results 
3.2.1 Selection of an appropriate housekeeping gene for qRT-PCR analysis 
To investigate changes in gene expression during the course of chondrogenesis, qRT-PCR analysis 
was used. To achieve this, a geNorm analysis was first used to identify a suitable housekeeping gene 
from a selection of 12 genes that would not alter expression across the various chondrogenic 
conditions being investigated, which has not been reported for this experimental set up previously. 
More specifically, geNorm analysis was performed on ATDC5 cells grown in both monolayer and 
micromass cultures and stimulated with or without insulin to induce chondrogenesis for 14 days, 
before RNA extraction. For more detail, please see section 2.1.2 and 2.2.4. Results showed that 
Actb, Ywhaz, Atp5b, Cyc1, Rpl13a, 18S and Gapdh were all suitable housekeeping genes for non-
induced or insulin-induced ATDC5 cells in either monolayer or micromass cultures (Figure 3.1), with 
Ywhaz and 18S being used in future experiments to normalise gene expression, and β-actin 
(encoded by Actb) being used as a loading control in subsequent western blot experiments. 
  
Figure 3.1 – Identifying suitable housekeeping genes that do not significantly alter expression 
during chondrogenic culture of ATDC5 cells via geNorm analysis. geNorm analysis performed 
on ATDC5 cells grown in monolayer or micromass in duplicate stimulated with or without insulin 
for 14 days. Genes with an M value below 0.5 were deemed acceptable for use as housekeeping 
genes. Line graph produced from geNorm M analysis using qbasePLUS software. Experiment 
performed once. 
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3.2.2 Time course of gene expression during ATDC5 differentiation 
To investigate gene expression changes over the course of differentiation, ATDC5 cells were 
cultured in micromasses induced to differentiate with insulin, stimulated with and without ascorbic 
acid for 7, 14 or 21 days, and compared with culture in monolayer or undifferentiated controls. 
Steady-state mRNA levels were examined by qRT-PCR analysis and preliminary results from one 
experiment are shown (Figure 3.2-3.5). Col2a1, Frzb, Tgfb1, Tgfb3, Col10a1, Alpl and Runx2 mRNA 
expression were analysed due to their roles in chondrogenesis, as well as articular and hypertrophic 
differentiation. Only significant statistical differences relating to time in culture are shown. No RNA 
(NR) was recoverable from the insulin-induced, ascorbic acid-stimulated, 21 day time-point 
monolayer condition as this condition peeled off and died before the end of the experiment. 
Expression of Col2a1, the major marker of chondrocytes which encodes type II collagen, was 
increased with increasing time in micromasses induced to differentiate with insulin (hereafter 
referred to as insulin-induced) (Figure 3.2 A). Frzb expression, a secreted wnt antagonist and a 
marker of articular differentiation, was also increased in a similar fashion in insulin-induced 
micromasses (Figure 3.2 B). Expression of Tgfb1 was largely up-regulated in insulin-induced 
micromasses (Figure 3.3 A), whilst Tgfb3 was largely unchanged with regards to time in culture 
(Figure 3.3 B). Col10a1, which encodes the hypertrophy-associated type X collagen, displayed 
increased expression with respect to time in insulin-induced micromasses (Figure 3.4 A). Similarly, 
levels of Alpl, which encodes the mineralising enzyme, alkaline phosphatase (Liver/Bone/Kidney), 
also increased with respect to time in differentiating micromass cultures. However, it was increased 
in other conditions stimulated with ascorbic acid in both monolayer and micromass cultures (Figure 
3.4 B). Interestingly, Runx2 expression, the major transcription factor driving hypertrophy, 
remained unchanged with respect to time in insulin-induced cultures, but was significantly up-
regulated after 21 days in culture in micromasses that had not been induced to undergo 
chondrogenesis with insulin (hereafter referred to as non-induced) (Figure  3.5).  
Based on these results, further experiments were performed at the 14 day culture time point, 
minimising any potentential hypertrophy whilst still providing adequate chondrogenic 
differentiation. This also allowed analysis across all culturing conditions as monolayer cultures 
induced with insulin and stimulated with ascorbic acid die before day 21 from overgrowth. 
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Figure 3.2 – Gene expression regulation of articular cartilage markers during ATDC5 
differentiation. Steady-state mRNA levels of Col2a1 (A) and Frzb (B) were analysed after 7, 14 
and 21 days of culture in monolayer or micromass, stimulated with or without insulin or 
ascorbic acid, normalised to Ywhaz housekeeping gene. Preliminary experiment performed 
once – time course data not repeated. Statistical analyses performed and shown in relation to 
time only. NR = No RNA obtained from samples because of cell death. ND = Not detected. CT 
values can be found in Appendix Table S3.1 
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Figure 3.3 – Gene expression regulation of the TGFβ family during ATDC5 differentiation. 
Steady-state mRNA levels of Tgfb1 (A) and Tgfb3 (B) were analysed after 7, 14 and 21 days of 
culture in monolayer or micromass, stimulated with or without insulin or ascorbic acid,, 
normalised to Ywhaz housekeeping gene. Preliminary experiment performed once – time 
course data not repeated. Statistical analyses performed and shown in relation to time only. 
NR = No RNA obtained from samples because of cell death. CT values can be found in Appendix 
Table S3.2 
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Figure 3.4 – Gene expression regulation of hypertrophic markers during ATDC5 
differentiation. Steady-state mRNA levels of Col10a1 (A) and Alpl (B) were analysed after 7, 
14 and 21 days of culture in monolayer or micromass, stimulated with or without insulin or 
ascorbic acid, normalised to Ywhaz housekeeping gene. Preliminary experiment performed 
once – time course data not repeated. Statistical analyses performed and shown in relation to 
time only. NR = No RNA obtained from samples because of cell death. ND = not detected. CT 
values can be found in Appendix Table S3.3 
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Figure 3.5 – Gene expression regulation of hypertrophic transcription factor Runx2 during 
ATDC5 differentiation. Steady-state mRNA levels of Runx2 were analysed after 7, 14 and 21 
days of culture, in monolayer or micromass, stimulated with or without insulin or ascorbic 
acid, normalised to Ywhaz housekeeping gene. Preliminary experiment performed once – time 
course data not repeated. Statistical analyses performed and shown in relation to time only. 
NR = No RNA obtained from samples because of cell death. CT values can be found in Appendix 
Table S3.4 
Runx2 
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3.2.3 Morphological differences and visual observations between different ATDC5 
culturing conditions 
Changes in cell morphology were observed during the 14 day culture period of  non-induced ATDC5 
cells cultured in monolayer or micromass compared to chondrogenic induction with insulin (insulin-
induced) and stimulated with or without ascorbic acid for the same time period (see section 2.1.2). 
In monolayer cultures, non-induced cells were flat and in a confluent sheet, which did not seem to 
change upon addition of ascorbic acid (Figure 3.6 A-B). Upon insulin induction, cells became smaller, 
rounder and more condensed, forming aggregates termed cartilage-like nodules (Figure 3.7), which 
were surrounded by larger, non-aggregating cells, suggesting a mixed population of cell 
morphologies. This was regardless of the stimulation with or without ascorbic acid as seen by the 
lack of differences seen between Figures 3.6 C and D which display regions absent of these 
aggregates. However, these aggregates were numerous when stimulated with ascorbic acid when 
observed at lower magnifications or with the naked eye.  
In non-induced micromass cultures, after 14 days, cells were flat and resembled monolayer cultures 
in appearance under the microscope (Figure 3.6 E-F). The central micromass in non-induced 
cultures became hard to see with naked eye with time, but was slightly more evident with addition 
of ascorbic acid. In contrast, insulin-induced micromass cultures were very evident by the naked 
eye. Cells were very condensed across the entirity of the central micromass (Figure 3.6 G-H) 
indicating a more uniform population of differentiated cells compared to insulin-induced 
monolayer cultures. Finally, addition of ascorbic acid had no discernable effect on cell morphology 
in insulin-induced micromasses, although the vast majority of cells are largely obscured by the sheer 
density of the produced matrix when cultures had been treated with insulin (Figure 3.6 G-H). 
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Figure 3.6 – Morphological changes during ATDC5 differentiation. ATDC5 cells were grown 
for 14 days in monolayer or micromass culture, stimulated with or without insulin (to induce 
differentiation) and stimulated with or without ascorbic acid. Images were taken at random 
locations within the wells using a phase contrast microscope at 10x mag. No differences are 
observed at this magnification between stimulation with or without ascorbic acid. Cartilage-
like nodules are not visible in the monolayer images (please see Figure 3.7 for an example at 
the same magnification to highlight the feature). Images of experiment taken once but 
observations made >5 times. Scale bar = 100 µm 
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Figure 3.7 – Cartilage-like nodule of ATDC5 cells. Aggregates formed in insulin-induced ATDC5 
cells culture in monolayer, surrounded by non-aggregating cells. Image taken after 14 days 
induction by phase contrast microscopy at 10x magnification. Image taken from same 
experiment as in Figure 3.6 at the same magnification and resolution, but focussing directly 
on a cartilage-like nodule not visible in Figure 3.6. Scale bar = 100 µm 
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3.2.4 Ascorbic Acid enhances proteoglycan deposition in both monolayer and 
micromass cultures 
Fixed cultures of ATDC5 cells grown for 14 days with and without insulin induction and ascorbic acid 
stimulation were stained with Alcian Blue to visualise proteoglycan deposition (see 2.3.1). Little 
staining was observed in monolayer cultures which were not induced to differentiate with insulin 
or stimulated with ascorbic acid (Figure 3.8 A). Little staining was also observed in non-induced 
micromass cultures (Figure 3.8 E), consistent with the morphological changes seen by phase 
contrast microscopy (Figure 3.6 E). This result suggests that micromass culture alone is not enough 
to stimulate chondrogenesis of ATDC5 cells. 
Addition of ascorbic acid to both non-induced monolayer and micromass cultures resulted in slight 
staining with Alcian Blue (Figure 3.8 B+F), but this was not deemed significant upon release of the 
dye (Figure 3.9), indicating that ascorbic acid stimulation alone was unable to significantly induce 
proteoglycan deposition, and thus chondrogenesis.  
Induction of chondrogenesis with insulin in monolayer cultures resulted in cartilage-like nodules 
that stained deeply with Alcian Blue (Figure 3.8 C), consistent with the original ATDC5 report 
(Atsumi, et al., 1990). Large areas in these cultures which did not stain with Alcian Blue indicate 
areas of cells which presumably did not deposit proteoglycan, suggesting a mixed population was 
observed of differentiated and undifferentiated cells, consistent with the mixed cellular 
morphologies observed by phase contrast microscopy. Quantification of Alcian Blue staining by 
measuring the absorbance of the Alcian Blue, released from the cultures by guanidine 
hydrochloride, revealed a significant increase in staining with the addition of ascorbic acid to 
monolayer cultures (Figure 3.9), however, the heterogeneity of the cell population remained 
(Figure 3.8 D). In contrast, insulin-induced micromass cultures were homogenously stained with 
Alcian Blue, suggesting a more uniform population of cells within it (Figure 3.8 G+H). Culture in 
micromass, regardless of the presence or absence of ascorbic acid, significantly increased Alcian 
Blue staining compared to their monolayer counterparts. Addition of ascorbic acid further 
increased the amount of Alcian Blue staining compared to insulin-induced micromass cultures 
(Figure 3.9) resulting in deeper staining of the central micromass, surrounded by a greater halo of 
stained matrix produced by migrated, differentiated cells (Figure 3.8 H).  
These findings indicate that both culture in three-dimensional micromasses and stimulation of 
ascorbic acid can enhance insulin-induced differentiation of ATDC5 cells, but cannot significantly 
induce chondrogenesis without the addition of insulin after 14 days of culture. 
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Figure 3.8 – Alcian Blue staining comparison during differentiation of ATDC5 cells after 14 
days in monolayer and micromass stimulated with or without insulin or ascorbic acid. 
Samples were fixed in ice cold methanol before staining with Alcian Blue. Alcian Blue staining 
represents proteoglycan deposition, an indicator of chondrogenesis. Representative 
experiment from four repeats shown. Scale bar = 1 mm. 
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Figure 3.9 – Quantification of Alcian Blue staining. Alcian Blue staining (seen in Figure 3.8) was 
released by 8 M Guanidine Hydrochloride and read at 630 nm in a spectrophotometer. Due to 
different number of cells input at the start of the culture between monolayer and micromass 
conditions, results are shown as a fold change relative to either monolayers or micromasses not 
induced to differentiate with insulin or stimulated with ascorbic acid. Experiment performed 
four times showing highly consistent results among 3 experiments, with representative data 
shown. 
* = significant compared to Monolayer. 
† = significant compared to No Ascorbic Acid.  
‡ = significant compared to No Insulin 
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3.2.5 The effect of micromass culture and ascorbic acid stimulation on gene 
expression of ATDC5 cells for 14 days 
To identify the individual and synergistic effects of ATDC5 culture in micromass and stimulated with 
ascorbic acid, gene expression analysis was carried out after the chosen 14 day culture period on 
genes known to be related to chondrogenesis and cartilage phenotype. This experiment was 
repeated 3 times and the most representative example of each gene shown. 
3.2.5.1 Chondrogenesis/Articular Differentiation 
Col2a1 expression was significantly increased after 14 days of culture using the traditional culturing 
method, as expected. This was significantly increased upon induction with insulin when put into 
micromass culture, and even further increased when combined with ascorbic acid stimulation 
(Figure 3.10 A). Without chondrogenic induction with insulin, Frzb was not expressed to appreciable 
levels consistently (CT ≥ 35). Upon insulin induction, Frzb was expressed, which was significantly 
increased in micromass culture when compared to monolayer culture, regardless or ascorbic acid 
stimulation (Figure 3.10 B). Conversely, an overall trend towards a reduction of Grem1 (gremlin-1) 
expression was observed with increasing chondrogenesis with an additional decrease in expression 
due to micromass culture in non-induced cells (Figure 3.10 C). A significant increase in Tgfb1 
expression was seen upon the induction of chondrogenesis with insulin in micromass cultures in 
the presence of ascorbic acid compared to non-induced micromass cultures in the presence of 
ascorbic acid. In two of three experiments, addition of ascorbic acid also trended towards an 
increase in Tgfb1 expression in insulin-induced micromass cultures compared to insulin-induced 
micromass cultures without ascorbic acid (Figure 3.10 D). Tgfb1 expression in monolayer cultures 
was not consistent between three experiments and so not shown. 
Levels of Acan mRNA, which encodes the core protein of aggrecan, could not be detected to any 
appreciable level (CT ≥ 35), along with Wnt3a, Wnt5a, Dkk3 and Col9a1 (type IX collagen), although 
known positive controls were not tested for these assays (data not shown). 
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Figure 3.10 – Changes in expression of various chondrogenic/articular markers during ATDC5 
chondrogenesis. Normalised steady-state mRNA expression levels of Col2a1 (A), Frzb (B), Grem1 
(C) and Tfb1 (D) were measured after 14 days of culture in monolayer or micromass, stimulated 
with or without insulin or ascorbic acid. Experiment performed three times and representative 
experiments are shown. Only data for micromass cultures shown for Tgfb1 due to inconsistent 
regulation in monolayer cultures. ND = not detected. CT values may be found in Appendix Table 
S3.5  
* = significant compared to Monolayer. 
† = significant compared to No Ascorbic Acid.  
‡ = significant compared to No Insulin 
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3.2.5.2 Hypertrophic Differentiation/Mineralisation 
In two out of three experiments, Col10a1 expression was barely detected in non-induced cells, 
becoming expressed with insulin induction when combined with culture in micromass and/or 
stimulation with ascorbic acid, with a signficiant increase with the combination of micromass 
culture and ascorbic acid stimulation when compared to either micromass culture or ascorbic acid 
stimulation alone in insulin-induced cells (Figure 3.11 A). However, in one out of the three 
experiments, no Col10a1 expression could be detected (data not shown).  
Ddr2 expression was seen to be decreased upon insulin-induction of ascorbic acid-stimulated cells 
and was down-regulated in non-induced micromass cultures compared to non-induced monolayer 
cultures. Expression did not change in micromass cultures upon insulin induction or ascorbic acid 
stimulation (Figure 3.11 B). 
Runx2, the major transcription factor driving hypertrophic differentiation, was not significantly 
regulated by any condition (Figure 3.11 C). 
In two out of three experiments, Alpl, which encodes the liver/bone/kidney form of alkaline 
phosphatase, was significantly up-regulated upon insulin-induction of ascorbic acid-stimulated 
monolayer cells and micromass cultures in the absence of ascorbic acid. Alpl was also up-regulated 
in insulin-induced micromass cultures in the absence of ascorbic acid compared to monolayer and 
up-regulated in the presence of ascorbic acid in insulin-induced monolayer cells (Figure 3.11 D).  
Tgfb3 was down-regulated upon insulin induction of both monolayer and micromass cultures. 
Micromass culture also significantly down-regulated Tgfb3 expression in non-induced cells. 
Ascorbic acid stimulation did not significantly alter Tgfb3 expression, although a clear trend towards 
down-regulation is seen with increasing differentiation (Figure 3.11 E).  
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Figure 3.11 – Changes in gene expression related 
to hypertrophic differenation during ATDC5 
differentiation. Normalised steady-state mRNA 
expression levels of Col10a1 (A), Ddr2 (B), Runx2 
(C), Alpl (D) and Tgfb3 (E) were measured after 14 
days of culture in monolayer or micromass, 
stimulated with or without insulin or ascorbic acid. 
Experiment performed three times and 
representative experiments are shown. ND = not 
detected. CT values may be found in Appendix 
Table S3.6  
* = significant compared to Monolayer. 
† = significant compared to No Ascorbic Acid.  
‡ = significant compared to No Insulin 
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3.2.5.3 CCN Growth Factors 
Of the CCN family of growth factors, expression of Cyr61 and Ctgf were readily detected. Expression 
of Cyr61 was significantly decreased upon chondrogenic induction with insulin in monolayer 
cultures in the presence of ascorbic acid. A similar trend was seen in micromass cultures, although 
this did not reach significance. Culture in micromass had no effect on the regulation of Cyr61 in 
comparison to monolayer (Figure 3.12 A).  
In contrast, micromass culture significantly down-regulated Ctgf expression in non-induced cells 
(Figure 3.12 B). Ctgf expression was also down-regulated upon insulin induction of monolayer 
cultures. The reduced levels of Ctgf expression in micromass cultures were not modulated by insulin 
induction or ascorbic acid stimulation. Interestingly, ascorbic acid stimulation significantly up-
regulated Ctgf expression in non-induced monolayer cells (Figure 3.12 B). Expression of Nov, Wisp1 
and Wisp2 were not consistent across experiments. Wisp3 was not detected in any experiment 
(data not shown). 
  
Figure 3.12 – Changes in CCN gene expression during ATDC5 differentiation. Normalised 
steady-state mRNA expression levels of Cyr61 (A) and Ctgf (B) were measured after 14 days of 
culture in monolayer or micromass, stimulated with or without insulin or ascorbic acid. 
Experiment performed three times and representative experiments are shown. CT values may 
be found in Appendix Table S3.7  
* = significant compared to Monolayer. 
† = significant compared to No Ascorbic Acid.  
‡ = significant compared to No Insulin 
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3.2.6 Type X Collagen is immunolocalised to a restricted region within the centre of 
micromasses 
Despite an increase in the articular marker Frzb, Col10a1 mRNA expression, a hypertrophic marker, 
was also increased with increasing chondrogenesis. To elucidate whether the majority of the 
culture was undergoing hypertrophic differentiation or whether this was restricted to particular 
cells/regions, type X collagen protein expression was explored by immunocytochemistry alongside 
type II collagen expression on fixed cells that had been cultured using the same conditions 
described above. In insulin-induced  monolayer and micromass cultures stimulated with ascorbic 
acid, very little type X collagen protein was detected, and only in one of two experiments. Detected 
type X collagen protein was largely found to be restricted to within the centre of the micromass, 
which mainly appeared to be localised close to possibly the cell surface, although no cell surface or 
PCM marker was used to confirm this (Figure 3.13). Intriguingly, no type X collagen positive “rings” 
were found in monolayer cultures (Figure 3.14). Although Col10a1 mRNA levels increased with 
increasing chondrogenesis, these results suggest little hypertrophic differentiation. 
In contrast to type X collagen, type II collagen protein was highly expressed in the interstitial matrix 
throughout the entirity of the cartilage-like nodules in monolayer culture and the micromass (Figure 
3.13). Interestingly, culture in monolayer gave rise to a higher average fluorescence intensity of 
type II collagen compared to micromass culture (Figure 3.15). However, this is based from one 
experiment with only two fields of view from one culture per condition. Although a second 
experiment was performed, quantifiable analysis cannot be carried as some samples cannot be 
normalised due to a lack of no primary control as they were destroyed accidentally during handling 
during the staining process due to their delicate nature. As such, further repeats with additional 
fields of view per well and additional wells per condition are necessary to confirm this finding 
statistically. 
  
 
 
 
 
  
Figure 3.13 – Optical sections of differentiated monolayer and micromass cultures 
immunostained for Type II Collagen and Type X Collagen. Cells were differentiated with 
insulin in the presence of ascorbic acid for 14 days in monolayer or micromass culture. Optical 
sections were taken using laser confocal microscopy for either Type II Collagen or Type X 
Collagen (both white). Nuclei were stained using DAPI (cyan). Monolayer images shown 
represent cartilage-like nodule. Cartoon representation of micromass highlights the location 
of the sections shown. Orange = cross section. Blue = sagittal section derived computationally 
from multiple images in the xy plane along the z-axis. N=2. Type X Collagen detected in only 
one experiment. Scale = 30 µm. 
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Figure 3.14 – Number of complete or partial Type X Collagen “rings”. ATDC5 cells were 
differentiated with insulin and stimulated with ascorbic acid for 14 days in monolayer or 
micromass culture and immunostained for Type X Collagen. Positive staining was detected 
throughout the culture by confocal microscopy, creating z-stacks with images 2 µm apart. 
Experiment performed twice with Type X Collagen detected in only experiment. Results shown 
are the average number of Type X Collagen-positive rings in one experiment for one well with 
two or three fields of view for monolayer and micromass respectively. 
Figure 3.15 – Average type II collagen fluorescence intensity of ATDC5 cells differentiated 
in monolayer and micromass. Fluorescence intensity was calculated using ImageJ per slice of 
each z-stack. Due to the different number of slices between images, the fluorescence 
intensity of each slice were added together and divided by the number of slices, normalised 
to the intensities of the no-primary controls. Results are derived from two fields of view from 
one culture per condition. Two experiments performed with results from one shown 
coinciding with the experiment analysed in Figures 3.13 and 3.14. 
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3.2.7 Confirmation of hypertrophic gene expression via western blot 
Western blot analysis was used to confirm whether patterns of gene expression of hypertrophy-
related genes were also true at the protein level to identify the state of hypertrophic differentiation 
in this ATDC5 model.  
DDR2 protein was found to be consistently decreased with increasing chondrogenesis (Figure 3.16), 
in contrast to the mRNA level  which remained unchanged in micromass cultures (Figure 3.11 B). 
Expression of RUNX2 protein remained largely unchanged (Figure 3.16), although in one of three 
experiments, a clear decrease was seen in a similar fashion to DDR2 expression. On the other hand, 
WNT5A, known to inhibit hypertrophic differentiation (Bradley & Drissi, 2010), was increased upon 
chondrogenic induction with insulin (Figure 3.17), although this was only tested once. 
Together, this suggests that with increasing chondrogenesis, hypertrophic differentiation is 
inhibited or limited. 
  
 
89 
 
  
Figure 3.16 – DDR2 and Runx2 protein expression decrease with increasing chondrogenesis 
after 14 days of culture in monolayer or micromass, stimulated with or without insulin or 
ascorbic acid. Equal loading of protein for western blot was confirmed by probing for β-Actin, 
shown to be stably expressed in this culture system at the mRNA level. Predicted Mr DDR2 
96.5 kDa; Runx2 57.43 kDa (isoform 1), 55.9 kDa (isoform 2), 49.47 kDa (isoform 3), 45.59 kDa 
(isoform 4); β-Actin 41.74 kDa, based on amino acid sequence, not including any post-
translational modifications. Western blot performed three times using three different samples 
obtained from two experimental repeats. Mono = monolayer. Micro = micromass. Asc = 
ascorbic acid.  
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Figure 3.17 – WNT5A expression increases during chondrogenesis after 14 days of culture in 
monolayer or micromass, stimulated with or without insulin or ascorbic acid. Equal loading of 
protein for western blot was confirmed by probing for β-Actin, shown to be stably expressed in 
this culture system at the mRNA level. Predicted Mr endogenous mouse WNT5A = 42.35 kDa 
(isoform 1) or 40.89 kDa (isoform 2); β-Actin 41.74 kDa, based on amino acid sequence, not 
including any post-translational modifications. Experiment performed once. Mono = 
monolayer. Micro = micromass. Asc = ascorbic acid.  
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3.3 Discussion 
3.3.1 Chondrogenic differentiation of ATDC5 cells over time 
Expression levels of Col10a1 and Alpl (alkaline phosphatase), two genes well charactised to be 
involved in the hypertrophic stages of chondrogenesis and endochondral ossification, were 
increased with respect to time in micromass cultures (Figure 3.4). Conversely, expression of Col2a1, 
Tgfb1 and Frzb were significantly up-regulated over time (Figure 3.2 and 3.3 A), three genes known 
to be involved in chondrogenesis and the articular phenotype. Therefore based on these data, the 
14 day timepoint was chosen to conduct further experiments investigating ATDC5 differentiation, 
since hypertrophic differentiation was less advanced at this stage compared to the 21 day point, 
whilst still increasing chondrogenesis over the 7 day time point. Furthermore, since a goal was to 
investigate the impact of each factor in the different models (three-dimensional culture, insulin and 
ascorbic acid), not all comparisons would be able to be made at the 21 day timepoint as insulin-
induced ATDC5 cells stimulated with ascorbic acid die from overgrowth and detach from the culture 
vessel. 
3.3.2 Micromass culture enhances insulin-induced ATDC5 chondrogenesis 
This study has shown enhanced chondrogenesis in ATDC5 cells cultured in micromass by the 
increase in Col2a1 expression (Figure 3.10 A) and proteoglycan deposition (Figure 3.9), which was 
more homogenous compared to monolayer cultures (Figure 3.8), suggesting a more uniform 
population of differentiated cells compared to large areas of undifferentiated cells in monolayer 
cultures. Although ATDC5 cells have been cultured in micromass previously (Lodewyckx, et al., 2012; 
Sun & Beier, 2014), this appears to be the first time the beneficial effects of micromass 
differentiation have been directly compared to monolayer differentiation. Micromass culture alone 
appears to be insufficient to induce maximal chondrogenesis in ATDC5 cells (Figure 3.5 E; 3.6; 3.7) 
unlike in chick limb bud cells which were used in the original micromass experiment (Ahrens, et al., 
1977).  
3.3.3 Ascorbic Acid enhances ATDC5 chondrogenesis 
The use of ascorbic acid in the culture of primary chondrocytes is well established to promote stable 
collagen structures. Ascorbic acid has also previously been used in the culture of ATDC5 cells, 
primarily in the induction of hypertrophic differentiation and mineralisation, whereby after 21 days, 
CO2 is dropped from 5% to 3% and DMEM/F12 culture medium is replaced by α-MEM (Shukunami, 
et al., 1997; Shukunami, et al., 1998; Swingler, et al., 2012), which contains ascorbic acid (Altaf, et 
al., 2006). One study identified that ascorbic acid was capable of shortening the prechondrogenic 
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proliferation stage of ATDC5 cells from 21 days to 7 days when cells had been pre-stimulated with 
ascorbic acid (in the form of ascorbate 2-phosphate) for 7 days before chondrogenic induction with 
insulin for 21 days (Altaf, et al., 2006). The effect of ascorbic acid on proliferation has also been 
seen in primary bovine chondrocytes, causing an increase in cell density and cell number (Hering, 
et al., 1994). Although this was not directly tested in this thesis, ascorbic acid did increase cellular 
aggregation in the form of nodules, which appeared apparantly larger and more numerous (Figure 
3.8), which was also described by Altaf, et al. in pre-stimulated ATDC5 cells.  
In addition, several studies have shown in chondrocytes that ascorbic acid can enhance levels of  
type II collagen mRNA and/or protein (Hajek & Solursh, 1977; Dozin, et al., 1992; Altaf, et al., 2006; 
Cigan, et al., 2013) and proteoglycan expression/GAG content (Hering, et al., 1994; Priddy, et al., 
2001; Altaf, et al., 2006; Cigan, et al., 2013), which was also seen in this thesis (Figures 3.6, 3.7 A), 
and could further enhance the already increased chondrogenic effect of micromass culture. 
However, Ronzière,  et al., (2003) reported that whilst ascorbic acid increased COL2A1 expression 
in bovine chondrocytes cultured on collagen sponge scaffolds, there was no change in matrix 
deposition of collagen or GAG content. On the other hand, Priddy, et al., (2001) noted that whilst 
ascorbic acid increased GAG content in canine chondrocytes cultured in agarose gels, the effect on 
type II collagen as measured by immunohistochemistry, was minimal. However, this may be due to 
the hydroxyproline already present in the RPMI-1640 medium used, since hydroxyproline, which 
stabilises the collagen structure, is the product of the enzyme prolyl-hydroxylase, of which ascorbic 
acid is the co-factor.  Therefore the addition of exogenous ascorbic acid may not have an additional 
effect over the hydroxyproline already present in the medium, suggesting the beneficial effect of 
ascorbic acid may be dependent on the culturing conditions. 
Together, this indicates ascorbic acid is an important factor in enhancing chondrogenesis, and in 
particular in ATDC5 cells cultured in micromass. 
3.3.4 Micromass culture and ascorbic acid stimulation inhibit hypertrophic 
differentiation and promote articular differentiation 
Articular cartilage and growth plate cartilage (which undergoes hypertrophic differentiation) have 
different functions within the body and thus have two different phenotypes. Articular cartilage 
escapes the hypertrophic process in order to provide its protective effects on the joint from various 
forces, whereas growth plate cartilage undergoes hypertrophy during endochondral ossification in 
order to produce and elongate the bone. These phenotypic differences are therefore important to 
distinguish when studying cartilage to identify the biological relevance of the model. 
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qRT-PCR and protein analysis revealed that hypertrophic differentiation, which can be problematic 
in chondrogenesis cultures in vitro, whilst expression of chondrogenic or articular factors increased. 
3.3.4.1 Type II Collagen and Type X Collagen 
Expression of Col10a1 was seen to be increased with increasing chondrogenesis in ATDC5 cells 
(Figure 3.11 A), which has previously been reported in ATDC5 cells induced to differentiate with 
both insulin and BMP-2 (Shibuya, et al., 2013), and in ATDC5 micromass culture (Sun & Beier, 2014). 
However, little type X collagen protein was detected after 14 days of induction, and was primarily 
immunolocalised to the centre of the micromass, possibly in the pericellular region with some faint 
staining in the interstitial region (Figure 3.13). Co-localisation with other PCM components, such as 
type VI collagen or perlecan, would be needed to confirm type X collagen in the PCM of this culture, 
although type X collagen has been previously found to be localised to the pericellular region of 
chondrocytes (Morrison, et al., 1996; Boos, et al., 1997).  
In comparison, type II collagen, which is characteristically decreased during hypertrophic 
differentiation (Weiss, et al., 2010) was widespread throughout the micromass and cartilage-like 
nodules in monolayer culture in the institial ECM (Figure 3.13), and was significantly up-regulated 
by both micromass culture and ascorbic acid, which was further increased when combined together 
at the mRNA level (Figure 3.10 A). 
3.3.4.2 Frzb and Grem1 
Upon ATDC5 cell differentiation, Frzb expression was induced and was significantly up-regulated by 
micromass culture (Figure 3.10 B). Frzb has been previously identified as a marker of articular 
cartilage, which is highly expressed in articular cartilage, along with Grem1 (gremlin 1), compared 
to growth plate cartilage (Leijten, et al., 2012) and osteophytic cartilage (Gelse, et al., 2012), 
suggesting results presented in this thesis may show articular differentiation in ATDC5 cells, which 
have commonly been used instead to model endochondral ossification when inducing hypertrophy.  
Attempts at confirming FRZB expression at the protein level were made, however, reliable 
detection and its effects of the phosphorylated state of β-catenin (which would indicate either 
activation or inhibition of the canonical β-catenin-dependent WNT signalling pathway) using 
antibodes bought from Abcam could not be achieved by western blotting (data not shown). 
Overexpression of Frzb in ATDC5 micromasses has been shown to significantly enhance the levels 
of the chondrogenic markers Col2a1 and Acan (aggrecan), whilst silencing of Frzb inhibited 
chondrogenesis (Lodewyckx, et al., 2012). Furthermore, stimulation of differentiating hBMSCs with 
FRZB down-regulated the hypertrophic markers ALPL and COL10A1 and decreased mineralisation, 
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with the authors suggesting that FRZB acts as a natural brake on hypertrophic differentiation 
(Leijten, et al., 2012). 
Interestingly, this thesis showed that Grem1 expression decreased with increasing chondrogenesis 
(Figure 3.10 C). However, although Grem1 has been found to be highly expressed in articular 
cartilage, recombinant human Gremlin-1 has been found to inhibit chondrogenesis in chick 
embryos (Merino, et al., 1999). It may therefore be interesting to examine how Grem1 expression 
changes throughout the course of chondrogenesis. 
3.3.4.3 CCN Growth Factors 
3.3.4.3.1 Cyr61 
With increasing chondrogenesis, a trend to a reduction in Cyr61 expression was seen (Figure 3.12 
A), in agreement with previous findings in hBMSCs, in which it was highly expressed prior to 
differentiation (Schütze, et al., 2005). Treatment of mouse limb bud cells with CYR61/CCN1 has 
been shown to increase cell aggregation in suspension culture and micromasses (Wong, et al., 1997), 
indicating a role in the early stages of chondrogenesis, which may explain the down-regulation in 
the most differentiated cultures (with ascorbic acid stimulation in insulin-induced cells), and not in 
less differentiated cells in monolayer without ascorbic acid stimulation (Figure 3.12 A). Additionally, 
Cyr61-/- mice die early in development, making detailed skeletal analysis difficult, although no 
obvious skeletal phenotype was observed by the time of death (Mo, et al., 2002). 
3.3.4.3.2 Ctgf 
Ctgf expression was found to be significantly decreased in differentiating monolayer cultures of 
ATDC5 cells (Figure 3.12 B). No effect was observed in differentiating micromass cultures, likely due 
to the already decreased expression of Ctgf as a result of micromass culture compared to 
undifferentiated monolayer cultures. This reduction in Ctgf expression with three-dimensional 
culture has previously been described in breast cancer cells irrespective of the nature of the three-
dimensional culture (Barbolina, et al., 2009). Interestingly, Ctgf expression has previously been 
reported to be increased in ATDC5 monolayer cultures that have been induced to differentiate with 
insulin for 14 days compared to earlier timepoints (Lafont, et al., 2005b), although this was not 
compared to undifferentiated cells that had been grown for the same timeframe, as in this thesis. 
CTGF/CCN2 involvement in hypertrophy has been well established and is strongly expressed in 
hypertrophic chondrocytes (Moritani, et al., 2003; Huang, et al., 2010), correlating with Col10a1 
expression over the timecourse of differentiation (Huang, et al., 2010). CTGF/CCN2, via stimulation 
and overexpression, has been shown to increase type X collagen mRNA/protein expression in a 
 
95 
 
human chondrosarcoma cell line (Nakanishi, et al., 2000), rabbit growth plate chondrocytes 
(Nishida, et al., 2002) and rabbit auricular chondrocytes (Fujisawa, et al., 2008), although 
interestingly not in rabbit articular chondrocytes (Nishida, et al., 2002). Global knockout of Ctgf in 
mice results in perinatal lethality minutes after birth from respiratory troubles brought upon by 
severe skeletal abnormalities. In these mice, an enlarged and disorganised hypertrophic zone is 
observed, with a decrease in aggrecan and link protein. Despite an enlarged hypertrophic zone, 
Ctgf-/- mice also have decreased amounts of VEGF in hypertrophic chondrocytes, another marker of 
hypertrophy that is important in growth plate angiogenesis (Ivkovic, et al., 2003). Down-regulation 
of Ctgf with increasing chondrogenesis in ATDC5 cells may therefore suggest inhibition of 
hypertrophic differentiation in this system. 
Additionally, CTGF/CCN2 has also been implicated in the initial condensation stages of 
chondrogenesis (Song, et al., 2007a), perhaps explaining the significant increase in expression in 
cells which had been stimulated with ascorbic acid in the absence of insulin (Figure 3.12 B) which 
have shown signs of early chondrogenesis from increased Col2a1 expression (Figure 3.10 A). 
3.3.4.3.3 Nov, Wisp1, Wisp2 and Wisp3 
Expression patterns of Nov, Wisp1 and Wisp2 were not consistent across experiments, and Wisp3 
was not detected in any experiment. However, previous reports have shown Nov to be increased 
over time during insulin-induced chondrogenesis in ATDC5 cells, peaking at day 8 (Lafont, et al., 
2005b), and has been shown to be expressed in the prehypertrophic and hypertrophic zones of the 
murine embryonic growth plate (Yu, et al., 2003). Gelse, et al., (2012) found Wisp3 to be highly 
expressed in articular cartilage compared to osteophytic cartilage, however, Wisp3 could not be 
detected in this present system using two different sets of primer/probes, one designed using the 
Universal ProbeLibrary (Roche) and one designed by PrimerDesign LTD (Southampton, UK). 
3.3.4.4 Mmp13 
In addition to increasing type X collagen and decreasing Type II Collagen, hypertrophic 
differentiation is also defined (amongst other factors) by an increase in alkaline phosphatase 
activity, which produces PO43- leading to mineralisation; MMP13 expression, involved in the 
remodelling of the matrix; and RUNX2 expression, which is the major transcription factor driving 
hypertrophic differentiation (Weiss, et al., 2010; Studer, et al., 2012). In this system, no Mmp13 
was detected across any condition, although it has been detected by others in ATDC5 cells at similar 
time points in differentiating monolayer cultures (Wang, et al., 2004), and has been shown to be 
enhanced by ascorbate stimulation in ATDC5 cells which were pre-stimulated for 7 days with 
ascorbate 2-phosphate before induction with insulin (Altaf, et al., 2006). As confirmation of a 
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working primer/probe set used in this study, the primer/probe sequences used for Mmp13 have 
previously been used successfully by another group in this department (personal communcation). 
3.3.4.5 Alpl (Alkaline Phosphatase) 
On the otherhand, Alpl, which encodes the liver/bone/kidney isoform of alkaline phosphatase, was 
significantly increased by ascorbic acid in differentiating monolayer cultures, but was not regulated 
by ascorbic acid in differentiating micromass cultures, likely due to the signficant increase by insulin 
in micromass cultures (Figure 3.11 D). However, further analysis would be needed to identify the 
effect of increased Alpl expression on mineralisation of ATDC5 ECM by measuring alkaline 
phosphatase activity, which has previously been detected in differentiating ATDC5 cells in 
monolayer (Mushtaq, et al., 2002; Nakatani, et al., 2007; Mitani, et al., 2013). 
3.3.4.6 TGFβ 
3.3.4.6.1 Tgfb3 
With increasing chondrogenesis, a decreasing trend in the level of Tgfb3 was observed, which was 
also significantly down-regulated by micromass culture in undifferentiated cells (Figure 3.11 E). The 
use of adding various isoforms of TGFβ exogenously to stimulate chondrogenesis is widely reported, 
particularly with the use of TGFβ3 (Chowdhury, et al., 2013; Song, et al., 2013; Tay, et al., 2014), 
including in ATDC5 cells (Tare, 2005; Zhai, et al., 2013). Tgfb3 has been shown to be down-regulated 
at the same timepoint (day 14) in ATDC5 cells by microarray analysis (Chen, et al., 2005), becoming 
up-regulated in ATDC5 cells when induced to undergo hypertrophic differentiation (Han, et al., 
2008). Further to this, TGFβ3-mediated induction of hBMSCs, in addition with BMP6, has been 
shown to promote a more growth plate phenotype, with down-regulation of the articular markers 
DKK1 (dickkopf 1), FRZB and GREM1 (gremlin 1), and up-regulation of LEF1 and PANX3 (pannexin 
3), which are up-regulated in growth plate cartilage compared to articular cartilage (Leijten, et al., 
2012). 
3.3.4.6.2 Tgfb1 
Tgfb1 expression was significantly increased by insulin induction in micromass cultures in the 
presence of ascorbic acid and trended towards increased expression by the addition of ascorbic 
acid in insulin-induced micromass cultures (Figure 3.10 D). TGFβ1-mediated induction of 
chondrogenesis has been reported to result in significantly less matrix mineralisation compared to 
TGFβ3-mediated chondrogenic induction of hBMSCs (Cals, et al., 2012) and has been shown to 
inhibit hypertrophic differentiation in rat epiphyseal chondrocytes (Ballock, et al., 1993).  
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The findings in this thesis correlate with these previous reports suggesting an inhibition of 
hypertrophy with decreasing Tgfb3 and increase in Tgfb1 expression. 
3.3.4.7 RUNX2 
No changes in Runx2 expression were obserbed between 7, 14 and 21 days of culture in monolayer 
or micromass in insulin-induced cells (Figure 3.5). At day 14, Runx2 expression was not regulated 
by any culturing condition, which was also confirmed at the protein level in two of three 
experiments (Figure 3.11 C), suggesting hypertrophic differentiation was not induced. Reports have 
previously shown Runx2 expression increases with time in differentiating ATDC5 cells in monolayer 
culture by day 14 (Wigner, et al., 2013), however, this study supplemented chondrogenic medium 
with β-glycerophosphate, a known inducer of matrix mineralisation (Farrell, et al., 2011), which is 
typically added in media to induce osteogenesis of MSCs (Cho, et al., 2014; Gawronska-Kozak, 2014; 
Peng, et al., 2014). 
RUNX2 is a transcription factor, strongly expressed in hypertrophic cartilage (Higashikawa, et al., 
2009) that regulates transcription of various hypertrophy-related genes, including Mmp13 
(Boumah, et al., 2009; Shimizu, et al., 2010) and Col10a1 (Takeda, et al., 2001; Higashikawa, et al., 
2009). As such, it would be interesting to immunolocalise its expression to see whether RUNX2 
translocates to the nuclei of the few type X collagen-positive cells or in any other cells in the 
differentiated conditions. This would indicate activation of RUNX2 which may promote expression 
of various hypertrophy-related genes and may give a clearer indication of any potential further 
(pre)hypertrophic regions within the three-dimensional cultures, which appeared to be minimal 
and restricted according to the type X collagen staining.  
3.3.4.8 DDR2 
DDR2 is a receptor tyrosine kinase that preferentially binds type II collagen which can stimulate 
hypertrophic differentiation in response to DDR2 ligation (Pulsatelli, et al., 2013). Such an 
interaction is normally preventented by an intact PCM (Xu, et al., 2011). This thesis has shown that 
at the mRNA level, Ddr2 expression is down-regulated in monolayer cultures when induced with 
insulin in the presence of ascorbic acid. No changes were observed due to insulin or ascorbic acid 
due to the already decreased levels in micromass culture (Figure 3.11 B). At the protein level, DDR2 
was down-regulated with increasing chondrogenesis (Figure 3.16). Ddr2 mRNA expression has 
previously been shown to be very slightly up-regulated at day 14 in ATDC5 monolayer cultures 
compared to earlier timepoints (Zhang, et al., 2011). However, this was not compared to ATDC5 
cells that had been maintained undifferentiated for the same time period, as in this thesis. 
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Knockdown of Ddr2 in ATDC5 cells has been shown to decrease mRNA expression of Runx2 (Kawai, 
et al., 2012) and inhibit RUNX2 protein activation and binding to DNA, leading to a decrease Col10a1 
expression (Zhang, et al., 2011). Additionally, overexpression of DDR2 has been shown to increase 
MMP13 expression in human OA chondrocytes (Xu, et al., 2005), which was not detected in this 
study, further suggesting inhibition of hypertrophy in micromass and ascorbic acid-stimulated 
ATDC5 cultures. 
3.3.4.9 WNT5A 
At the protein level, WNT5A was observed to be increased upon insulin induction of ATDC5 cells 
(Figure 3.17). Studies have shown that stimulation of micromass cultures with exogenous WNT5A, 
or overexpression of WNT5A, can increase chondrogenesis in both chick and mouse limb cells 
(Church, et al., 2002; Bradley & Drissi, 2010). Additionally, WNT5A has been shown to inhibit 
hypertrophic differentiation via NF-κB-mediated inhibition of RUNX2 (Hartmann & Tabin, 2000; 
Bradley & Drissi, 2010). This increase in WNT5A upon insulin induction further suggests inhibition 
of hypertrophy. More detailed discussions on WNT5A can be found in Chapters 1, 4 and 5. 
3.4 Summary 
Many genes were regulated during the chondrogenesis of ATDC5 cells, briefly summarised in Table 
3.1. Taken together, despite the increases in Col10a1 and Alpl (alkaline phosphatase), the down-
regulation of several hypertrophy-associated genes and proteins and the limited type X collagen 
that was detected suggest that hypertrophy was inhibited in this system by differentiating ATDC5 
cells for 14 days with insulin with the combination of micromass culture and stimulation with 
ascorbic acid. High expression of Frzb and widespread type II collagen staining may suggest that this 
culture system instead generates a more articular cartilage-like phenotype. This is in contrast to 
many reports that use ATDC5 cells to model changes that occur during endochondral ossification 
and the use of ascorbic acid in ATDC5 mineralisation (Shukunami, et al., 1997; Faith, et al., 2012; 
Swingler, et al., 2012; Miron, et al., 2013) highlighting the diverse nature of ATDC5 cells and their 
usefulness in their adaptibility to study different cartilage phenotypes.  
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Gene 
Association/Family 
Up-regulated Down-regulated No Regulation 
Chondrogenesis 
Col2a1 
Frzb 
Tgfb1 
Grem1  
Hypertrophy 
Col10a1 
Alpl 
Ddr2 (monolayer) 
Tgfb3 
Ddr2 (micromass) 
Runx2 
CCNs 
 Cyr61 
Ctgf (monolayer) 
Ctgf (micromass) 
Table 3.1 – Summary of gene regulatory changes with increasing chondrogenesis of ATDC5 
cells cultured for 14 days in monolayer or micromass and stimulated with/without insulin and 
ascorbic acid using information from Figures 3.10-12. For more specific changes per condition 
tested, please see original individual figures given above. 
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Chapter 4 
Investigating WNT5A and cytokine signalling in ATDC5 cells 
Chapter 4 – Investigating WNT5A and cytokine signalling in ATDC5 cells 
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4.1 Introduction 
4.1.1 WNT signalling in osteoarthritis and skeletal disease 
WNT signalling is tightly implicated with the progression of osteoarthritis (see Chapter 1). As such, 
many members of the WNT signalling family, as well as known modulators of the WNT signalling 
pathway, are aberrantly expressed in osteoarthritic joints, including WNT3A (Nakamura, et al., 
2005), FRZB (Nakamura, et al., 2005; Velasco, et al., 2010) and WISP3 (Sen, et al., 2004; Baker, et 
al., 2012), reviewed in (Staines, et al., 2012). Expression of WNT5A is also highly up-regulated in 
osteoarthritic cartilage compared to normal cartilage as seen by microarray (Karlsson, et al., 2010; 
Thorfve, et al., 2011), qRT-PCR and immunofluorescence (Thorfve, et al., 2011). WNT5A expression 
has also been shown to be increased in knee OA osteoblasts but decreased in hip OA osteoblasts 
compared to hip fracture osteoblasts (Velasco, et al., 2010). Furthermore, Wnt5a-/- mice have a 
strong skeletal phenotype, exhibiting truncated limbs (Yamaguchi, et al., 1999). Missense 
mutations in WNT5A have also been associated with Robinow syndrome, a form of dwarfism 
(Person, et al., 2010). 
Many studies have investigated WNT5A in a developmental context, identifying the role of WNT5A 
in promoting early stage chondrogenesis and inhibiting hypertrophic differentiation (Hartmann & 
Tabin, 2000; Church, et al., 2002; Bradley & Drissi, 2010). However, little work has been reported 
on the mechanisms and potential role of WNT5A induction in cartilage pathophysiology. It has been 
reported that WNT5A is up-regulated in chondrocytes by IL-1β stimulation via the NF-κB pathway 
(Ge, et al., 2011). Furthermore, WNT5A has been shown to be a potent inducer of matrix 
degradation in chick beak cartilage via up-regulation of various metalloproteinases, including 
ADAMTS5 (Hosseini-Farahabadi, et al., 2013), a major enzyme involved in the destruction of 
cartilage in osteoarthritis, discussed previously. However, the exact mechanisms and the impact on 
other signalling pathways in osteoarthritis remain to be elucidated. 
4.1.2 Cytokine signalling in osteoarthritis 
The involvement of inflammatory cytokines in the development of osteoarthritis is well 
documented. Interleukin (IL)-1β, one of the key inflammatory cytokines in osteoarthritis, is elevated 
in osteoarthritic chondrocytes (Melchiorri, et al., 1998) and is commonly used to model 
osteoarthritic-like changes in vitro (Clutterbuck, et al., 2013; Yang, et al., 2014; Zhang, et al., 2014). 
The combination of IL-1α and oncostatin M (OSM) is also used to the same effect  to induce 
expression of a number of metalloproteinases, including ADAMTS4 and ADAMTS5 (Hui, et al., 2001; 
Koshy, et al., 2002; Milner, et al., 2003; Baker, et al., 2012). In 2012, Baker, et al., reported IL-1α 
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and OSM-induced expression of ADAMTS5 was repressed by overexpression of WISP3 (WNT1-
inducible secreted protein 3) via the beta-catenin-dependent pathway. As previously mentioned, 
IL-1β has also been shown to induce expression of WNT5A in rabbit chondrocytes (Ge, et al., 2011) 
and increase WNT5A and its receptor ROR2 expression during osteogenesis (Sonomoto, et al., 2012). 
Together, this highlights growing evidence for the interplay between the cytokine and WNT 
signalling pathways, however, this interplay and its involvement in osteoarthritis is not fully 
understood. 
4.1.3 Aims 
It was hypothesised that WNT5A may regulate gene expression during osteoarthritis and that 
cytokine signalling may also regulate the WNT signalling pathway in ATDC5 cells. 
To test this, a number of approaches were taken: 
1. Stable clones of ATDC5 overexpressing WNT5A were generated and gene expression 
changes investigated. 
2. Naïve, differentiated ATDC5 cells were stimulated with neat WNT5A-conditioned medium 
generated by transiently transfecting separate ATDC5 cells, and stimulated in combination 
with IL-1α and OSM cytokines to induce osteoarthritic-like changes. 
3. A mixture of candidate and unbiased studies were carried out via qRT-PCR and microarray 
analysis respectively to investigate gene regulation as a result of WNT5A and/or cytokine 
signalling.  
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4.2 Results 
4.2.1 Generation of stable clones overexpressing WNT5A 
Non-induced ATDC5 cells were transfected with human WNT5A tagged at the C-terminus with an 
in-frame FLAG tag for ease of detection and selected for based on resistance to Zeocin™. Several 
clones were eventually generated after two separate attempts at cloning from single cells, and were 
expanded in culture before confirming WNT5A protein expression, and the lack of WNT5A in cells 
transfected with the empty pcDNA4-FLAG vector only (hereafter referred to as Vector Only). Six 
clones were chosen for further analysis; three Vector Only clones and three WNT5A clones (Figure 
4.1). For more information on the generation of the plasmids and the transfection/cloning process, 
please see sections 2.4 and 2.5. 
  
Figure 4.1 – Confirmation of WNT5A overexpressing clones. Cell lysates from stable ATDC5 
clones overexpressing WNT5A or Vector Only control were examined for WNT5A expression 
using the anti-FLAG antibody. Protein lysates were taken from clones expanded in monolayer 
from single cells. Transiently transfected cells transfected were used as positive and negative 
controls. Predicted Mr WNT5A-FLAG = 44.99 kDa based on amino-acid sequence. N=2 
 
104 
 
4.2.2 Gene regulation in non-induced overexpressing WNT5A clones 
Expression of candidate genes associated with WNT5A signalling and the chondrocytic phenotype 
were explored by qRT-PCR in non-induced clones plated in monolayer or micromass for four days. 
Three Vector Only clones and three WNT5A clones were used for the analysis and the experiment 
was performed once as a preliminary experiment. Results are expressed as the average of three 
separate WNT5A clones and three separate Vector Only clones, with results from individual clones 
displayed on the right-hand side. 
Overexpression of WNT5A did not result in any regulation of its receptor, Ror2 (Figure 4.2 A). 
Although clones were not induced to differentiate with insulin, low Col2a1 expression was detected 
with CT values averaging around 33 (Appendix Table S4.1). CT values of Col2a1 in WNT5A clones was 
detected largely above CT 35, which is deemed not to be expressed, suggesting WNT5A 
overexpression may inhibit Col2a1 expression (Figure 4.2 B).  Expression of Adamts4 and Adamts5 
were low, with CT values close to 35 or above. No regulation of Adamts4 was seen by WNT5A, 
although interestingly, Adamts5 may be down-regulated by WNT5A which was not detected in 
most WNT5A clones (Figure 4.2 C-D). Neither Runx2 nor Ddr2, two genes involved in hypertrophic 
differentiation, were regulated by WNT5A overexpression (Figure 4.2 E-F). Grem1, which is 
enriched in articular cartilage, was up-regulated by WNT5A, whilst Alpl (alkaline phosphatase), an 
enzyme involved in matrix mineralisation, was down-regulated by WNT5A (Figure 4.2 G-H). Of the 
CCN growth factor family, Cyr61, which encodes CYR61/CCN1, was up-regulated by WNT5A in both 
monolayer and micromass culture, whereas Ctgf (CTGF/CCN2) and Nov (NOV/CCN3) were not 
(Figure 4.2 I-K). A slight down-regulation of Wisp1 (WISP1/CCN4) was seen in monolayer culture 
and of Wisp2 (WISP2/CCN5) in micromass culture in WNT5A overexpressing clones compared to 
Vector Only (Figure 4.2 L-M). The final member of the CCN family, Wisp3 (WISP3/CCN6) could not 
be detected (data not shown). 
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Ror2 
(Receptor tyrosine kinase-like orphan 2) 
Col2a1 
(Type II Collagen) 
A 
B 
Figure 4.2 A-B – Gene regulation in stable WNT5A-overexpressing, non-induced ATDC5 
clones. Steady-state mRNA expression levels of Ror2 (A) and Col2a1 (B) in WNT5A-
overexpressing, non-induced ATDC5 clones cultured in monolayer or micromass for four 
days compared to Vector Only clones as measured by qRT-PCR. Left hand figure composed 
from averaging all three clones per condition shown in right-hand figure. CT values can be 
found in Appendix, Table S4.1. Experiment performed once. ND = Not Detected 
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  Adamts4 
(A disintegrin and metalloproteinase with thrombospondin motif 4) 
Adamts5 
(A disintegrin and metalloproteinase with thrombospondin motif 5) 
C 
D 
Figure 4.2 C-D – Gene regulation in stable WNT5A-overexpressing, non-induced ATDC5 
clones. Steady-state mRNA expression levels of Adamts4 (C) and Adamts5 (D) in WNT5A-
overexpressing, non-induced ATDC5 clones cultured in monolayer or micromass for four 
days compared to Vector Only clones as measured by qRT-PCR. Left hand figure composed 
from averaging all three clones per condition shown in right-hand figure. ND = Not 
detected. CT values can be found in Appendix, Table S4.1.  Experiment performed once. 
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  Runx2 
(Runt-related transcription factor 2) 
Ddr2 
(Discoidin domain receptor 2) 
E 
F 
Figure 4.2 E-F – Gene regulation in stable WNT5A-overexpressing, non-induced ATDC5 
clones. Steady-state mRNA expression levels of Runx2 (E) and Ddr2 (F) in WNT5A-
overexpressing, non-induced ATDC5 clones cultured in monolayer or micromass for four 
days compared to Vector Only clones as measured by qRT-PCR. Left hand figure composed 
from averaging all three clones per condition shown in right-hand figure. CT values can be 
found in Appendix, Table S4.1.  Experiment performed once. 
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  Grem1 
(Gremlin-1) 
Alpl 
(Alkaline phosphatase, liver/bone/kidney) 
G 
H 
Figure 4.2 G-H – Gene regulation in stable WNT5A-overexpressing, non-induced ATDC5 
clones. Steady-state mRNA expression levels of Grem1 (G) and Alpl (H) in WNT5A-
overexpressing, non-induced ATDC5 clones cultured in monolayer or micromass for four 
days compared to Vector Only clones as measured by qRT-PCR. Left hand figure composed 
from averaging all three clones per condition shown in right-hand figure. CT values can be 
found in Appendix, Table S4.1.  Experiment performed once. 
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  Cyr61 
(Cysteine-rich protein 61/CCN1) 
Ctgf 
(Connective Tissue Growth Factor/CCN2) 
I 
J 
Figure 4.2 I-J – Gene regulation in stable WNT5A-overexpressing, non-induced ATDC5 
clones. Steady-state mRNA expression levels of Cyr61 (I) and Ctgf (J) in WNT5A-
overexpressing, non-induced ATDC5 clones cultured in monolayer or micromass for four 
days compared to Vector Only clones as measured by qRT-PCR. Left hand figure composed 
from averaging all three clones per condition shown in right-hand figure. CT values can be 
found in Appendix, Table S4.1.  Experiment performed once. 
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  Nov 
(Nephroblastoma overexpressed/CCN3) 
Wisp1 
(Wnt1-inducible secreted protein/CCN4) 
K 
L 
Figure 4.2 K-L – Gene regulation in stable WNT5A-overexpressing, non-induced ATDC5 
clones. Steady-state mRNA expression levels of Nov (K) and Wisp1 (L) in WNT5A-
overexpressing, non-induced ATDC5 clones cultured in monolayer or micromass for four 
days compared to Vector Only clones as measured by qRT-PCR. Left hand figure composed 
from averaging all three clones per condition shown in right-hand figure. ND = not 
detected. CT values can be found in Appendix, Table S4.1.  Experiment performed once. 
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Wisp2 
(Wnt1-inducible secreted protein 2/CCN5) 
M 
Figure 4.2 M – Gene regulation in stable WNT5A-overexpressing, non-induced ATDC5 
clones. Steady-state mRNA expression levels of Wisp2 in WNT5A-overexpressing, non-
induced ATDC5 clones cultured in monolayer or micromass for four days compared to 
Vector Only clones as measured by qRT-PCR. Left hand figure composed from averaging 
all three clones per condition shown in right-hand figure. CT values can be found in 
Appendix, Table S4.1.  Experiment performed once. 
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4.2.3 Stable clones failed to undergo chondrogenesis 
The effect of WNT5A overexpression on gene regulation was examined in clones induced to 
undergo chondrogenesis with insulin and stimulated with ascorbic acid for 14 days. Twenty four 
hour stimulation with IL-1α and OSM (hereafter referred to as “cytokines” in experiments) was also 
used after differentiation had occurred to investigate gene regulation in osteoarthritic-like 
conditions and whether this affected WNT5A-mediated gene regulation. For more information, 
please see section 2.5.7.  
Despite not directly comparing insulin-induced clones to non-induced clones, it was apparent that 
both WNT5A and Vector Only clones failed to differentiate. This was evident by visual observations, 
whereby cells had a larger, flatter appearance with a lack of aggregation in monolayer cultures (data 
not shown). Expression of Col2a1 was also low with CT values above 30 (Table 4.1), with many 
samples over the detection limit (CT ≥ 35). Non-induced clones investigated previously also had a 
similar CT range (Appendix Table S4.1). One WNT5A clone (Clone 6) partially differentiated, but 
despite the slight increase in Col2a1 compared to the rest of the clones (Figure 4.3), still did not 
visually appear to differentiate fully, with flat cells and a lack of aggregation (data not shown). Since 
adequate chondrogenesis did not occur even in Vector Only clones, further investigations in insulin-
induced clones were not conducted. 
 
  
Col2a1 Min CT Max CT Normalised SEM 
Monolayer 
Vector Only 
No Cytokines 30.16 38.58 0.30 0.09 
Cytokines 33.11 39.67 0.04 0.01 
WNT5A 
No Cytokines 28.20 36.59 1.33 0.97 
Cytokines 28.75 39.02 1.33 0.44 
Micromass 
Vector Only 
No Cytokines 30.89 39.90 0.38 0.16 
Cytokines 31.59 35.61 0.16 0.08 
WNT5A 
No Cytokines 26.64 38.43 2.95 2.43 
Cytokines 27.20 39.07 3.82 2.47 
Table 4.1 – Expression of Col2a1 in insulin-induced clones cultured for 14 days in 
monolayer or micromass then stimulated with or without IL-1α and OSM cytokines for 24 
h without insulin. Steady-state expression levels of Col2a1, highlighting the CT range for 
three individual clones, combined, and their normalised values. Expression of individual 
clones can be found in Figure 4.3.  Experiment performed once 
 
113 
 
 
  
Col2a1 
(Type II Collagen) 
Figure 4.3 – Col2a1 expression in insulin-induced clones with cytokine stimulation. 
Normalised steady-state expression levels of Col2a1 are shown for individual insulin-
induced clones grown for 14 days then stimulated with and without IL-1α and OSM 
cytokines without insulin for 24 h. CT values for combined clones can be found in Table 
4.1. Experiment performed once. 
(A
.U
.)
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4.2.4 Generation of WNT5A conditioned medium for naïve ATDC5 cell stimulation 
Since chondrogenesis failed to occur in both Vector Only and WNT5A-overexpressing ATDC5 clones, 
investigations were then carried out using naïve ATDC5 cells instead, stimulating 14-day old insulin-
induced, ascorbic acid-stimulated ATDC5 micromass cultures with conditioned media for 24 hours 
generated from transiently transfecting separate ATDC5 cells, with and without cytokines for the 
same 24 hour period (see section 2.6) 
Prior confirmation of WNT5A protein secretion into media from transient transfections was carried 
out by western blot before stimulating naïve differentiated cells. Additionally, the time to start the 
24 hour media conditioning was optimised to see if there was a difference in protein 
expression/secretion with the 24 hour period starting either directly after the 5 hour transfection 
(Day 1) or 24 (Day 2) or 48 hours (Day 3) after the transfection. No appreciable differences were 
observed between conditioning media for 24 hours starting immediately after the five hour 
transfection (Day 1) or the following day (Day 2), with perhaps a slight decrease in WNT5A protein 
by Day 3 (Figure 4.4). Therefore subsequent experiments used media conditioned for 24 hours 
starting immediately after the five hour transfection, confirming the presence or absence of WNT5A 
(via anti-FLAG) with each batch of WNT5A or Vector Only conditioned media respectively (data not 
shown). 
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Figure 4.4 – Detection of WNT5A protein from transient transfection timecourse. 
WNT5A was probed for (via anti-FLAG antibody) in TCA-precipitated conditioned media 
generated from 7 ml media (A) and cell lysates (B) at indicated time points after 
transiently transfecting non-induced ATDC5 cells with Vector Only or WNT5A plasmids for 
5 h. Predicted Mr WNT5A-FLAG = 44.99 kDa based on amino acid sequence. Day 1 = First 
24 h period. Day 2 = Second 24 h period. Day 3 = Third 34 h period. N=1 
A 
B 
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4.2.5 Gene regulation in conditioned media- and cytokine-stimulated naïve ATDC5 
cells 
Naïve, 14-day differentiated ATDC5 micromass cultures (as described previously) were stimulated 
after differentiation for 24 hours with WNT5A conditioned medium and co-stimulated with and 
without cytokines to investigate the effect of osteoarthritic-like changes on gene regulation and 
identify whether WNT5A-mediated gene regulation is dependent on, or regulated in, an 
osteoarthritic-like environment. For a more in-depth description of the stimulation method, please 
see section 2.6.  
In experiment 1, regulation by WNT5A conditioned medium stimulation was seen across a number 
of candidate genes tested by qRT-PCR analysis, chosen based on their involvement in 
chondrogenesis, WNT5A signalling or osteoarthritis. Subsequent repeats however, failed to 
reproduce the results from experiment 1. However, expression of Ror2, Col2a1 and Adamts4 were 
consistently not regulated by WNT5A over four experiments (Figure 4.5 A-C). In experiment 1, 
expression of Runx2, Ddr2, Ctgf and Nov were all down-regulated by WNT5A conditioned medium 
stimulation in the presence of cytokines. No effects were seen by WNT5A stimulation in the absence 
of cytokines (Figure 4.5 D, E, G, H; left-hand figures). No significant differences in Runx2, Ddr2, Ctgf 
and Nov expression were observed in three subsequent repeats by WNT5A stimulation in the 
presence or absence of cytokines (Figure 4.5 D, E, G, H; right-hand figures). No regulation of Cyr61, 
Wisp1, Wisp2, Frzb or Col10a1 by WNT5A stimulation in any experiment by qRT-PCR (Figure 4.5 F, 
I-L). 
Cytokine stimulation caused a trend towards down-regulation of Ror2 in the presence or absence 
of WNT5A in three out of four experiments, although this only reached statistical significance in 
one of the examples shown in the presence of WNT5A by ANOVA + Tukey post-hoc test (Figure 4.5 
A). Similarly, cytokine stimulation caused an overall down-regulation of Col2a1 (Figure 4.5 B). In 
contrast, as expected, a rise in Adamts4 expression, an aggrecanase, was seen consistently with 
cytokine stimulation (Figure 4.5 C). Expression of Runx2 was down-regulated consistently by 
cytokine stimulation (Figure 4.5 D). Regulation of Ddr2 by cytokine stimulation was largely 
inconsistent, being down-regulated in two out of four experiments in the presence of WNT5A but 
up-regulated in one experiment in the absence of WNT5A (Figure 4.5 E). No conclusions can 
therefore be drawn regarding Ddr2 regulation by cytokine stimulation. Similarly, in two of four 
experiments, Ctgf was down-regulated by cytokine stimulation regardless of WNT5A, but was up-
regulated by cytokine stimulation in one experiment in the absence of cytokines (Figure 4.5 G). Nov, 
on the other hand, was also up-regulated in one experiment in the absence of WNT5A by cytokine 
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stimulation, but no differences were seen in the other three experiments, suggesting that cytokine 
stimulation does not regulate Nov expression (Figure 4.5 H). In contrast, expression levels of Cyr61, 
Wisp1, Wisp2, Frzb and Col10a1 consistently decreased with cytokine expression (Figure 4.5 F, I-L).  
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Ror2 
(Receptor tyrosine kinase-like orphan 2) 
Col2a1 
(Type II Collagen) 
Adamts4 
(A disintegrin and metalloproteinase with thrombospondin motif 4) 
A 
B 
C 
Figure 4.5 A-C – Gene regulation in WNT5A and cytokine stimulated differentiated ATDC5 
micromass cultures. Steady-state mRNA expression levels of Ror2 (A), Col2a1 (B) and Adamts4 
(C) in micromass cultures stimulated with insulin and ascorbic acid for 14 days then treated with 
WNT5A conditioned medium (or Vector Only control) with/without IL-1α and OSM cytokines 
for 24 h. Experiment performed four times. Left-hand figure from experiment 1. Right-hand 
figure from representative example from three further repeats, also sent for microarray 
analysis. CT values can be found in Appendix, Table S4.2. * = significant compared to Vector 
Only. # = significant compared to no cytokines. 
Experiment 1 Representative Experiment 
Also analysed by microarray 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
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Runx2 
(Runt-related transcription factor 2) 
Ddr2 
(Discoidin domain receptor 2) 
D 
E 
Figure 4.5 D-E – Gene regulation in WNT5A and cytokine stimulated differentiated ATDC5 
micromass cultures. Steady-state mRNA expression levels of Runx2 (D) and Ddr2 (E) in 
micromass cultures stimulated with insulin and ascorbic acid for 14 days then treated with 
WNT5A conditioned medium (or Vector Only control) with/without IL-1α and OSM cytokines 
for 24 h. Experiment performed four times. Left-hand figure from experiment 1. Right-hand 
figure from representative example from three further repeats, also sent for microarray 
analysis. CT values can be found in Appendix, Table S4.2. * = significant compared to Vector 
Only. # = significant compared to no cytokines. 
Experiment 1 Representative Experiment 
Also analysed by microarray 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
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Cyr61 
(Cysteine-rich protein 61/CCN1) 
F 
Ctgf 
(Connective Tissue Growth Factor/CCN2) 
G 
Figure 4.5 F-G – Gene regulation in WNT5A and cytokine stimulated differentiated ATDC5 
micromass cultures. Steady-state mRNA expression levels of Cyr61 (F) and Ctgf (G) in micromass 
cultures stimulated with insulin and ascorbic acid for 14 days then treated with WNT5A 
conditioned medium (or Vector Only control) with/without IL-1α and OSM cytokines for 24 h. 
Experiment performed four times. Left-hand figure from experiment 1. Right-hand figure from 
representative example from three further repeats, also sent for microarray analysis. CT values 
can be found in Appendix, Table S4.2. * = significant compared to Vector Only. # = significant 
compared to no cytokines. 
Experiment 1 Representative Experiment 
Also analysed by microarray 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
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n=1 
Nov 
(Nephroblastoma Overexpressed/CCN3) 
H 
I 
Figure 4.5 H-I – Gene regulation in WNT5A and cytokine stimulated differentiated ATDC5 
micromass cultures. Steady-state mRNA expression levels of Nov (H) and Wisp1 (I) in 
micromass cultures stimulated with insulin and ascorbic acid for 14 days then treated with 
WNT5A conditioned medium (or Vector Only control) with/without IL-1α and OSM cytokines 
for 24 h. Experiment performed four times. Left-hand figure from experiment 1. Right-hand 
figure from representative example from three further repeats, also sent for microarray 
analysis. WNT5A+Cytokine condition for Wisp1 from Experiment 1 (Left-hand figure) consists 
of one sample only (n=1) as two samples were not detected.  CT values can be found in 
Appendix, Table S4.2. * = significant compared to Vector Only. # = significant compared to no 
cytokines. 
Wisp1 
(Wnt-inducible secreted protein 1/CCN4) 
Experiment 1 Representative Experiment 
Also analysed by microarray 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
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Wisp2 
(Wnt-inducible secreted protein 2/CCN5) 
J 
K Frzb 
(Frizzled-related protein) 
Figure 4.5 J-K – Gene regulation in WNT5A and cytokine stimulated differentiated ATDC5 
micromass cultures. Steady-state mRNA expression levels of Wisp2 (J) and Nov (K) in micromass 
cultures stimulated with insulin and ascorbic acid for 14 days then treated with WNT5A 
conditioned medium (or Vector Only control) with/without IL-1α and OSM cytokines for 24 h. 
Experiment performed four times. Left-hand figure from experiment 1. Right-hand figure from 
representative example from three further repeats, also sent for microarray analysis. CT values 
can be found in Appendix, Table S4.2. * = significant compared to Vector Only. # = significant 
compared to no cytokines. 
Experiment 1 Representative Experiment 
Also analysed by microarray 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
 
(A
.U
.)
 
 
123 
 
 
 
  
L Col10a1 
(Type X Collagen) 
Figure 4.5 L – Gene regulation in WNT5A and cytokine stimulated differentiated ATDC5 
micromass cultures. Steady-state mRNA expression levels of Col10a1 (L) in micromass cultures 
stimulated with insulin and ascorbic acid for 14 days then treated with WNT5A conditioned 
medium (or Vector Only control) with/without IL-1α and OSM cytokines for 24 h. Experiment 
performed four times. Left-hand figure from experiment 1. Right-hand figure from 
representative example from three further repeats, also sent for microarray analysis. CT values 
can be found in Appendix, Table S4.2. * = significant compared to Vector Only. # = significant 
compared to no cytokines. 
Experiment 1 Representative Experiment 
Also analysed by microarray 
(A
.U
.)
 
(A
.U
.)
 
 
124 
 
4.2.6 Microarray analysis of WNT5A and cytokine-stimulation in differentiated 
ATDC5 cells 
An unbiased approach was also taken to investigate the effect of WNT5A and cytokine stimulation 
on differentiated ATDC5 micromass cultures by carrying out microarray analysis of total RNA to 
identify potentially novel regulation of genes or pathways. 
4.2.6.1 Cytokine stimulation strongly regulated gene expression 
Principle component analysis (PCA), which highlights similarities or differences in expression 
patterns across samples based on visual proximity, revealed differences in the expression from the 
45,000 probe sets tested across the four conditions. The most striking difference between 
conditions was revealed to be through the addition of cytokines, regardless of the presence or 
absence of WNT5A. Samples treated with WNT5A in the presence of cytokines also clustered apart 
from Vector Only-treated samples, indicating that WNT5A had some regulatory effect on gene 
expression. Interestingly, this difference was not as apparent in samples without cytokines, 
suggesting that some WNT5A-mediated regulation may in part be dependent on cytokine signalling 
(Figure 4.6).  
The striking regulation by cytokine stimulation can also be seen by hierarchical clustering in the 
form of a heat map, highlighting the differences in colour temperature and thus expression, which 
is more apparent with the addition of cytokines compared to no cytokines (Figure 4.7) 
 
Figure 4.6 – Principle Component Analysis (PCA) of WNT5A and cytokine stimulated 
micromass cultures from microarray analysis. Clustering of samples indicates similar 
expression patterns.  
 
 
Figure 4.7 – Hierarchical clustering of WNT5A and Cytokine-treated micromass cultures 
by microarray analysis. Expression from all 12 samples (columns) analysed by microarray 
shown as a heat map based on expression levels of each probe (rows). Red = high 
expression. Blue = low expression. Clustering based on expression levels and samples. 
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4.2.6.2 Selecting genes for subsequent analysis 
Four comparisons were made based on the four conditions to investigate the following questions: 
1. What effect does WNT5A stimulation have on gene regulation in the absence of cytokines? 
(Vector only, no cytokines vs. WNT5A, no cytokines) 
2. What effect does WNT5A stimulation have on gene regulation in the presence of cytokines? 
(Vector only with cytokines vs. WNT5A with cytokines) 
3. What effect does cytokine stimulation have on gene regulation in the absence of WNT5A? 
(Vector only, no cytokines vs. Vector only with cytokines) 
4. What effect does cytokine stimulation have on gene regulation in the presence of WNT5A? 
(WNT5A, no cytokines vs. WNT5A with cytokines) 
 
Volcano plots were created, plotting fold change regulation based upon the above comparisons 
against P-values determined by pairwise comparisons using student’s t-test. Probe sets displaying 
an absolute fold-change (positive or negative) greater than or equal to 1.5x with a P-value less than 
0.05 were chosen for further analysis, highlighted in red on the volcano plots (Figure 4.8, 4.9). As 
evidenced by the number of red marks, addition of cytokines significantly regulated more genes 
above an absolute fold change of 1.5x. Table 4.2 quantifies this difference, revealing around 20-30x 
the number of probe sets significantly regulated by the addition of cytokines in comparison to the 
number of probe sets significantly regulated by the addition of WNT5A.  
Furthermore, the volcano plots reveal that not only were more probe sets significantly regulated 
more than 1.5-fold by the addition of cytokines, but the effect was much greater, reaching fold 
changes in the region of 3000x compared to around 3x by the addition of WNT5A (Figure 4.8, 4.9). 
The top 50 for each comparison, ranked by absolute fold change, can be found in Appendix Table 
S4.3, S4.4, S4.5 and S4.6. 
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Effect of adding WNT5A without cytokines 
Figure 4.8 – Volcano plot of effect of WNT5A with and without cytokine stimulation on gene 
regulation in ATDC5 micromass cultures. Probe sets plotted according to fold change regulation 
(x axis) against P-value (y axis). Highlighted probe sets have absolute fold change ≥ 1.5 and P-
value < 0.05. 
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Figure 4.9 – Volcano plot of effect of cytokines with and without WNT5A stimulation on gene 
regulation in ATDC5 micromass cultures. Probe sets plotted according to fold change regulation 
(x axis) against P-value (y axis). Highlighted probe sets have absolute fold change ≥ 1.5 and P-
value < 0.05. 
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However, due to the nature of performing multiple t-tests, it was suspected that a large number of 
these significant differences were ‘false positives’. To test for this, a more stringent analysis was 
performed using the Benjamini-Hochberg procedure to calculate Q-values that take into 
consideration the false discovery rate. Using the more stringent analysis based on using Q-values, 
no probe sets were significantly regulated by WNT5A (Table 4.3), suggesting that the WNT5A was 
either not active, or the cells were non-responsive to it. In comparison, only a relatively small 
number of probe sets were excluded when comparing the effects of cytokines, losing just 12.8 % 
and 11.2 % of probe sets in the absence and presence of WNT5A respectively compared to the 100 % 
lost when comparing the effects of WNT5A with/without cytokines (Table 4.3). 
Despite no significant differences based on the Q-values for the effect of WNT5A, differences were 
found in the number of probe sets that were regulated by cytokines depending on the presence or 
absence of WNT5A. Results revealed that 2356 probe sets were only regulated by cytokines in the 
presence of WNT5A and 1858 probe sets were only regulated by cytokines in the absence of WNT5A 
(Figure 4.10), suggesting there may have been some effect after all. 
  
  
Effect of 
Number of probe sets regulated 
Up-regulated Down-regulated Total 
1 WNT5A without cytokines 152 156 308 
2 WNT5A with cytokines 270 255 525 
3 Cytokines without WNT5A 4608 5979 10587 
4 Cytokines with WNT5A 4626 6333 10959 
Effect of 
Number of probe sets regulated 
Up-regulated Down-regulated Total 
1 WNT5A without cytokines 0 0 0 
2 WNT5A with cytokines 0 0 0 
3 Cytokines without WNT5A 3971 5262 9233 
4 Cytokines with WNT5A 4095 5636 9731 
Table 4.2 – Number of significantly regulated probe sets according to P-Value based on 
absolute fold change greater than or equal to 1.5 and P-Value less than 0.05 by multiple 
t-tests 
Table 4.3 – Number of significantly regulated probe sets according to Q-Value using 
Benjamini–Hochberg procedure to take into account false discovery rate 
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Appendix Table S4.7 highlights the top 50 cytokine-regulated genes that were only regulated in the 
presence of WNT5A. Of these, Kruppel-like factor 9 (Klf9) and Protocadherin 7 (Pcdh7) were the 
most up-regulated and down-regulated genes respectively, excluding any hypothesised genes. 
Interestingly, using the less stringent analysis based on P-Values rather than Q-Values, only Pcdh7 
was regulated by WNT5A in the absence of cytokines, and interestingly was up-regulated as 
opposed to the down-regulation by cytokines in the presence of WNT5A. However, as stated, this 
is based on using P-Values, which may therefore have been a false positive. It would therefore be 
interesting to observe any changes using qRT-PCR to validate the finding. 
 
 
  
 1858 2356 7375 
-WNT5A +WNT5A 
Figure 4.10 – Distribution of cytokine-regulated probe sets with respect to presence or 
absence of WNT5A based on probe sets deemed to be significantly regulated by cytokines 
according to Q-values. 
 
131 
 
4.2.6.3 Comparison of candidate genes between qRT-PCR analysis and microarray analysis 
The samples used in the right-hand figures in Figure 4.5 were used for the microarray analysis. After 
calculating which genes were significantly regulated according to the threshold criteria described 
previously, the data were compared back to the qRT-PCR analysis for confirmation of the same 
changes in gene expression. Since qRT-PCR was used to validate any findings from the microarray, 
comparisons against the microarray were based on the less-stringent P-values only to observe any 
similarities or differences that may have been hidden due to much more stringent parameters. A 
full comparison for each gene and each condition can be found in Table 4.4. 
Table 4.4 reveals that the microarray analysis was largely consistent with the findings seen by qRT-
PCR analysis, with only a small number of exceptions. Microarray analysis revealed an increase in 
Cyr61 and a decrease in Col10a1 expression by WNT5A in the absence of cytokines and an increase 
in Frzb expression by WNT5A in the presence of cytokines. However, qRT-PCR analysis of the most 
representative samples, all from the same experiment which was also analysed by the microarray, 
showed this was not the case. These are therefore false positives on the microarray. On the other 
hand, a lack of regulation of Ror2, Col2a1, Adamts4, Runx2, Ddr2, Ctgf, Nov, Wisp1 and Wisp2 by 
WNT5A conditioned medium was seen by microarray analysis in agreement with the qRT-PCR 
analysis. 
Similarly, significant down-regulation of Col2a1, Wisp1, Wisp2 and Frzb by cytokines in Vector Only 
conditioned medium, seen by the microarray analysis was in agreement with representative data 
from the qRT-PCR analysis. Similarly, up-regulation of Adamts4 and down-regulation of Cyr61, 
Wisp1, Wisp2 and Frzb by cytokines in the presence of WNT5A seen by microarray analysis was also 
in agreement with the qRT-PCR analysis. However, results obtained from the microarray did not 
agree with results for Ror2, Ctgf and Nov by cytokines either in Vector Only or WNT5A conditioned 
media, or with Col2a1 and Col10a1 by cytokines only in the presence of WNT5A. 
Together, this shows that the microarray findings were largely consistent with the findings seen by 
qRT-PCR. 
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4.2.6.4 Confirmation of gene regulation proposed by microarray analysis 
In addition to the candidate genes previously investigated, microarray analysis revealed significant 
regulation of a number of interesting genes related to the topics investigated in this thesis. qRT-
PCR was used to validate these findings. 
Using the less stringent parameters by analysing P-values only, by microarray analysis, expression 
of Anxa1, which encodes the Ca2+/phospholipid-binding protein, Annexin 1 (Sheu, et al., 2014) and 
is involved in cell migration (Cote, et al., 2010), was up-regulated by WNT5A in the absence of 
cytokines and paradoxically up-regulated by cytokines in the absence of WNT5A (Table 4.4). 
However, no such regulation was seen after Benjamini-Hochberg analysis using Q-values, and 
expression was unchanged in three experiments by qRT-PCR analysis (Figure 4.11 A; Table 4.4), 
confirming the results seen using the more stringent parameters. 
Matn3, which encodes the cartilage matrix component, matrilin 3, was down-regulated by WNT5A 
in the absence of cytokines by microarray analysis when observing P-values only (Table 4.4), 
however, this remained unchanged by qRT-PCR analysis (Figure 4.11 B; Table 4.4). However, 
microarray analysis revealed a significant down-regulation of Matn3 by cytokines in both Vector 
Only and WNT5A conditioned media after Benjamini-Hochberg analysis. qRT-PCR analysis revealed 
a similar change in expression, with CT values around 32-34 in the absence of cytokines to CT values 
around 35 and higher in the presence of cytokines (Appendix Table S4.8), and was therefore 
deemed to not be expressed in the presence of cytokines. This suggests that expression of Matn3 
was repressed by cytokine stimulation and validates the findings from the microarray. 
Conversely, expression of Prg4, which encodes Proteoglycan 4, more commonly known as lubricin, 
was significantly up-regulated by cytokine stimulation as seen by the microarray analysis after 
Benjamini-Hochberg analysis (Table 4.4). In agreement, massive up-regulation of Prg4 was seen by 
qRT-PCR, with CT values higher than the limits of detection (35+) in the absence of cytokines to 
around 27-29 in the presence of cytokines (Appendix Table S4.8). This therefore suggests the Prg4 
was induced by cytokine stimulation.  
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  Anxa1 
(Annexin A1) 
Matn3 
(Matrilin 3) 
A 
B 
Figure 4.11 – Confirmation of gene regulation changes seen by microarray analysis by qRT-
PCR. Steady-state mRNA expression levels of Anxa1 (A), Matn3 (B) and Prg4 (C) were analysed 
by qRT-PCR. Data shown from the same samples used for microarray analysis (and right-hand 
figures in Figure 4.5), which were representative across three experiments. ND = not detected. 
CT values can be found in Appendix Table S4.8 
Prg4 
(Proteoglycan 4/Lubricin) 
C 
ND ND 
ND ND 
(A
.U
.)
 
(A
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.)
 
(A
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4.2.6.5 Pathway Analysis 
All significantly regulated probe sets, as determined by Benjamini-Hochberg analysis using Q-values, 
were subject to pathway analysis using the freely available DAVID software to identify entire 
pathways that may be regulated by cytokine stimulation, based upon known genes within the 
pathway. Table 4.5 highlights the top 10 pathways that were significantly regulated in each 
comparison, ranked by their significance as determined by Benjamini-Hochberg analysis. Since no 
genes were regulated by WNT5A conditioned media stimulation as determined by the Benjamini-
Hochberg analysis, only probe sets identified by the effect of cytokine stimulation were analysed. 
Pathway analysis results showed similar pathways were being regulated by cytokines irrespective 
of the presence or absence of WNT5A (Table 4.5). Interestingly, the results showed that cytokine 
stimulation of differentiated ATDC5 micromass cultures highly regulated WNT signalling (Table 4.5). 
Closer inspection of the result revealed that both the canonical and non-canonical pathways were 
regulated, with all genes listed in the WNT5A pathway being regulated and several genes in the 
canonical pathway (Figure 4.12). However, due to the limitations of the DAVID software, the results 
do not determine whether the pathways were up-regulated or down-regulated as DAVID only 
calculates results based on the gene IDs entered and not any fold changes. Closer inspection of 
individual genes revealed that Wnt5a itself was down-regulated by cytokine stimulation (around 
3.5x to 10x down-regulated, depending on probe set). This decrease in Wnt5a was also confirmed 
at the protein level (n=1) in both cell lysates and conditioned media (Figure 4.14). Its main receptor, 
Ror2, was also down-regulated as previously stated (Table 4.4). These results suggest cytokine 
stimulation of ATDC5 micromass cultures inhibit the WNT5A pathway.  
Another interesting pathway that was highly regulated by cytokine stimulation was the focal 
adhesion pathway (Figure 4.13), with down-regulation of several pathway members including 
various genes that encode for integrin members, ROCK, JNK and ERK1/2 (fold change data not 
shown), suggesting inhibition of the pathway. Since focal adhesions are important in migration, this 
may have ramifications for the data described in Chapter 5, which focuses on adhesion and 
migration of ATDC5 cells 
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Rank Pathway P-value BH Q-value 
    
Effect of cytokines in the absence of WNT5A   
1 Pathways in cancer 1.80E-12 3.40E-10 
2 Ubiquitin mediated proteolysis 1.40E-11 1.40E-09 
3 Cell cycle 3.20E-09 2.10E-07 
4 Wnt signalling pathway 1.90E-07 9.20E-06 
5 Colorectal cancer 2.90E-07 1.10E-05 
6 Prostate Cancer 1.40E-06 4.10E-05 
7 Renal cell carcinoma 1.60E-06 4.40E-05 
8 MAPK signalling pathway 1.70E-06 4.60E-05 
9 Spliceosome 4.60E-06 9.80E-05 
10 Insulin signalling pathway 1.20E-05 2.30E-04 
11 Progesterone-mediated oocyte maturation 1.30E-05 2.40E-04 
12 Focal adhesion 1.60E-05 2.50E-04 
13 Chronic myeloid leukaemia 2.20E-05 3.30E-04 
14 Pyrimidine metabolism 4.10E-05 5.60E-04 
15 Endocytosis 7.00E-05 9.00E-04 
    
Effect of cytokines in the presence of WNT5A   
1 Pathways in cancer 2.00E-10 3.80E-08 
2 Ubiquitin mediated proteolysis 5.20E-10 5.10E-08 
3 Wnt signalling pathway 2.20E-09 1.40E-07 
4 Renal cell carcinoma 1.50E-07 7.30E-06 
5 Insulin signalling pathway 4.60E-07 1.80E-05 
6 MAPK signalling pathway 7.40E-07 2.40E-05 
7 Chronic myeloid leukaemia 1.10E-06 2.90E-05 
8 Prostate cancer 2.60E-06 6.20E-05 
9 Neurotrophin signalling pathway 5.60E-06 1.20E-04 
10 Adherens junction 9.50E-06 1.80E-04 
11 Colorectal cancer 1.00E-05 1.80E-04 
12 mTOR signalling patway 2.30E-05 3.70E-04 
13 ErbB signalling pathway 3.90E-05 5.80E-04 
14 Focal adhesion 5.50E-05 7.50E-04 
15 Glioma 8.30E-05 1.10E-03 
Table 4.5 – Effect of cytokines on pathway regulation. Top 15 significantly regulated pathways 
in the absence and presence of WNT5A as determined using DAVID software ranked by 
Benjamini-Hochberg (BH) Q-Values 
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Figure 4.14 – Cytokine stimulation down-regulates WNT5A. Changes in WNT5A expression by 
microarray were confirmed by western blot in cell lysates and TCA-precipitated conditioned 
media after 24 hours and 48 hours, probing for WNT5A using a WNT5A-specific antibody. Arrow 
= possible detection of human WNT5A-FLAG present in conditioned medium used to stimulate 
cells. Ability for WNT5A antibody to detect WNT5A-FLAG confirmed in Appendix Figure S4.1. 
Endogenous mouse WNT5A = 42.35 kDa (isoform 1) or 40.89 kDa (isoform 2). Human WNT5A-
FLAG = 44.99 kDa. β-Actin used as loading control (41.74 kDa). Molecular weights based on 
amino acid sequence. Experiment performed once. 
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4.3 Discussion 
Understanding gene regulation in an osteoarthritic-like setting is important to help understand the 
mechanisms of the disease. This chapter took a number of approaches and described a new model 
with similarities to an established model of early OA, revealing novel gene regulation. 
4.3.1 Gene regulation in non-induced WNT5A-overexpressing clones 
4.3.1.1 Ror2 
Overexpression of WNT5A in non-induced ATDC5 cells revealed interesting results. A slight trend 
was observed towards increased expression of Ror2 in WNT5A-overexpressing cells, although this 
did not reach significance (Figure 4.2 A). WNT5A expression has been shown to positively correlate 
with ROR2 expression, and can positively regulate ROR2 expression in various cell lines at the RNA 
and protein levels (O'Connell, et al., 2010; Yuan, et al., 2011). Interestingly, inducible 
overexpression of WNT5A in a transgenic mouse decreased ROR2 expression at the protein level in 
vivo in embryonic and adult intestinal cells, but had no effect at the RNA level, suggesting ROR2 
may undergo endocytosis and lysosomal degradation (Bakker, et al., 2012). Identification of ROR2 
protein expression was not carried out in this study, so it remains unknown whether WNT5A may 
regulate ROR2 expression in a similar manner in this system. 
4.3.1.2 Adamts4 and Adamts5 
WNT5A also did not regulate Adamts4 or Adamts5 expression in non-induced overexpressing clones, 
although micromass culture did increase expression of Adamts4 both in Vector Only and WNT5A 
clones (Figure 4.2 C-D). Exogenous WNT5A has previously been shown to regulate expression of 
ADAMTS5 in chick beak mesenchyme micromass cultures, which led to the destruction of the 
proteoglycan rich matrix (Hosseini-Farahabadi, et al., 2013). To date, no such link between WNT5A 
and Adamts4 has been made. 
4.3.1.3 Grem1 
Up-regulation of Grem1 (gremlin-1) was observed in WNT5A-overexpressing clones (Figure 4.2 G). 
Gremlin-1 is a secreted BMP antagonist that may indirectly antagonise WNT signalling (Gazzerro, et 
al., 2007). No direct link has been made between WNT5A signalling and Grem1 expression. 
However, WNT5A has been shown to be important in BMP-2-induced osteogenesis, such that 
inhibition of WNT5A, which is up-regulated in BMP-2-induced osteogenesis, inhibits osteogenesis 
in the mouse MC3T3-E1 pre-osteoblastic cell line (Nemoto, et al., 2012). BMP-2 is known to increase 
Grem1 expression, and Gremlin-1 is known to bind and inhibit BMP-2, creating a negative feedback 
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loop (Pereira, et al., 2000), although this may be concentration dependent (Nissim, et al., 2006). It 
would therefore be interesting to identify the state of BMP-2 regulation in this system. 
4.3.1.4 Alpl, Runx2 and Ddr2 
Down-regulation of Alpl (alkaline phosphatase) was seen in WNT5A overexpressing cells (Figure 4.2 
H), consistent with reports that WNT5A prevents hypertrophy (Hartmann & Tabin, 2000; Church, 
et al., 2002; Bradley & Drissi, 2010), however, levels of Runx2 and Ddr2 were not regulated by 
WNT5A overexpression (Figure 4.2 E-F), two important factors in hypertrophic differentiation, 
discussed in Chapter 3. However, it is important to note that overexpressing clones were not 
induced to undergo differentiation with insulin and did not exhibit increased levels of Col2a1 (Figure 
4.2 B), so any WNT5A-mediated regulation of other hypertrophic factors may depend on the 
differentiation status of the cell. 
4.3.1.5 CCN Growth Factor Family 
Of the CCN family of growth factors, WNT5A overexpression increased expression of Cyr61 (Figure 
4.2 I). No direct regulation of Cyr61 by WNT5A has been reported, although WNT5A and CYR61 
have been reported to be both up-regulated in liver fibrosis at the protein level (Rashid, et al., 2012) 
and dermal remodelling following CO2 laser-mediated ablative fractional resurfacing of human skin 
following abdominoplasty (“tummy tuck”) at both the mRNA and protein levels (Kim, et al., 2013b). 
Microarray analysis did reveal a significant increase of Cyr61 with WNT5A conditioned medium 
stimulation of differentiated cells, although subsequent validation by qRT-PCR analysis revealed 
this not to be the case (discussed later). A slight decrease in Wisp1 expression was also seen (Figure 
4.2 L), although expression in the individual clones did not seem to differ apart from in one clone. 
Interestingly, WNT5A has been suggested to increase WISP1 expression after crush injury of human 
saphenous vein based on their expression from microarray data, although this was not confirmed 
by qRT-PCR or further experiments (Price, et al., 2004). 
It is important to note however that these data are from a preliminary experiment performed once 
and so absolute conclusions about the effect of WNT5A-overexpression in non-induced ATDC5 cells 
cannot be made without further experiments. A summary of the data can be found in Table 4.6. 
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4.3.2 ATDC5 clones failed to differentiate 
Upon identification of gene regulation in non-induced cells, gene regulation was to be investigated 
in insulin-induced cells to identify potential differential regulation based upon the differentiated 
state of the cells. Unfortunately, ATDC5 clones failed to differentiate, as noted by low Col2a1 
expression, the lack of cartilage-like nodules and rich matrix observed macroscopically and flatter, 
larger cells reminiscent of undifferentiated cells (data not shown). 
It is possible upon stable integration into the genome that the linearised plasmid interfered with 
the expression of, or knocked out genes crucial to differentiation. Due to the nature of cloning, it is 
possible that not all clones generated may have interfered with this pathway, as evidenced by the 
increased expression of Col2a1 in Clone 6 (WNT5A-overexpressing clone), which macroscopically 
did appear to, at least partially, undergo chondrogenesis. 
However, due to this uncertainty and the lack of chondrogenesis in even Vector Only clones and 
interesting results in another model using conditioned media on differentiated cells, the decision 
was made to pursue results found in the conditioned media model. 
4.3.3 WNT5A-mediated gene regulation using conditioned media on differentiated 
ATDC5 micromass cultures 
Since the generated clones tested appeared to fail to undergo chondrogenesis, conditioned 
medium from ATDC5 cells transiently overexpressing WNT5A was used. This also enabled the 
observation of the effect of WNT5A in already differentiated cells, and in a disease-like context, 
Gene 
Association/Family 
Up-regulated Down-regulated No Regulation 
Chondrocytic 
 Col2a1 (micromass) 
Alpl 
Col2a1 (monolayer) 
Runx2 
Ddr2 
WNT Signalling 
Grem1 (micromass)  Grem1 (monolayer) 
Ror2 
CCNs 
Cyr61 Wisp1 (monolayer) 
Wisp2 (micromass) 
Ctgf 
Nov 
Wisp1 (micromass) 
Wisp2 (monolayer) 
Metalloproteinases 
  Adamts4 
Adamts5 
Table 4.6 – Summary of basal gene regulation in non-induced WNT5A clones compared to 
Vector Only clones  
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since most studies of WNT5A in cartilage have investigated its effect on chondrogenesis. 
Experiments were analysed both by qRT-PCR to investigate candidate genes and by microarray for 
a global investigation. 
4.3.3.1 Cyr61 
Interestingly, microarray analysis revealed 1.8-fold up-regulation of Cyr61 by WNT5A in the absence 
of cytokines (Table 4.4), reminiscent of the up-regulation previously found in, albeit non-induced, 
WNT5A-overexpressing clones (Figure 4.2 I). However, qRT-PCR analysis of four individual 
experiments revealed no such regulation and this was not deemed to be significant after Benjamini-
Hochberg analysis of Q-values. Although a slight increase in Cyr61 expression by WNT5A in the 
absence of cytokines was found by qRT-PCR in two experiments, including the samples sent for 
microarray analysis, this did not reach significance (Figure 4.11 A) and no trend was found in the 
other two experiments. 
4.3.3.2 Col10a1 
Similarly, Col10a1 was revealed to be significantly decreased 1.5-fold by microarray analysis by 
WNT5A (Table 4.4). However, by qRT-PCR analysis, this regulation was only seen in one out of three 
experiments, and intriguingly not in the samples that were also used for the microarray (Figure 4.11 
B), suggesting that this was another false-positive. However, Col10a1 was decreased by cytokine 
stimulation, in contrast to the established increase seen in osteoarthritic cartilage (von der Mark, 
et al., 1995; Girkontaite, et al., 1996). However, in agreement with the cytokine effect confirmed 
by qRT-PCR, COL10A1 has previously been shown to be decreased by cytokine stimulation by TNFα 
in porcine chondrocyte micromass cultures (Schlichting, et al., 2014). 
4.3.3.3 Anxa1 (Annexin A1) 
Microarray analysis revealed Anxa1, which encodes annexin A1, a lipocortin protein involved in 
calcium and phospholipid binding (Damazo, et al., 2007), was up-regulated 1.5-fold in response to 
WNT5A stimulation in the absence of cytokines, however, this was not seen by qRT-PCR analysis of 
three experiments and was not deemed to be significant after Benjamini-Hochberg analysis of Q-
values (Figure 4.11 A; Table 4.4). No direct link between Anxa1 and WNT5A has previously been 
made. However, annexin A1 is an important component in the induction of migration and invasion 
in a number of cell types, including endothelial cells (Cote, et al., 2010), breast carcinoma cells (Kang, 
et al., 2012) and myoblasts (Bizzarro, et al., 2012), as is WNT5A, discussed in Chapter 5. It has also 
been shown to be important for the normal development of the mouse skull, with knockout mice 
having a delay in the formation of the sagittal suture system and having a thicker, more mineralised 
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frontal bone (Damazo, et al., 2007).  It would therefore be interesting to see if migration of ATDC5 
cells is mediated by Annexin A1, for example, by silencing Anxa1 expression. 
4.3.3.4 Matn3 (Matrilin 3) 
Expression of Matn3, which encodes the non-collagenous ECM component matrilin 3, was 
significantly down-regulated 2.1-fold by WNT5A stimulation in the absence of cytokines, making it 
the 39th most regulated probe in that comparison, although it was not deemed significant based on 
Q-values (Appendix Table S4.3). qRT-PCR analysis of three experiments also revealed no such 
changes in expression (Figure 4.11 B; Table 4.4). No direct link has been made with WNT5A and 
Matn3 expression. However, functional Matn3 knockout mice exhibit an enlarged hypertrophic 
zone in the growth plate, with increases in type X collagen, indicating that matrilin 3-null 
chondrocytes prematurely enter hypertrophic differentiation (van der Weyden, et al., 2006). A 
down-regulation of Matn3 seen by the microarray would therefore suggest entry into hypertrophic 
differentiation, in contrast to WNT5A’s established role in preventing this (discussed previously). 
However, a lack of increase in other hypertrophic markers by WNT5A stimulation, such as Col10a1, 
Runx2 and Ddr2, and a lack of regulation seen by qRT-PCR, suggest this is not the case.  
4.3.3.5 Variation in WNT5A-mediated gene regulation between experiments 
Interesting regulation by WNT5A was found in a number of candidate genes by qRT-PCR in an initial 
experiment, however, as just described, these were not reproducible. This may highlight a potential 
problem with using conditioned media from transiently transfecting cells. Although care was taken 
to ensure each transfection was performed under the same conditions, confirming the presence of 
WNT5A in each batch of conditioned medium via western blotting, batch to batch variation may 
still occur, affecting expression levels, potency and activity.  
In future, it may therefore be necessary to confirm activity of each batch of generated conditioned 
media using a reporter assay. One such assay that is used in the literature is the WNT5A-mediated 
inhibition of β-catenin-dependent WNT signalling via a TCF/Lef reporter, such as TOPFlash (Ekstrom, 
et al., 2011). An initial attempt was made using the TOPFlash reporter, however, the results were 
inconclusive as no luminescence could be read for any condition, including a positive control using 
rHWNT3A stimulation (data not shown). It is not known whether this was due to user error or lack 
of optimisation of the protocol. Regardless, depending on the receptor context, WNT5A may not 
inhibit β-catenin-dependent WNT signalling, but enhance it (Mikels & Nusse, 2006). Since WNT5A 
is known to activate other pathways, such as the JNK/AP-1 pathway, an AP-1 reporter could also be 
used to confirm WNT5A activity in conditioned media before stimulating experiments (De Cat, 2003; 
Nishita, et al., 2010).  
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However, principle component analysis of microarray data did reveal separation of Vector Only and 
WNT5A-stimulated samples (Figure 4.6), indicating different gene expression patterns between the 
conditions. Indeed, 308 and 525 probe sets were significantly (P < 0.05) regulated at least 1.5-fold 
due to WNT5A stimulation in the absence or presence of cytokines (Table 4.2) although these may 
have been false positives as these were not deemed to be significant after Benjamini-Hochberg 
analysis. 
However, it has been reported that FRZB (also known as secreted Frizzled-Related Protein 3/SFRP3) 
can bind to WNT5A (Yamada, et al., 2013) and inhibit WNT5A signalling and WNT5A-mediated 
migration and invasion in a human malignant melanoma cell line (Ekstrom, et al., 2011). This thesis 
has previously shown that insulin-induced, ascorbic acid-stimulated micromass cultures of ATDC5 
cells, used in the WNT5A stimulation experiments, express high levels of Frzb at the mRNA level 
(Figure 3.10 B). However, other reports have shown WNT5A may inhibit the activity of FRZB, as 
shown in mouse cochlear extension, which is inhibited by incubation with FRZB and rescued with 
WNT5A (Qian, et al., 2007), suggesting that the antagonistic roles of WNT5A and FRZB on each 
other may be context dependent. 
4.3.4 Cytokine-mediated gene regulation by qRT-PCR in differentiated ATDC5 
micromass cultures 
In comparison to WNT5A, cytokines had a more dramatic effect, with microarray analysis revealing 
significant regulation of 20-30 fold more genes using the less stringent P-values (Table 4.2), and to 
a much greater extent (Appendix Table S4.5 and S4.6). 
4.3.4.1 Ror2 
Cytokine stimulation revealed consistent and interesting results. By qRT-PCR, a consistent trend 
towards down-regulation was observed in Ror2 expression with cytokine stimulation (Figure 4.5 A). 
This is an interesting and apparently novel finding. Of interest, an increase in ROR2 expression was 
seen in cells differentiating along the osteogenic lineage in response to IL-1β in human BMSCs 
(Sonomoto, et al., 2012) or IL-6, of which family OSM is a member of (Richards, 2013), along with 
soluble IL-6 receptor (sIL-6R) in human ADSCs (Fukuyo, et al., 2014). In keeping with this, the ROR2 
ligand, WNT5A, was also down-regulated by cytokine stimulation, revealing novel regulation, 
discussed later. 
4.3.4.2 Col2a1 
Expression of Col2a1 was also decreased with cytokine stimulation (Figure 4.5 B). Stimulation of 
porcine chondrocyte micromasses with TNF-α to induce osteoarthritic-like changes also revealed 
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down-regulation of COL2A1 (Schlichting, et al., 2014). IL-1β has also been reported to decrease 
COL2A1 expression in human OA chondrocytes (Roman-Blas, et al., 2007; Akhtar, et al., 2011) and 
bovine articular chondrocytes cultured on polyHEMA to preserve the differentiated phenotype, 
discussed in Chapter 1 (Roman-Blas, et al., 2007). Expression of Col2a1 was also decreased in a 
mouse DMM model of OA six hours post-surgery by microarray analysis, validated by qRT-PCR 
(Burleigh, et al., 2012). This finding is therefore in line with other works reported in literature. 
Interestingly, WNT5A has previously been shown to enhance IL-1β-mediated decrease in type II 
collagen in rabbit articular chondrocytes (Ryu & Chun, 2006). 
4.3.4.3 Runx2 and Ddr2 
Decreases in Runx2 and Ddr2 were also seen with cytokine stimulation (Figure 4.5 D-E). As 
previously discussed in Chapter 3, RUNX2 and DDR2 are key players in hypertrophic differentiation, 
both of which have been shown to mediate expression of MMP13 (Xu, et al., 2005; Boumah, et al., 
2009; Shimizu, et al., 2010), a major collagen-degrading enzyme in osteoarthritis. However, 
cytokine stimulation with TNFα or IL-1β has been shown to decrease expression of RUNX2 in pre-
osteoblastic cells and during osteogenesis (Gilbert, et al., 2002; Ding, et al., 2009). Interestingly in 
cho/+ mice, a chondrodysplasia model that uses a frameshift mutation in Col11a1 a1 to model OA-
like changes (Li, et al., 1995), expression of DDR2 mRNA and protein is increased compared to wild-
type mice (Xu, et al., 2005). DDR2 has also been found to be increased in cartilage from humans 
with OA and in mice with surgically-induced OA (Xu, et al., 2007a). Culture of chondrocytes on type 
II collagen has been reported to lead to a DDR2-mediated increase in Mmp13 expression, but no IL-
1 transcripts could be detected (Xu, et al., 2005). Similarly, treatment of a human immortalised 
chondrocyte cell line with IL-1 receptor antagonist (IL-1RA) failed to inhibit the DDR2-mediated 
increase in MMP13 expression (Xu, et al., 2007a), indicating IL-1 is not involved in MMP13 
regulation by DDR2. The cytokine-mediated down-regulation of Ddr2 in this present study is 
therefore an intriguing and novel finding, and would therefore be interesting to see whether DDR2 
protein is affected in the same manner. 
4.3.4.4 CCN Growth Factor Family 
4.3.4.4.1 Cyr61 
Microarray and qRT-PCR analysis revealed a significant decrease in Cyr61 expression by cytokine 
stimulation in the presence of WNT5A, with a definite trend towards down-regulation in three out 
of four experiments by cytokine stimulation in Vector Only conditioned medium by qRT-PCR 
analysis. Similarly, a previous study has shown expression of CYR61 decreased in a human 
chondrocyte cell line by stimulation with TNFα, another inflammatory cytokine (Moritani, et al., 
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2005). However, in human osteoblasts and osteoblast-like cells, various cytokines, including IL-1β, 
IL-6, OSM and TNFα, increased expression of CYR61/CCN1 protein and mRNA (Schutze, et al., 1998; 
Wu, et al., 2012). Cytokine-mediated regulation of Cyr61 may therefore be cell/context dependent. 
This decrease in expression may therefore potentially reveal novel regulation of Cyr61 in 
chondrocytes by IL-1α and OSM specifically. 
4.3.4.4.2 Ctgf 
Ctgf, which is increased in human osteoarthritic cartilage with worsening severity (Omoto, et al., 
2004), was decreased by cytokine stimulation. Basal levels of CTGF and TGFβ-induced CTGF have 
been shown to be decreased by IL-1α at the mRNA and protein level, and by IL-1β at the mRNA 
level in human dermal fibroblasts (Nowinski, et al., 2010). Similarly, CTGF/CCN2 protein expression 
is decreased by TNFα and IL-1β in human Nucleus Pulposus cells via NF-κB signalling (Tran, et al., 
2014) and IL-1β is known to down-regulate CTGF expression in human OA chondrocytes (Masuko, 
et al., 2010). Interestingly, CTGF/CCN2 can also suppress the induction of IL-1β-regulated genes in 
Nucleus Pulposus cells, such as ADAMTS5 and MMP3 (Tran, et al., 2014), indicating CTGF/CCN2 has 
anti-catabolic properties. Nevertheless, the down-regulation of Ctgf in this thesis is therefore in-
line with previously published reports on cytokine signalling. 
4.3.4.4.3 Wisp1 
Regardless of the presence or absence of WNT5A, cytokine stimulation of differentiated ATDC5 
micromass cultures significantly down-regulated expression of Wisp1, as seen by both microarray 
and qRT-PCR analysis (Table 4.4). WISP1/CCN4 protein was found to be up-regulated in murine OA 
knee joints after collagenase-induced OA, as well as in the STR/Ort mouse model of spontaneous 
OA and also in human OA cartilage (Blom, et al., 2009). Interestingly, injection of Wisp1 adenovirus 
into murine knee joints, which resulted in increased expression of Adamts4 and Adamts5 in the 
synovium in wild-type mice, revealed no significant differences in Adamts4 or Adamts5 expression, 
nor changes in cartilage destruction/neo-epitope formation in IL-1α/IL-1β-null mice compared to 
wild-type, suggesting that the effects of WISP1/CCN4 in cartilage-destruction is not dependent on 
the downstream effects of IL-1α and IL-1β (Blom, et al., 2009). The reduction of Wisp1 as a result 
of cytokine stimulation in this thesis is therefore an interesting finding. 
4.3.4.4.4 Wisp2 
Similar to Wisp1, expression of Wisp2 also decreased with cytokine stimulation as seen by both 
microarray and qRT-PCR analysis (Table 4.4). Little is known about the involvement of WISP2/CCN5 
and osteoarthritis in comparison to the other CCN members, although it has been shown at the 
mRNA level to be preferentially detected in the synovium of RA patients compared to OA patients 
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(Tanaka, et al., 2005). However, shear stress at 0.82 Pa of human OA chondrocytes did reveal a 1.6-
fold decrease in WISP2 expression by microarray analysis (Lee, et al., 2009). However, in a mouse 
DMM model of OA, microarray analysis revealed a significant up-regulation of Wisp2 six hours post-
surgery, 4.6-fold as validated by qRT-PCR (Burleigh, et al., 2012), and was also up-regulated in a rat 
medial meniscus tear model 1.6-2.2-fold 3-21 days post-surgery by microarray analysis (Wei, et al., 
2010). This decrease in Wisp2 by IL-1α and OSM stimulation in this thesis is therefore an interesting 
and potentially novel finding. 
4.3.4.5 Lcn2 (Lipocalin 2) 
The most regulated gene by cytokine stimulation, regardless of the presence or absence of WNT5A, 
was Lcn2 (Appendix Table S4.5 and S4.6), which encodes the adipokine lipocalin 2. This has 
previously been shown to be very strongly up-regulated by IL-1β stimulation in ATDC5 cells, a 
human chondrocytic cell line and in primary human chondrocytes at the mRNA and protein levels 
(Conde, et al., 2011). Lipocalin 2 is also expressed in osteoarthritic cartilage and has been shown to 
form a complex with MMP9, protecting it from degradation, demonstrating a possible mechanism 
for lipocalin 2 to contribute to cartilage degradation (Gupta, et al., 2007). It has also been suggested 
to be a marker of late-phase/hypertrophic differentiation, increasing in expression in differentiating 
ATDC5 cells when cells switched from Col2a1 expression to Col10a1 expression (Conde, et al., 2011). 
The increase in Lcn2 in this present study is therefore in agreement with previously published work 
and highlights the relevance of this model to osteoarthritis and osteoarthritic changes. 
4.3.4.6 Prg4 (Proteoglycan 4/Lubricin) 
Also amongst the most highly up-regulated genes by cytokine stimulation regardless of the 
presence or absence of WNT5A was Prg4 (Table 4.4; Appendix Table S4.5, S4.6), which encodes the 
superficial zone marker, proteoglycan 4, more commonly known as lubricin. Lubricin has a well-
defined role in protecting cartilage, as the name suggests, by providing lubrication to the joint, 
protecting the joint from damage (Rhee, et al., 2005; Jay, et al., 2010). Interestingly, IL-1α 
stimulation of primary rat mandibular condylar chondrocytes and cartilage explants from bovine 
stifle joints have previously been shown to decrease expression of Prg4/lubricin (Schmidt, et al., 
2008; Cheng, et al., 2010), in contradiction to the results seen in this thesis by microarray. A 
decrease in PRG4/lubricin expression was also found in a sheep model of early OA by lateral 
meniscectomy (Young, et al., 2006). The increase of Prg4 observed in this thesis by cytokine 
stimulation may therefore present novel regulation of Prg4 by IL-1α and OSM. However, in a bovine 
articular cartilage explant injury model, levels of PRG4/lubricin increased following injury (Jones, et 
al., 2009), suggesting lubricin may act in response to cartilage damage to help protect the cartilage 
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from further damage. In agreement with this, mice overexpressing Prg4 under the control of the 
Col2a1 promoter are protected from the development of OA (Ruan, et al., 2013). 
4.3.4.7 WNT Pathway 
Pathway analysis revealed strong down-regulation of the WNT5A pathway, regardless of the 
presence or absence of WNT5A in the conditioned media (Table 4.5; Figure 4.12). This was 
confirmed in one experiment at the protein level in both cell lysates and conditioned medium 
(Figure 4.14). Not only was Wnt5a itself significantly down-regulated, but a number of members in 
the WNT5A signalling cascade were also down-regulated, including its cognate receptor, Ror2, and 
many members of the frizzled receptors. This is in contrast to previously established regulation of 
WNT5A which has been shown to be increased in response to IL-1β stimulation (Ge, et al., 2011; 
Sonomoto, et al., 2012), revealing novel regulation of WNT5A by cytokine stimulation. 
Intriguingly, strong down-regulation of the canonical pathway was also observed by cytokine 
stimulation, including a down-regulation of Ctnnb1 (β-catenin) and TCF/LEF (Table 4.5; Figure 4.11; 
fold change data not shown), suggesting a total overall down-regulation of the WNT pathways. 
However it should be noted that Wnt5a, which can also activate the canonical WNT pathway 
depending on receptor context, was the only WNT ligand that was significantly regulated by 
cytokine stimulation (data not shown). Since aberrant WNT signalling is often associated with 
osteoarthritis, down-regulation of the WNT pathways may suggest an attempt at protecting against 
damage, in agreement with the very strong up-regulation of Prg4 also seen. 
4.3.4.8 Focal Adhesion Pathway 
Pathway analysis revealed strong regulation of the focal adhesion pathway due to cytokine 
stimulation of ATDC5 micromass cultures. Several members of this pathway were down-regulated, 
including genes that encode for ROCK, JNK and ERK1/2. It has been shown in adherent fibroblasts 
that focal adhesions are enriched with IL-1 receptors required for IL-1 signalling (Qwarnstrom, et 
al., 1988; Dower, et al., 1990), as well as in chondrocytes (Luo, et al., 1997), which can mediate 
ROCK, JNK and ERK signalling (Wang, et al., 2011; Rafferty, et al., 2012). Down-regulation of a 
number of these genes may therefore represent a negative feedback loop to protect the cell from 
the potential harmful effects of the cytokines, as also seen by the large increase in Prg4, as 
previously discussed. 
4.3.5 Similarities with an OA model microarray 
In addition to the similarities in expression of Col2a1 and Adamts4 previously discussed, the 
microarray analysis revealed a number of other genes with similar expression patterns to a 
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microarray analysis conducted on a DMM model of OA, six hours post-surgery. Expression of Saa3 
(serum amyloid a3), Il6, Ccl7 (chemokine (C-C motif) ligand 7) and Mmp3 were amongst the top 15 
most highly up-regulated genes in this thesis following cytokine stimulation both in the presence or 
absence of WNT5A (Appendix Table S4.5, S4.6) and were also amongst the most highly up-regulated 
six hours post DMM surgery (Burleigh, et al., 2012). These genes, amongst others, were not 
significantly regulated four weeks post-surgery in the DMM model (Burleigh, et al., 2012). Together, 
these similarities further suggest cytokine-stimulated ATDC5 micromass cultures may be a good 
alternative model of experimental osteoarthritis. This enables investigation into the gene 
regulation changes and signalling events in a model resembling cartilage changes in early 
osteoarthritis which otherwise may not be possible from cartilage obtained from patients with end-
stage OA undergoing joint replacement surgery. 
4.4 Summary 
Several genes were found to be regulated by WNT5A in differentiated ATDC5 micromass cultures 
by microarray analysis, revealing potentially novel pathways stimulated by WNT5A, including Anxa1 
(annexin a1), which has been associated with increased migration and invasion in a number of cells, 
which WNT5A has also been attributed to. However, of three genes chosen for validation by qRT-
PCR, no such regulation by WNT5A was revealed, indicating these may have been false positives. 
Variation in WNT5A-mediated signalling seen by qRT-PCR between experiments revealed possible 
batch to batch variation in the potency and activity of WNT5A in conditioned media from transiently 
transfected ATDC5 cells, highlighting the need for a more consistent approach by testing the activity 
of WNT5A via various reporter assays, or using a commercially available active source. 
Finally, cytokine stimulation, which very strongly regulated several genes, revealed interesting and 
novel results, down-regulating the WNT5A pathway regardless of the presence or absence of 
WNT5A in the conditioned media as well as several CCN family members, adding to the previously 
established link between the cytokine, WNT signalling and CCN signalling pathways in some novel 
ways. 
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Chapter 5 
Investigating ATDC5 migration and invasion and the potential 
modulation by cytokine and WNT signalling 
Chapter 5 – Investigating ATDC5 migration and invasion and the potential modulation by cytokine and 
WNT signalling 
  
 
152 
 
5.1 Introduction 
5.1.1 Migration and invasion in cartilage and chondrogenesis 
One of the initial stages of chondrogenesis during the development of cartilage is the migration of 
chondroprogenitor cells from the developing paraxial mesoderm, lateral plate mesoderm or cranial 
neural crest via cellular condensation to form aggregates of chondroprogenitor cells, directed by 
cell-cell and cell-matrix interactions to form the axial, limb and craniofacial skeletons respectively 
(Olsen, et al., 2000). One such matrix component, fibronectin, is enriched in cellular aggregates 
during chondrogenesis (Dessau, et al., 1980; Gehris, et al., 1997) and has previously been shown to 
increase cellular condensation during chondrogenesis via peanut agglutinin (PNA) staining by 
plating micromass cultures on top of it (White, et al., 2003).  
Chondroprogenitor cells are characterised by their enhanced ability to adhere to fibronectin 
compared to differentiated chondrocytes (Dowthwaite, et al., 2004; Williams, et al., 2010). It is 
therefore apparent that fibronectin plays an important role in the adhesion and migration of 
chondroprogenitor cells. Furthermore, chondroprogenitor cells in cartilage have previously been 
shown to be migratory. This migratory ability can be modulated in response to both cartilage 
damage and cytokine stimulation (Seol, et al., 2012; Joos, et al., 2013).  
5.1.2 WNT5A and migration/invasion 
WNT5A has been known to modulate migration and invasion in numerous cell types and tissues, 
both positively and negatively. For example, overexpression of WNT5A in various pancreatic cancer 
cell lines have been shown to enhance migration in 2D wound healing scratch assays (Bo, et al., 
2013; Wei, et al., 2013), whereas overexpression of WNT5A in a hepatocarcinoma cell line has been 
shown to decrease migration (Bi, et al., 2014). WNT5A has also been shown to act as a 
chemoattractant to primary human neutrophils (Jung, et al., 2013) and as a haptotactic agent in the 
developing palate (He, et al., 2008). Furthermore, WNT5A stimulation promoted invasion of the 
typically non-invasive breast carcinoma cell line, MCF-7 (Pukrop, et al., 2006), whereas WNT5A 
overexpression in the highly invasive mouse breast carcinoma cell line, 4T1, inhibited migration in 
a transwell assay and inhibited lung invasion and colonisation (Jiang, et al., 2013). The role of 
WNT5A on migration and invasion may therefore be context-dependent.  
5.1.3 Aims 
Since WNT5A is expressed in osteoarthritic cartilage (Nakamura, et al., 2005), and 
chondroprogenitor cells have been shown to migrate to sites of cartilage damage (Seol, et al., 2012), 
it was hypothesised that WNT5A may modulate chondroprogenitor cell migration and invasion.  
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To test this, non-induced ATDC5 cells were used as a model for chondroprogenitor cells. Migration 
of non-induced ATDC5 cells was investigated using a range of biologically relevant substrates, as 
well as tissue culture-treated plastic (hereafter simply referred to as plastic) in combination with 
0.2 % FCS, which also contains fibronectin (Hayman & Ruoslahti, 1979).  
Potential chemokinetic and chemoattractive abilities of WNT5A was also investigated in both 
physiological and pathophysiological settings by the use of the inflammatory cytokines, IL-1α and 
OSM. This was investigated both in 2D random migration, where cytokines were used in 
conjunction with WNT5A to stimulate the migrating cells directly, as well as 3D invasion into 
differentiated micromasses, where cytokines were used to initiate potential breakdown of the 
matrix before the invasion of non-induced cells took place towards a WNT5A gradient. In some 
experiments, WNT3A was also used to investigate the difference between the impact of non-
canonical and canonical WNT signalling. 
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5.2 Results 
5.2.1 Non-induced ATDC5 cells adhere better to fibronectin than to type II collagen 
The ability for non-induced ATDC5 cells to adhere to fibronectin or type II collagen at various 
concentrations was investigated following 60 min of adhesion. Adhesion was calculated based on 
the absorbance of staining with methylene blue, which was proportional to the number of adhered 
cells after non-adhered cells were washed off (for more detailed information on the adhesion assay, 
please see section 2.7).  
After plating for 60 min, significantly more non-induced ATDC5 cells adhered to fibronectin 
compared to type II collagen above 2 µg/ml (Figure 5.1). Adhesion did not occur at concentrations 
of 0.4 µg/ml or below on either substrate. Dose response curves were evident, with increased 
adhesion as a result of increasing concentration of substrate used. Maximal adhesion to fibronectin 
occurred at lower concentrations than to type II collagen, with adhesion to fibronectin plateauing 
around 10 µg/ml compared to 50 µg/ml to type II collagen (Figure 5.1). Based on these results, 
future experiments were conducted using 10 µg/ml fibronectin and 50 µg/ml type II collagen.  
Figure 5.1 – Adhesion of non-induced ATDC5 cells to Fibronectin and Type II Collagen at 
different concentrations. Non-induced ATDC5 cells were allowed to adhere to either fibronectin 
or type II collagen for 60 min and non-adhered cells were washed off. Results expressed as 
average absorbance at OD 630 nm of methylene blue staining, normalised to adhesion to BSA. 
Significance tested by ANOVA + Dunnett post-hoc test compared to 0.08 µg/ml substrate. N=4 
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5.2.2 Type II Collagen substrate impedes non-induced ATDC5 random migration 
To investigate the ability for non-induced ATDC5 cells to randomly migrate, time-lapse microscopy 
was used to observe and measure the speed of migration on plastic, fibronectin and on type II 
collagen in the presence of 0.2 % FCS. This was calculated based on the tracking of 20 individual 
cells per condition, frame by frame, on different matrix substrates over 17 hours, with images taken 
every 10 min. For more detailed information, please see section 2.8. 
Non-induced ATDC5 cells migrated more slowly on type II collagen than on plastic or fibronectin 
(Figure 5.2). This result was seen consistently across three experiments comparing plastic to type II 
collagen and in three out of four experiments comparing fibronectin to type II collagen. The 
comparison between plastic and fibronectin was only made once as results were not significantly 
different. Additionally, the use of 0.2 % FCS provided a fibronectin-containing matrix. Together, 
these data suggest that type II collagen impedes random two-dimensional migration in non-induced 
cells. 
  
Figure 5.2 – Non-induced ATDC5 random migration. Non-induced ATDC5 cells were plated on 
either plastic, 10 µg/ml fibronectin or 50 µg/ml type II collagen, all in the presence of 0.2 % FCS 
for 17 hours. Data expressed as average cell speed over 17 hours, tracking 20 cells across 
quadruplicate wells. Plastic to fibronectin comparison performed once. Type II Collagen to 
plastic or fibronectin comparisons performed three and four times respectively. 
* = significant compared to Plastic 
† = significant compared to Fibronectin 
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5.2.3 Differentiated ATDC5 cells are less migratory than undifferentiated cells 
Cells isolated using trypsin from insulin-induced ATDC5 cells cultured in micromass and stimulated 
with ascorbic acid were allowed to randomly migrate over 17 hours on plastic or on type II collagen 
in media containing 0.2 % FCS. Non-induced cells which had been maintained in their 
undifferentiated state were used as a comparison as described previously. For more detailed 
information, please see section 2.8.  
ATDC5 cells isolated from induced micromass cultures were significantly slower than non-induced 
cells on plastic. No significant reduction in speed was seen in two out of three experiments when 
micromass-isolated cells were plated on type II collagen compared to non-induced cells. Non-
induced cells were also significantly slower when migrating on type II collagen compared to plastic.  
Removal of insulin and ascorbic acid from differentiated cells had no effect on the average speed 
(Figure 5.3 A).  
At the end of the migration assay, 21 hours after isolating cells from differentiated micromass 
cultures, cells had retained their differentiated status, as noted by significantly higher levels of 
Col2a1 compared to undifferentiated cells. Interestingly, micromass-isolated cells which were kept 
in differentiating medium (insulin and ascorbic acid) had lower expression of Col2a1 compared to 
cells which had insulin and ascorbic acid removed (Figure 5.3 B). However, this change in Col2a1 
expression was only seen once in cells plated on plastic, compared to consistently across three 
experiments when plated on type II collagen. 
On plastic, non-induced cells were flat and spread throughout the time-course (Figure 5.4 A-B). Cells 
isolated from micromass cultures began with a slightly more round, less spread morphology, which 
became flatter and more spread with time (Figure 5.4 C-F). On type II collagen, most cells from all 
conditions started with a round, unspread morphology, with those coming from non-induced cells 
exhibiting slightly more spread cells (Figure 5.5 A, C, E). With time on type II collagen, some cells 
from all conditions became flatter and more spread (Figure 5.5 B, D, F). 
These results indicate that differentiated ATDC5 cells are less migratory than non-induced, 
undifferentiated cells. 
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Figure 5.3 – Comparison of speed in randomly migrating undifferentiated and differentiated 
ATDC5 cells. A) Average speed in µm/hr of ATDC5 cells isolated from 14-day insulin-induced, 
ascorbic acid-stimulated micromass cultures, with (Ins + Asc Retained) and without (Ins + Asc 
Removed) insulin and ascorbic acid was compared to non-induced, undifferentiated cells 
migrating on plastic or type II collagen in media containing 0.2 % FCS over 17 hours, tracking 20 
cells across quadruplicate wells. B) Expression of Col2a1 after tracking migration of cells used in 
A, normalised to Ywhaz expression. 
* = significant compared to Plastic 
† = significant compared to Non-induced 
‡ = significant compared to Ins + Asc Removed 
B 
A 
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Figure 5.4 – Morphological differences on plastic over time after isolating cells from 
differentiated micromass cultures. ATDC5 cells were isolated from 14-day insulin-induced 
micromass cultures stimulated with ascorbic acid and plated onto plastic in the presence of 
0.2 % FCS. A-B) Non-induced ATDC5 cells obtained from maintained monolayer cultures. C-D) 
ATDC5 cells isolated from micromass cultures with removal of insulin and ascorbic acid from 
medium before plating (Ins + Asc Removed). E-F) ATDC5 cells isolated from micromass cultures 
retaining insulin and ascorbic acid in the media over the 17 hours (Ins + Asc Retained). Images 
shown are from 0 hours from time-lapse analysis (4 hours after isolation)(A,C,E), or at 17 hours 
at the end of the time-lapse analysis (21 hours after isolation) (B,D,F). Scale = 100 µm 
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Figure 5.5 – Morphological differences on type II collagen over time after isolating cells from 
differentiated micromass cultures. ATDC5 cells were isolated from 14-day insulin-induced 
micromass cultures stimulated with ascorbic acid and plated onto 50 µg/ml type II collagen in 
the presence of 0.2 % FCS. A-B) Non-induced ATDC5 cells obtained from maintained monolayer 
cultures. C-D) ATDC5 cells isolated from micromass cultures with removal of insulin and ascorbic 
acid from medium before plating (Ins + Asc Removed). E-F) ATDC5 cells isolated from micromass 
cultures retaining insulin and ascorbic acid in the media over the 17 hours (Ins + Asc Retained). 
Images shown are from 0 hours from time-lapse analysis (4 hours after isolation)(A,C,E), or at 
17 hours at the end of the time-lapse analysis (21 hours after isolation) (B,D,F). Scale = 100 µm 
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5.2.4 Effect of WNT stimulation on non-induced ATDC5 migration  
Potential modulation of migration in non-induced ATDC5 cells by WNT stimulation was explored by 
stimulating ATDC5 cells at the start of the 17 hour migration period with either WNT3A (thought to 
typically induce canonical wnt signalling), or WNT5A (thought to typically induce non-canonical wnt 
signalling) conditioned media generated from transiently overexpressing ATDC5 cells, in the 
presence of 0.2 % FCS. For more information, please see section 2.8. 
By pairwise comparison, no modulation of migration was seen by WNT5A stimulation regardless of 
substrate (Figure 5.6 A). However, a small but significant increase was seen in the speed of 
migration when cells were stimulated with WNT3A conditioned medium compared to Vector Only 
medium when plated on type II collagen (Figure 5.6 B).  
Comparisons were also made when stimulating the cells with and without cytokines to represent 
an osteoarthritic-like context. However, data between some conditions were inconsistent when 
cytokines were present and so are not shown, although WNT5A was seen to decrease the speed of 
migration compared to WNT3A in the presence of cytokines when plated on type II collagen across 
two experiments (Appendix Figure S5.1).  
However, it should be noted that due to time constrictions, only two experiments were performed, 
so more experiments are needed to confirm any changes or lack thereof. 
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Figure 5.6 – Effect of WNT5A and WNT3A stimulation on non-induced ATDC5 migration. Non-
induced ATDC5 cells were plated on either plastic or type II collagen, both in the presence of 
0.2 % FCS and stimulated with WNT5A conditioned medium (A), or WNT3A conditioned medium 
(B) for 17 hours. Data expressed as average cell speed over 17 hours, tracking 20 cells across 
quadruplicate wells. Experiment performed twice, with one example shown, displaying 
consistent changes. 
† = significant compared to Vector Only 
‡ = significant compared to Plastic 
B 
A 
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5.2.5 Modelling chondroprogenitor cell invasion through cartilage 
No effect was observed in random migration assays due to WNT5A stimulation compared to the 
Vector Only conditioned medium control, indicating that the WNT5A conditioned medium used did 
not act as a chemokinetic agent. Therefore the potential ability to act as a chemoattractant to non-
induced ATDC5 cells was investigated. 
To investigate this in a more physiologically-relevant environment, non-induced ATDC5 cells (plated 
on the underside of a transwell) were allowed to invade towards a gradient of WNT5A conditioned 
medium through methanol-fixed, insulin-induced and ascorbic acid-stimulated micromasses (in the 
upper chamber of the transwell) that had been previously stimulated with or without cytokines for 
48 hours at the end of the 14-day chondrogenesis induction period to simulate osteoarthritic-like 
cartilage prior to fixation. For a more in-depth description of this novel assay, please see section 
2.9. 
All conditions exhibited some invasion, with non-induced cells commonly featuring extended cells 
processes found in invading cells (Zamora, et al., 1980; Witz, et al., 2003) (Figure 5.7 arrows), 
indicating that non-induced ATDC5 chondroprogenitor cells are able to invade through a cartilage-
like matrix. 
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Figure 5.7 – Extended focus comparison of non-induced ATDC5 cells invading towards WNT5A. 
Non-induced ATDC5 cells were allowed to invade towards WNT5A conditioned medium (or 
Vector Only control) for 48 hours through methanol-fixed 14-day insulin/ascorbic acid-treated 
micromass cultures which had previously been stimulated with or without IL-1α and OSM 
cytokines for 48 hours. Fixed and dead cells were stained with ethidium homodimer-1 (red) and 
live cells were stained with calcein-AM (green). Optical sections were taken every 2 µm and 
images shown are an extended focus view, compressing all sections into one image with a top-
down perspective, with a higher WNT5A concentration above the image and lower 
concentration through the image). White arrows show extended cell processes. Inserts = 
magnified image of dotted area highlighting an extended cell process. Scale = 50 µm 
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When micromasses had not previously been stimulated with cytokines, a trend towards increased 
invasion towards WNT5A conditioned medium was observed in two out of three experiments, 
although this did not reach significance (Figure 5.8). Cytokine pre-stimulation of the micromass 
cultures before invasion resulted in a decrease of invasion towards WNT5A conditioned medium, 
but not towards the Vector Only control, likely due to the slight increase in invasion exhibited 
towards WNT5A in micromass cultures which were not pre-stimulated with cytokines (Figure 5.8). 
This may suggest that any potential chemoattractive ability of WNT5A on non-induced ATDC5 cells 
may be dependent an intact matrix. 
  
Figure 5.8 – Identifying the potential chemoattractive ability of WNT5A on non-induced 
ATDC5 cells invading through fixed differentiated micromass cultures. Non-induced ATDC5 
cells were allowed to invade for 48 hours through methanol-fixed 14-day, insulin/ascorbic acid 
stimulated micromass cultures that had previously been stimulated with or without cytokines 
for 48 hours. Results expressed as number of invading cells above transwell membrane. 
Experiment performed three times with representative experiment shown. * = significant 
compared to No Cytokines. 
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To explore further the trend of increased invasion towards WNT5A, recombinant human 
(rh)WNT5A was used (a kind gift from Dr. Victoria Sherwood, UEA) instead of WNT5A conditioned 
medium, using a carrier control (0.1 % BSA stock). In line with results obtained from conditioned 
media, rhWNT5A led to a slight increase in invasion through micromass cultures that had not been 
previously stimulated with cytokines, however, this again did not reach significance (Figure 5.9). 
Interestingly, invasion was significantly increased towards rhWNT5A when micromass cultures 
were pre-stimulated with cytokines, in contrast to the results seen in Figure 5.8, which reflect 
interaction of WNT5A with other ATDC5 media constituents in the conditioned medium experiment. 
However, it should be noted that this experiment was only performed once and further repeats are 
needed. 
  
Figure 5.9 – Confirming invasion of non-induced ATDC5 cells through fixed micromass cultures 
using rhWNT5A. Non-induced ATDC5 cells were allowed to invade for 48 hours through 
methanol-fixed 14-day, insulin/ascorbic acid stimulated micromass cultures that had previously 
been stimulated with or without cytokines for 48 hours towards rhWNT5A or Carrier control. 
Results expressed as number of invading cells above transwell membrane. Experiment 
performed once. † = significant compared to Carrier. 
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5.3 Discussion 
5.3.1 Non-induced ATDC5 cells adhere better to fibronectin than to type II collagen 
In a short-term adhesion assay, more non-induced ATDC5 cells adhered to fibronectin than to type 
II collagen, with maximal adhesion occuring at a lower concentration of fibronectin compared to 
type II collagen (Figure 5.1). These data agree with studies where both human and bovine 
chondroprogenitor cells isolated from the superficial zone of articular cartilage have an enhanced 
ability to adhere to fibronectin compared to mature chondrocytes and can be selected by this 
adhesion potential (Dowthwaite, et al., 2004; Williams, et al., 2010). 
Little work has been conducted investigating the adhesion of chondroprogenitor cells to type II 
collagen. In contrast to this thesis, it has previously been reported that chondroprogenitor cells 
isolated from human osteoarthritic cartilage adhered equally well to both fibronectin and type II 
collagen (Koelling, et al., 2009) plated at 10 µg/cm2, which would be the equivalent of a 
concentration of 36 µg/ml if used in this study.  By interpolation at this concentration, roughly a 
two-fold difference was seen in this thesis (Figure 5.1). However, it is not known how long the cells 
were allowed to adhere in the Koelling study, which could allow for increased adhesion if cells were 
allowed to adhere over a longer time period.  Furthermore, as previously noted, these cells were 
isolated from human osteoarthritic cartilage. It would therefore be interesting to see if the same 
results were seen in human non-OA chondroprogenitor cells or if a difference would be seen in 
cytokine-challenged ATDC5 cells. Additionally, the chondroprogenitor cells were isolated from the 
cartilage based on their ability to migrate away from the explant culture rather than their enhanced 
ability to adhere to fibronectin. 
Similarly in another study, chondrocytes extracted from calf patellae by collagenase II digestion 
exhibited similar adhesion to both type II collagen and fibronectin (Schmal, et al., 2006). However, 
upon sequential passaging, which induces de-differentiation of chondrocytes, P2 chondrocytes 
exhibited increased adhesion to fibronectin and a decreased adhesion to type II collagen compared 
to P0 chondrocytes cultured for 3 days, resulting in roughly a five-fold increase in adhesion to 
fibronectin compared to type II collagen in the P2 chondrocytes (Schmal, et al., 2006). This suggests 
that chondrocyte adhesion to matrix components may depend on the differentiated status of cell. 
Since the ATDC5 cells used in this thesis were non-induced, the preference for fibronectin 
compared to type II collagen would correlate with the findings in this study, although adhesion 
using insulin-induced ATDC5 cells was not tested to see how this might change with differentiation. 
 
167 
 
5.3.2 Type II Collagen impedes the speed of migration 
Non-induced cells migrating on fibronectin showed a similar migratory speed averaged over 17 
hours to those migrating on plastic. Migration studies however were performed in the presence of 
0.2 % FCS, which is known to contain various ECM components, including fibronectin (Hayman & 
Ruoslahti, 1979). Cells migrating on type II collagen migrated significantly more slowly compared to 
those migrating on fibronectin (Figure 5.5). Figure 5.1 showed that non-induced ATDC5 cells adhere 
significantly more to fibronectin than to type II collagen. This may partly explain the decrease in 
migration observed on type II collagen in Figure 5.5. It is known that cells require an optimal 
strength or amount of adhesion to the substratum to promote migration; too strong or too much 
adhesion and cells may be unable to detach their rear end from the substratum efficiently to move 
forward, potentially immobilising the cell; too weak or too little adhesion and there may not be 
enough traction for the cells to pull themselves forward, generating a biphasic dependence on 
adhesion for migration to occur (DiMilla, et al., 1993; Palecek, et al., 1997; Ware, et al., 1998; Cox, 
et al., 2001). 
5.3.2.1 DDR2 
Since a reduction in migration was observed by type II collagen, it is relevant to consider the type II 
collagen-binding receptor, DDR2. This thesis has shown that at the protein level, DDR2 was down-
regulated with increasing chondrogenesis in ATDC5 cells (Figure 3.16). DDR2 is known to bind to 
both types I and II collagen (Leitinger, et al., 2004; Konitsiotis, et al., 2008). Knockdown of DDR2 in 
fibroblasts has been shown to decrease migration both in 2D and 3D using a type I collagen matrix 
(Herrera-Herrera & Quezada-Calvillo, 2012; Ruiz & Jarai, 2012; Kim, et al., 2013a), and antibody-
mediated inhibition of DDR2 has been shown to decrease chemotactic migration to IL-8 in 
neutrophils (Afonso, et al., 2013). Overexpression in HEK293 cells has been shown to increase 
adhesion to type I collagen and activation of DDR2 can promote α1β1 and α2β1 integrin activation 
and mediated adhesion (Xu, et al., 2012). Conversely, no signficant differences were found in 
adhesion and migration on type I collagen between Ddr2+/+ and Ddr2-/- smooth muscle cells. 
However, the importance of DDR2 and adhesion to or migration on type II collagen in chondrocytes 
remains to be elucidated. It would therefore be interesting to investigate differences in adhesion 
and migration to type II collagen by modulating DDR2 expression in ATDC5 cells. 
5.3.3 The differentiated state of ATDC5 cells affects the migratory potential 
This study has shown that non-induced ATDC5 cells have a migratory phenotype. In accordance 
with this, faster migrating ATDC5 cells were flat and spread, exhibiting extended processes 
associated with a migratory phenotype (Figure 5.4 A-B). However, ATDC5 cells isolated from 
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differentiated micromasses migrated more slowly (Figure 5.3 A). Many of these cells were rounded, 
representitive of the chondrocytic phenotype, which became flatter and more spread with time. 
Although flat spread cells are less reminiscent of the chondrocytic phenotype, qRT-PCR analysis 
revealed that at the end of the 17 hour migration assay, 21 hours after isolation, these cultures still 
expressed large amounts of Col2a1 compared to non-induced cells, indicating these cells were still 
differentiated (Figure 5.3 B). Whilst it is known that chondrocytes begin to de-differentiate upon 
isolation and passaging in monolayer culture, this process is still time dependent. Previous studies 
have shown isolated chondrocytes migrating across a transwell membrane retain their 
differentiated status (Chang, et al., 2003) and that morphological differences are not enough to 
distinguish de-differentiation (von der Mark, et al., 1977; Benya, et al., 1988; Chang, et al., 2003). 
Chondroprogenitor cells, which are not fully differentiated into chondrocytes (Koelling, et al., 2009; 
Zhou, et al., 2014), are a subpopulation of cells that reside within cartilage (Dowthwaite, et al., 2004; 
Koelling, et al., 2009; Seol, et al., 2012; Matta, et al., 2014). These cells, which are enriched in 
osteoarthritic cartilage (Alsalameh, et al., 2004), can be isolated from osteoarthritic cartilage based 
on their ability to migrate away from cartilage explant cultures (Koelling, et al., 2009; Joos, et al., 
2013; Matta, et al., 2014), as well as their increased adhesion to fibronectin (Dowthwaite, et al., 
2004; Seol, et al., 2012). The migratory and adhesive phenotype of non-induced undifferentiated 
ATDC5 cells in this study is therefore reminiscent of the migratory and adhesive phenotype of 
primary chondroprogenitors. 
Since non-induced ATDC5 cells have a migratory phenotype similar to primary chondroprogenitor 
cells compared to insulin-induced ATDC5 cells, and that chondroprogenitor cells are enriched in 
osteoarthritic cartilage and are able to elicit a migratory response to damage signals, only non-
induced ATDC5 cells were used in further experiments investigating migration. 
5.3.3.1 Aquaporin-1 
As previously discussed, adhesion to type II collagen, and subsequently possibly migration, may 
depend on the differentiated status of the cell, with a negative correlation between the 
differentiated state of the cell and its ability to adhere to type II collagen previously reported 
(Schmal, et al., 2006).  
A decrease in adhesion to type II collagen has also been reported in aquaporin-1 knockout (Aqp1-/-) 
primary mouse articular chondrocytes (Liang, et al., 2008). Aquaporin-1 is part of the aquaporin 
family of membrane proteins involved in water transport, and sometimes small solutes such as 
glycerol, across the cell membrane (Verkman, 2005; Monzani, et al., 2009). Aquaporin-1 has also 
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been shown to modulate cell migration, such that overexpression increases migration and/or 
knockdown decreases migration in a number of cell types, including a human melanoma cell line 
(Monzani, et al., 2009), human and mouse endothelial cells (Saadoun, et al., 2005; Monzani, et al., 
2009), a human glioblastoma cell line (McCoy & Sontheimer, 2007), rat BMSCs (Meng, et al., 2014) 
and mouse articular chondrocytes (Liang, et al., 2008). It has been proposed that aquaporins 
enhance cell migration due to a local increase in hydrostatic pressue due to water influx which may 
cause membrane protrusions associated with migration, creating space for actin polymerisation 
(Verkman, 2005). In rat BMSCs, it was reported that aquaporin-mediated migration was via the 
focal adhesion kinase (FAK) and β-catenin pathways, which in addition to its role in the canonical 
WNT signalling pathway, is also important in modulation of the actin cytoskeleton, linking actin at 
the cell surface via α-catenin (Meng, et al., 2014). 
A recent study showed mRNA levels of AQP1 significantly increased with increasing chondrogenesis 
in differentiating human MSCs (Ishihara, et al., 2014). In insulin-induced ATDC5 cells, Aqp1 was 
significantly up-regulated at the early stages of chondrogenesis, reaching peak expression after 3-
4 days of insulin-induction, corresponding with the very early increases in Col2a1 expression, but 
decreased in expression from days 4-11 as Col2a1 expression reached its peak expression (Ishihara, 
et al., 2014). These results suggest that aquaporin-1-mediated plasma membrane water 
permeability may play a role in chondrocyte migration and adhesion, and the differences in 
migration seen between non-induced and induced cells may be due in part to the different levels 
of aquaporin-1 in differentiating chondrocytes. It would therefore be interesting to compare the 
levels of Aqp1 in the isolated ATDC5 chondrocytes from the micromass cultures to the non-induced 
ATDC5 chondroprogenitor cells to see whether these correlated with the differences in migration. 
5.3.4 Modulation of migration and invasion by WNT5A and WNT3A 
Stimulation of non-induced ATDC5 cells with WNT5A conditioned medium did not modulate the 
speed of migration regardless of substratum (Figure 5.6 A). On type II collagen, speed of migration 
was increased by stimulation with WNT3A conditioned medium (Figure 5.6 B). Additionally, in the 
presence of cytokines, WNT5A impeded the speed migration compared to WNT3A conditioned 
medium (Appendix Figure S5.1).  
In contrast, a non-significant trend to increase in invasion towards WNT5A conditioned medium 
was observed when non-induced ATDC5 cells were allowed to invade through differentiated 
micromass cultures (Figure 5.8). When rhWNT5A was used to validate these findings, a significant 
increase was seen when micromasses had been pre-stimulated with cytokines along with the 
similar trend towards increased invasion when micromass cultures had not been pre-stimulated 
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(Figure 5.9), suggesting a potential ability of WNT5A to act as a chemokinetic agent for 
chondroprogenitor cells. Given that rhWNT5A promoted invasion in the one experiment performed, 
it would be interesting to see if rhWNT5A also modulated 2D migration, to confirm whether the 
lack of significant effects with WNT5A conditioned medium is real or due to a lack of activity of the 
generated WNT5A. Further experiments are also needed to validate the potential chemokinetic 
ability of rhWNT5A and whether a higher concentration may further enhance this. Additionally, 
non-induced ATDC5 cells were not observed to invade far beyond the transwell filter and so longer 
periods of invasion may result in greater differences between conditions, leading to more 
significant results. 
As previously discussed, WNT5A has been known to both positively and negatively regulate 
migration in a variety of cells (see section 5.1). Similarly, WNT3A is known to regulate migration in 
a number of cell types. For example, stimulation with WNT3A promoted migration of trophoblast 
cells in a transwell assay (Sonderegger, et al., 2010) and inhibition of WNT3A has been shown to 
decrease migration of glioma stem cells (Kaur, et al., 2013). WNT3A has also been reported to act 
as a chemoattractant, promoting migration of HUVECs in a transwell assay across a WNT3A gradient 
(Samarzija, et al., 2009). 
Little data has been reported investigating the roles of WNT5A or WNT3A in the migration or 
invasion of chondrocytes or chondroprogenitor cells. However, there are several reports of 
migration modulated by WNT5A/WNT3A non-canonical/canonical signalling in MSCs, which are 
capable of differentiating into chondrocytes and share a similar transcriptomic phenotype with 
chondroprogenitor cells (Seol, et al., 2012). WNT3A has been shown to increase migration of rat 
BMSCs in a scratch assay and act as a chemoattactant in a transwell assay (Shang, et al., 2007). 
Similarly, treatment of mouse BMSCs with WNT3A has been shown to increase migration towards 
FCS and acute lung injury extracts (Liu, et al., 2013a). However, another paper reported a decrease 
in invasion across a matrigel-coated transwell of mouse BMSCs pre-treated with WNT3A migrating 
towards mouse serum (Karow, et al., 2009). The differences seen in the modulation of migration 
and invasion may therefore be due to different experimental approaches despite both groups using 
mouse BMSCs, suggesting that the use of matrigel or the different types of serum may interact or 
interfere with the canonical WNT signalling pathway. 
Conversely, the same group reporting a decrease in invasion had previously reported an increase 
in invasion of human MSCs pre-treated with WNT3A invading through human placental ECM 
towards human serum (Neth, et al., 2006), and suggest the differences seen between mouse and 
human MSCs may be partially explained by the differential regulation of MT1-MMP, known to 
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modulate cell migration and invasion (reviewed in Seiki, et al. (2003)), which was down-regulated 
in mouse MSCs but no significant differences were seen in human MSCs when treated with WNT3A. 
In comparison to WNT3A, less is known about the effect of WNT5A on MSC migration. However, 
one group has reported that migration was increased in mouse MSCs overexpressing either Ror2 (a 
non-canonical WNT5A receptor) or Ctnnb1 (which encodes β-catenin), and decreased by shRNA 
inhibition (Cai, et al., 2014).  
Taken together, this indicates that both non-canonical and canonical WNT signalling may modulate 
migration in MSCs, both in a positive and negative manner. This thesis has extended this knowledge 
to the ATDC5 chondroprogenitor model, observing the ability for WNT5A to act as a potential 
chemoattractant (Figure 5.8) and WNT3A to act as a potential chemokinetic agent (Figure 5.6 B).  
5.4 Summary 
This thesis has identified that ATDC5 cells have an adhesive and migratory phenotype reminscent 
of primary chondroprogenitor cells and chondrocytes, depending on the state of chondrogenesis. 
Additionally, it was found that type II collagen impedes the speed of 2D migration, which may have 
ramifications for the ability of chondroprogenitor cells to migrate in vivo. 
This thesis also identified that WNT5A and WNT3A may act as potential chemoattractant and 
chemokinetic agents respectively in ATDC5 cells. Since WNT5A is known to promote early-stage 
chondrogenesis (Bradley & Drissi, 2010), is known to be expressed in osteoarthritic cartilage 
(Nakamura, et al., 2005) and that chondroprogenitor cells migrate to sites of cartilage injury (Seol, 
et al., 2012), it could be hypothesised that chondroprogenitor cells could be recruited to sites of 
osteoarthritic cartilage by WNT5A in an attempt to repair any damage, enhanced by the 
chemokinetic abilities of WNT3A, which is also expressed in osteoarthritic cartilage (Nakamura, et 
al., 2005). However, further experiments are needed to confirm these effects on ATDC5 cells. 
Regardless of the effect of WNT signalling, this thesis also described apparently for the first time a 
quantitive invasion model of chondroprogenitor cells invading through a cartilage-like matrix, by 
combining and building upon two techniques. Given that chondroprogenitor cells are known to 
migrate to sites of cartilage injury, this somewhat novel model may therefore be important in 
understanding the factors modulating chondroprogenitor cell translocation to help us further 
understand the events that occur during cartilage injury and osteoarthritis. A summary of all the 
findings from Chapter 5 can be found in Table 5.1. 
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Component 
Effect On… 
Adhesion Migration Invasion 
Fibronectin  
↑ 
with increasing 
concentration 
  
Type II Collagen 
↑  
with increasing 
concentration 
↓  
compared to plastic 
 
Differentiated 
chondrocytes 
 
↓  
compared to 
undifferentiated 
cells 
 
WNT3A CM  ↔  
WNT5A CM  ↔ ↔ 
Cytokine-treated 
micromass 
  
↓  
towards WNT5A 
gradient 
rhWNT5A   ↑ 
Table 5.1 – Summary of the effect of various components on adhesion, migration and 
invasion of ATDC5 cells. Compiled using information from section 5.2. For more details on the 
individual experiments and conditions used, please refer to the original figures in section 5.2. 
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Chapter 6 
General Discussion 
Chapter 6 – General Discussion 
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6.1 General Discussion 
Understanding chondrogenic differentiation and gene expression changes which relate to 
osteoarthritis require robust in vitro model systems to test relevant hypotheses to help further 
understand the mechanisms of the osteoarthritis and how the cartilage might attempt to repair 
itself. 
In this thesis, data have been provided identifying the changes in gene and protein regulation during 
chondrogenic differentiation of the murine chondroprogenitor cell line, ATDC5. Data showed that 
this model of chondrogenesis could be further enhanced by combining techniques used for the 
culture of primary chondrocytes, producing a cartilage-like tissue that had similar expression 
patterns to articular cartilage previously reported. 
These cultures were then used to investigate regulation of molecular pathways in both a 
physiological and disease-like context by stimulation with by exogenous factors or overexpression 
of WNT5A, leading to the identification of novel regulation of a number of genes.  
Additionally, migration studies revealed that undifferentiated cells and differentiated cells had 
similar migratory phenotypes to the previously reported migratory phenotypes of primary 
chondroprogenitor cells and mature chondrocytes respectively. A novel method to model invasion 
by chondrocytic cells was also developed. 
Together, this indicates that the ATDC5 cell line may be a good model for understanding many 
aspects of articular cartilage biology and pathology. 
6.1.1 An enhanced ATDC5 chondrogenesis model 
In chapter 3, data revealed that modification of the standard ATDC5 chondrogenesis model by 
culturing in a three-dimensional micromass culture, in combination with stimulation with ascorbic 
acid, enhanced chondrogenesis, producing a type II collagen- and proteoglycan-rich cartilage-like 
tissue in comparison to the heterogeneity observed with standard induction by insulin in monolayer 
which had large areas of undifferentiated cells surrounding differentiated nodules. An increase in 
Col10a1 steady-state mRNA, a marker of chondrocyte hypertrophy, coincided with only small 
regions of type X collagen protein immunolocalisation within the central micromass cultures, whilst 
expression of other hypertrophy markers decreased, such as Tgfb3, Ctgf and DDR2. Furthermore, 
expression of Frzb, which is enriched in articular cartilage (Leijten, et al., 2012), was significantly 
increased. Together, this suggests that the modified ATDC5 chondrogenesis model is an enhanced 
model, more reminiscent of articular cartilage compared to growth plate cartilage. This makes the 
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enhanced ATDC5 chondrogenesis model a suitable and desirable model for investigating 
osteoarthritis-related changed, a disease characterised by the degradation of articular cartilage and 
not growth plate cartilage. 
Nevertheless, it has been reported that a more growth plate/hypertrophic cartilage-like tissue can 
also be obtained by adapting the culturing conditions in monolayer, including culturing for longer 
periods of time, reducing CO2 levels and switching medium to α-MEM (Shukunami, et al., 1997; 
Swingler, et al., 2012), indicating the adaptability and usefulness of ATDC5 cells to model different 
types of cartilage. 
It is known that the extracellular microenvironment plays a very important role in modulating the 
behaviour and actions of a cell. This is especially true in chondrocytes which only sparsely populate 
mature cartilage and are surrounded by extensive matrix in all three dimensions. The use of high 
density cultures therefore may be thought of as a peculiar method to enhance chondrogenesis. 
However, it is thought that this high-density culture recapitulates events during early 
chondrogenesis whereby progenitor cells condense into aggregates, increasing cell-cell contacts, as 
discussed previously. Other models exist which also enhance chondrogenesis by increasing the 
three-dimensional cell-cell contacts, such as the pellet culture described previously in Chapter 1, 
including in ATDC5 cells (Tare, et al., 2005). However, compared to micromass cultures, pellet 
cultures are typically grown in 15 ml centrifuge tubes, requiring a larger amount of space in the 
incubator. Additionally, only one pellet can be placed in one tube, making scaling of experiments 
difficult. On the other hand, micromass cultures are grown in standard multi-well plates and 
multiple cultures can be grown in the same well, making the micromass culture system an ideal 
system for high-throughput screening experiments. 
In summary, this thesis appears to be the first time the beneficial effects of the combination of both 
micromass culture and ascorbic acid stimulation, over their use alone in ATDC5 cells, have been 
established, and importantly, directly compared to the standard culture of ATDC5 cells in 
monolayer with insulin-induction alone. 
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6.1.2 Novel cytokine-mediated regulation of the WNT and CCN molecular signalling 
pathways 
The role of WNT5A during cartilage development has been well established, however, the 
involvement of WNT5A in cartilage in a pathological setting remained to be elucidated. 
Furthermore, whilst it is known that cytokines play an important role in the development of 
osteoarthritis, inducing the up-regulation of a number of metalloproteinases to degrade the 
cartilage matrix, and knowing that cytokines may modulate the WNT signalling pathways, the 
mechanisms behind this interaction and how this attributed to the progression of osteoarthritis 
remained unclear. 
Several approaches were taken to address these points, including over-expression of WNT5A and 
exogenous WNT5A/cytokine stimulation of the enhanced ATDC5 chondrogenesis model described 
in Chapter 3. Data from this thesis provided interesting results by stimulating differentiated 
micromass cultures with a combination of WNT5A conditioned medium with the IL-1α and OSM 
cytokines. Pathway analysis from data obtained from the microarray revealed strong down-
regulation of the WNT5A pathway. qRT-PCR analysis similarly revealed down-regulation of the 
WNT5A receptor, Ror2, and western blotting confirmed the down-regulation of WNT5A itself with 
cytokine stimulation.  
This down-regulation is an apparently novel finding, with several reports describing up-regulation 
of WNT5A following stimulation from a number of different cytokines, (including IL-α, IL-1β, IL-6 
and TNFα) in a number of cell types, including myofibroblasts, melanomas, keratinocytes, MSCs and 
chondrocytes (Gudjonsson, et al., 2010; Ge, et al., 2011; Rauner, et al., 2012; Raymond, et al., 2012; 
Sonomoto, et al., 2012; Briolay, et al., 2013; Linnskog, et al., 2014). Since WNT5A is known to induce 
metalloproteinases such as ADAMTS5 in chondrocytes to degrade matrix (Hosseini-Farahabadi, et 
al., 2013), it may be speculated that down-regulation of WNT5A may be an attempt to protect the 
cartilage from damage. In agreement with this, a strong up-regulation of Prg4 (lubricin) was also 
seen, which is known to help protect cartilage from damage (Ruan, et al., 2013). Additionally, 
cytokine stimulation resulted in the down-regulation of several CCN members, with the down-
regulation of Wisp1 and Wisp2 being apparently novel findings. Together, these findings further 
strengthen the interrelationship between cytokine, WNT and CCN signalling in novel ways. 
Finally, comparisons made between the cytokine-stimulated model described in this thesis 
compared to established models of osteoarthritis revealed similarities in the steady-state 
expression of a number of genes. Taken together, the findings in this thesis suggest that cytokine 
stimulation of differentiated ATDC5 micromass cultures may provide a good alternative model of 
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early osteoarthritis, enabling investigations of signalling pathway regulation that may not be 
possible from cartilage explants obtained from patients with end-stage OA undergoing joint 
replacement surgery. 
6.1.3 ATDC cells can be used to model chondroprogenitor migration and invasion 
In addition to chondrocytes, it has been previously reported that chondroprogenitor cells are also 
resident within articular cartilage. It has also been shown that these chondroprogenitor cells, which 
can either be isolated based on their affinity to fibronectin or their ability to migrate away from 
explant cultures, can migrate to sites of cartilage damage (Seol, et al., 2012). 
Data from thesis showed that ATDC5 cells have a similar adhesion and migratory phenotype similar 
to chondroprogenitor cells and chondrocytes, depending on the state of chondrogenesis. Type II 
collagen was found to have a negative effect on the speed of migration on non-induced ATDC5 cells, 
which may have ramifications for the ability of chondroprogenitor cells to migrate in vivo and may 
possibly add to the inability for cartilage to adequately repair itself. 
By combining and adapting the inverted invasion assay already used in our laboratory for 
macrophage invasion (Murray, et al. (2013) and based on Hennigan, et al. (1994)) with the 
micromass culturing technique, this thesis described a relatively novel way of modelling 
chondroprogenitor cell invasion through a cartilage-like matrix. Using WNT5A conditioned medium, 
a positive trend towards increased invasion towards WNT5A was observed. Validation of this 
finding in one experiment using rhWNT5A similarly resulted in an increased trend towards 
increased invasion, which was deemed significant when invading through micromass cultures that 
had been pre-stimulated with cytokines to induce potential osteoarthritic-like degradation of the 
matrix. These results may suggest that WNT5A, which is over-expressed in osteoarthritic cartilage, 
may act as a potential chemoattractant for primary chondroprogenitor cells towards sites of 
cartilage damage. Given that WNT5A is also important in promoting the early stages of 
chondrogenesis, it may be speculated that WNT5A produced by damaged cartilage may also help 
induce differentiation of the chondroprogenitor cells to produce more matrix to repair the damage. 
Further experiments are needed to validate this finding. 
In summary, this thesis has revealed that ATDC5 cells may also be a good model for investigating 
the translocation of cells in cartilage in response to cartilage damage, which may provide useful 
insights for potential future therapies for osteoarthritis. 
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6.1.4 Summary of findings 
An overall scheme of key findings described in section 6.1 can be found in Figure 6.1.  
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6.2 Future Work 
6.2.1 Transcriptomic analysis and comparison with articular cartilage 
Results in Chapter 3 revealed that the enhanced ATDC5 model is more reminiscent of articular 
cartilage compared to growth plate cartilage, which is important when wanting to investigate 
changes that occur during osteoarthritis, which results in the degradation of articular cartilage. 
However, these were not compared directly to primary cultures. 
Using transcriptomic analysis, using either microarray or RNA-seq, it would be interesting to directly 
compare the enhanced ATDC5 culture model, along with the standard monolayer model, to primary 
articular and growth plate chondrocytes. Using principle component analysis, as seen in Chapter 4, 
clustering of samples would indicate similarities in the expression of mRNA. Close proximity of 
enhanced ATDC5 cultures with primary articular chondrocytes would further strengthen the idea 
that the enhanced ATDC5 cultures described in this thesis are reminiscent of articular cartilage, 
reinforcing the notion that the enhanced ATDC5 cultures are a good model for investigating 
osteoarthritis. 
In addition to changes in the steady-state levels of mRNA, the use of next generation technologies, 
such as RNA-seq, would also allow the investigation of alternatively spliced mRNA transcripts and 
post-transcriptional modifications, as well as investigating other RNA species such as microRNAs 
(miRNA) (Cullum, et al., 2011; Qian, et al., 2014). Using this next generation technology may 
therefore reveal other novel markers of articular differentiation in addition to Frzb, Grem1 (gremlin-
1) and Dkk1 (dickkopf 1) previously reported (Leijten, et al., 2012) that may have otherwise been 
missed by standard microarray analysis, such as isoform switching. Additionally, this might provide 
insight into the mechanisms of the fate determination of escaping the endochondral process to 
become articular chondrocytes compared to becoming growth plate chondrocytes during 
endochondral ossification. 
6.2.2 Epigenetic regulation of WNT5A 
It has been well-established that epigenetic changes occur during osteoarthritis (reviewed in Barter 
and Young (2013)). 
One form of epigenetic regulation is DNA methylation occurring at CpG islands in the promoter 
regions of genes. DNA methylation is a mechanism for silencing gene expression and so 
demethylation of DNA may result in inappropriate gene activation. Studies have shown 
dysregulation of the methylation of osteoarthritic chondrocytes in the promoter regions of a 
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number of matrix degrading enzymes, including MMP3, MMP13 and ADAMTS4 (Roach, et al., 2005; 
Cheung, et al., 2009). Differences in the methylation status of genes have also been reported 
between different stages of OA, revealing hypermethylation of Wnt11 in more severe OA (Moazedi-
Fuerst, et al., 2014). Interestingly, Wnt11 is down-regulated by IL-1β stimulation and exogenous 
WNT11 can induce type II collagen expression in chondrocytes (Ryu & Chun, 2006). 
Expression of WNT5A may also be regulated by DNA methylation and dysregulation of WNT5A 
methylation has been associated with various diseases such as colorectal cancer (Rawson, et al., 
2011; Zhang, et al., 2013), Epstein-Barr virus-associated gastric carcinoma (Liu, et al., 2013b), 
leukaemia (Deng, et al., 2011) and prostate cancer (Wang, et al., 2007). 
It would therefore be interesting to observe the methylated state of the WNT5A promoter in 
osteoarthritic cartilage, as well as in the cytokine-stimulated ATDC5 cells described in this thesis. 
Since WNT5A was observed to be decreased following cytokine stimulation, it may be hypothesised 
that the Wnt5a promoter was hypermethylated to decrease transcription. Use of a DNA 
methyltransferase inhibitor to inhibit DNA methylation may reveal whether epigenetic changes are 
the cause of this novel regulation of WNT5A. 
Furthermore, it would be interesting to see whether epigenomic analysis to identify the global state 
of methylation would correlate with the findings from the microarray, identifying which genes are 
most regulated by epigenetic changes induced by cytokine stimulation. This may provide insight 
into the mechanisms behind gene regulation in early osteoarthritis. 
In addition to DNA methylation, epigenetic regulation of genes can occur due to the changes in 
histone acetylation, whereby deacetylation causes chromatin condensation, impeding access of 
transcription factors to the promoter regions of genes. Interestingly, it has been shown that 
extended administration of a histone deacetylase (HDAC) inhibitor in mice (which prevents 
chromatin condensation and thus allows for greater access of transcription factors to promoter 
regions) decreased type II collagen expression by directly up-regulating the transcription of Wnt5a 
(Huh, et al., 2007). It would therefore also be interesting to see whether the down-regulation of 
WNT5A observed in this thesis as a result of cytokine stimulation could also be due to histone 
deacetylation. 
6.3.3 Osteoarthritic cartilage secretome 
As previously mentioned, chondroprogenitor cells resident with osteoarthritic cartilage are able to 
migrate to sites of cartilage injury, and it was reported that the alarmin, high mobility group box 
chromosomal protein 1 (HMGB-1), may be one factor produced by damaged chondrocytes to elicit 
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the migratory response of chondroprogenitor cells (Seol, et al., 2012). This thesis has proposed that 
WNT5A and possibly WNT3A may also be potential candidates for the induction of 
chondroprogenitor migration. 
Proteomic analysis to identify the global expression levels of proteins could be used to identify the 
largest changes in protein expression (both positively and negatively) of the osteoarthritic cartilage 
secretome compared to non-OA cartilage, which could be generated by conditioning media with 
cartilage explants. After identifying the most up-regulated and down-regulated proteins, 
conditioned media could be generated from cells overexpressing these proteins, or alternatively if 
available, commercial recombinant proteins could be sourced. These media or purified proteins, 
along with other alarmins such as S100A8 (which was highly up-regulated in the microarray analysis 
of cytokine-stimulated ATDC5 cells (Appendix Table S4.5, S4.6) and known to induce 
migration/invasion of other cell types including breast and gastric cancer cells (Kwon, et al., 2013; 
Yin, et al., 2013)), could then be used in conjunction with the migration assay and cartilage invasion 
assay described in this thesis to observe whether these proteins modulated translocation of non-
induced ATDC5 cells or primary chondroprogenitor cells. This may reveal potentially novel proteins 
that may either be up-regulated to promote invasion or down-regulated to inhibit proteins that 
may otherwise impede invasion. 
6.3.4 High-throughput screening 
Additionally, proteomic analysis of the osteoarthritic secretome could help reveal novel candidates 
that might mediate the destruction of cartilage by regulating expression of various 
metalloproteinases. Conditioned media generated by transient overexpression of regulated 
proteins found via proteomic analysis, or commercially available purified proteins, could be used to 
stimulate cultures in a high-throughput screening assay. Steady-state gene expression of known 
cartilage-degrading enzymes could be measured to identify which proteins may induce catabolism. 
Degradation of cartilage could then be examined by using either the dimethyl methylene blue 
(DMMB) assay or the hydroxyproline assay, which are colorimetric assays to measure the release 
of GAGs from proteoglycans or the hydroxproline content from cleaved collagens respectively into 
the media.  
Potential drug candidates could also been screened in a similar manner to detect changes in enzyme 
expression and prevent cartilage destruction, mediated by cytokines or potential components of 
the secretome. The nature of ATDC5 micromass cultures, their ease of culturing in multi-well plates 
and the ability to easily scale up cultures by plating multiple micromass cultures in the same well, 
makes ATDC5 micromass cultures an attractive model for high-throughput screening assays to help 
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identify mediators of osteoarthritis and potential drug candidates to prevent or reverse cartilage 
damage. 
6.3 Summary 
In summary, this thesis has shown that ATDC5 cells are a versatile cell type that may be used for 
several applications. The enhanced ATDC5 chondrogenesis model, by combining micromass culture 
and ascorbic acid stimulation, produces a cartilage-like tissue reminiscent of articular cartilage, 
which is important for studying osteoarthritis. Indeed, cytokine stimulation of these cultures 
revealed similarities in gene expression to early OA models, which is useful for studying events that 
occur in early OA that may not occur in end-stage OA, which would otherwise be missed when 
examining cartilage from patients undergoing joint replacement surgery. Furthermore, this thesis 
showed that ATDC5 cells have a similar migratory phenotype to both chondroprogenitor cells and 
chondrocytes, depending on the differentiation status, and may be used to model 
chondroprogenitor invasion through cartilage, an event that occurs in vivo in response to cartilage 
damage. 
Therefore this thesis has shown that the ATDC5 cell line is an effective tool in studying several 
aspects of cartilage biology and pathology. 
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  Table S3.1 – TaqMan CT values for Figure 3.2 with normalised averages and SEM 
Minimum Ct Maximum Ct Average SE
No Ascorbic Acid 30.81 31.86 0.036 0.003
Ascorbic Acid 28.90 30.85 0.099 0.065
No Ascorbic Acid 29.82 30.78 0.089 0.010
Ascorbic Acid 27.58 30.54 0.234 0.081
No Ascorbic Acid 28.22 30.39 0.209 0.058
Ascorbic Acid 26.64 26.64 0.897 0.236
No Ascorbic Acid 25.84 26.65 1.321 0.312
Ascorbic Acid 24.25 26.45 4.597 1.282
No Ascorbic Acid 30.27 31.91 0.066 0.022
Ascorbic Acid 29.35 29.98 0.211 0.037
No Ascorbic Acid 29.75 30.08 0.184 0.037
Ascorbic Acid 26.56 27.64 2.903 0.847
No Ascorbic Acid 28.81 29.44 0.209 0.021
Ascorbic Acid 28.18 29.59 0.650 0.159
No Ascorbic Acid 25.55 26.55 3.846 0.430
Ascorbic Acid 23.53 24.89 20.747 6.804
No Ascorbic Acid 28.80 32.82 0.149 0.075
Ascorbic Acid 28.79 29.56 0.411 0.052
No Ascorbic Acid 28.60 31.77 0.225 0.067
Ascorbic Acid
No Ascorbic Acid 26.41 29.40 0.928 0.364
Ascorbic Acid 25.52 28.04 2.832 1.097
No Ascorbic Acid 21.79 23.80 32.350 12.587
Ascorbic Acid 21.48 22.23 52.202 9.479
Micromass
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 21
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 14
Monolayer
No Insulin
Insulin
Col2a1
Day 7
Monolayer
No Insulin
Insulin
Minimum Ct Maximum Ct Average SE
No Ascorbic Acid 35.60 36.57
Ascorbic Acid 33.32 34.38 0.003 0.003
No Ascorbic Acid 32.89 33.36 0.010 0.002
Ascorbic Acid 29.53 30.34 0.095 0.017
No Ascorbic Acid 32.24 33.04 0.014 0.002
Ascorbic Acid 31.44 31.44 0.022 0.006
No Ascorbic Acid 26.88 27.80 0.576 0.030
Ascorbic Acid 26.59 27.79 0.966 0.155
No Ascorbic Acid 34.07 36.74 0.006
Ascorbic Acid 32.46 33.29 0.019 0.003
No Ascorbic Acid 30.43 32.28 0.089 0.026
Ascorbic Acid 27.60 28.30 1.389 0.265
No Ascorbic Acid 33.08 33.42 0.010 0.001
Ascorbic Acid 31.93 32.96 0.045 0.005
No Ascorbic Acid 26.11 26.86 2.749 0.431
Ascorbic Acid 25.33 25.68 7.024 1.733
No Ascorbic Acid 33.19 35.18 0.011 0.002
Ascorbic Acid 30.82 32.27 0.067 0.020
No Ascorbic Acid 29.99 31.23 0.123 0.041
Ascorbic Acid
No Ascorbic Acid 31.41 34.26 0.023 0.009
Ascorbic Acid 29.00 32.42 0.152 0.065
No Ascorbic Acid 24.19 25.19 7.529 0.557
Ascorbic Acid 23.48 24.08 11.621 1.046
Frzb
Day 7
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 14
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 21
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
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 Table S3.2 – TaqMan CT values for Figure 3.3 with normalised averages and SEM 
Minimum Ct Maximum Ct Average SE
No Ascorbic Acid 28.83 29.34 1.318 0.324
Ascorbic Acid 28.63 28.78 1.362 0.069
No Ascorbic Acid 29.76 30.08 0.915 0.113
Ascorbic Acid 28.98 30.91 0.992 0.250
No Ascorbic Acid 28.36 28.92 1.702 0.136
Ascorbic Acid 28.73 28.73 2.041 0.204
No Ascorbic Acid 28.49 29.01 1.340 0.278
Ascorbic Acid 28.77 29.27 1.666 0.114
No Ascorbic Acid 29.32 29.65 1.621 0.123
Ascorbic Acid 29.03 29.61 1.791 0.160
No Ascorbic Acid 29.52 29.82 1.608 0.273
Ascorbic Acid 29.59 29.79 2.741 0.499
No Ascorbic Acid 28.75 29.89 1.346 0.203
Ascorbic Acid 29.15 29.48 3.275 0.458
No Ascorbic Acid 28.44 29.09 3.020 0.166
Ascorbic Acid 27.73 28.80 4.671 1.179
No Ascorbic Acid 28.77 29.17 2.276 0.191
Ascorbic Acid 28.87 29.66 2.433 0.090
No Ascorbic Acid 28.78 30.64 1.438 0.287
Ascorbic Acid
No Ascorbic Acid 28.60 29.51 2.466 0.259
Ascorbic Acid 28.14 28.63 3.219 0.322
No Ascorbic Acid 27.07 28.01 4.319 0.345
Ascorbic Acid 26.46 27.25 5.517 0.342
Tgfb1
Day 7
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 14
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 21
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Minimum Ct Maximum Ct Average SE
No Ascorbic Acid 28.47 28.90 9.275 2.312
Ascorbic Acid 28.37 28.78 8.750 1.390
No Ascorbic Acid 29.56 29.93 5.887 0.382
Ascorbic Acid 29.98 30.96 3.080 0.491
No Ascorbic Acid 29.38 29.94 5.207 0.350
Ascorbic Acid 29.58 29.58 6.926 0.237
No Ascorbic Acid 29.82 30.71 3.205 0.672
Ascorbic Acid 30.62 31.35 3.163 0.258
No Ascorbic Acid 28.91 29.16 11.922 0.841
Ascorbic Acid 28.85 29.76 10.249 1.140
No Ascorbic Acid 30.11 30.41 6.452 1.039
Ascorbic Acid 31.30 31.78 5.685 1.064
No Ascorbic Acid 29.47 30.04 6.196 0.994
Ascorbic Acid 30.12 30.98 9.491 1.054
No Ascorbic Acid 30.82 31.41 5.010 0.550
Ascorbic Acid 30.87 32.28 4.014 1.020
No Ascorbic Acid 28.85 29.47 12.529 1.481
Ascorbic Acid 29.97 30.50 9.129 0.855
No Ascorbic Acid 29.87 30.73 6.237 1.345
Ascorbic Acid
No Ascorbic Acid 29.15 29.65 11.325 1.553
Ascorbic Acid 29.96 30.29 7.037 0.497
No Ascorbic Acid 30.11 30.97 4.397 0.349
Ascorbic Acid 29.98 30.91 3.811 0.243
Tgfb3
Day 7
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 14
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 21
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
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Table S3.3 – TaqMan CT values for Figure 3.4 with normalised averages and SEM 
Minimum Ct Maximum Ct Average SE
No Ascorbic Acid 35.87 35.87
Ascorbic Acid 36.60 37.76
No Ascorbic Acid 34.09 37.36 0.027
Ascorbic Acid 34.51 37.58
No Ascorbic Acid 34.72 37.88 0.020
Ascorbic Acid 35.61 35.61
No Ascorbic Acid 34.50 35.43 0.030
Ascorbic Acid 33.92 35.53 0.045 0.007
No Ascorbic Acid 35.77 37.98
Ascorbic Acid 34.14 35.03 0.044
No Ascorbic Acid 36.19 37.68
Ascorbic Acid 32.94 33.64 0.160 0.035
No Ascorbic Acid 33.50 36.15 0.044
Ascorbic Acid 36.11 36.62
No Ascorbic Acid 30.73 31.63 0.367 0.066
Ascorbic Acid 29.33 29.87 1.162 0.249
No Ascorbic Acid 36.22 37.46
Ascorbic Acid 34.62 37.49 0.034
No Ascorbic Acid 32.73 35.38 0.053 0.007
Ascorbic Acid
No Ascorbic Acid 34.85 36.54 0.029
Ascorbic Acid 33.74 35.73 0.056 0.008
No Ascorbic Acid 28.26 29.28 1.245 0.027
Ascorbic Acid 27.33 28.36 1.712 0.063
Day 21
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 14
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Col10a1
Day 7
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Minimum CtMaximum CtAverage SE
No Ascorbic Acid 28.23 28.70 1.251 0.229
Ascorbic Acid 27.24 27.73 2.395 0.439
No Ascorbic Acid 27.98 28.08 1.940 0.170
Ascorbic Acid 26.97 28.30 2.286 0.463
No Ascorbic Acid 27.91 28.40 1.649 0.101
Ascorbic Acid 28.19 28.19 1.944 0.167
No Ascorbic Acid 26.80 27.36 2.598 0.472
Ascorbic Acid 27.09 28.20 2.565 0.171
No Ascorbic Acid 28.58 28.79 1.796 0.164
Ascorbic Acid 27.63 27.91 3.140 0.281
No Ascorbic Acid 27.92 28.72 2.748 0.545
Ascorbic Acid 27.64 27.73 6.267 0.862
No Ascorbic Acid 28.07 29.10 1.473 0.201
Ascorbic Acid 28.48 28.94 3.370 0.440
No Ascorbic Acid 26.77 27.40 5.612 0.172
Ascorbic Acid 27.04 28.44 4.587 1.148
No Ascorbic Acid 27.99 28.49 2.539 0.215
Ascorbic Acid 27.05 27.96 5.353 0.331
No Ascorbic Acid 27.05 28.28 3.126 0.496
Ascorbic Acid
No Ascorbic Acid 27.70 28.47 3.196 0.154
Ascorbic Acid 26.76 27.20 5.546 0.568
No Ascorbic Acid 25.53 26.23 7.834 0.451
Ascorbic Acid 25.42 26.31 7.286 0.345
Day 21
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 14
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Alpl
Day 7
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
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Minimum Ct Maximum Ct Average SE
No Ascorbic Acid 26.20 26.52 1.253 0.315
Ascorbic Acid 26.04 26.37 1.485 0.278
No Ascorbic Acid 26.98 27.19 0.991 0.110
Ascorbic Acid 26.38 27.23 1.000 0.191
No Ascorbic Acid 26.60 27.02 1.007 0.060
Ascorbic Acid 26.74 26.74 1.332 0.112
No Ascorbic Acid 26.28 26.92 1.007 0.163
Ascorbic Acid 26.64 27.43 1.047 0.076
No Ascorbic Acid 26.83 27.02 1.439 0.093
Ascorbic Acid 26.58 26.75 1.722 0.126
No Ascorbic Acid 27.20 28.06 1.111 0.223
Ascorbic Acid 27.40 27.68 2.029 0.391
No Ascorbic Acid 26.52 27.08 1.213 0.178
Ascorbic Acid 26.97 27.44 2.309 0.332
No Ascorbic Acid 26.46 27.10 1.997 0.141
Ascorbic Acid 26.76 27.53 1.864 0.428
No Ascorbic Acid 26.71 26.96 1.606 0.143
Ascorbic Acid 26.57 27.28 2.110 0.129
No Ascorbic Acid 26.74 27.84 1.244 0.272
Ascorbic Acid
No Ascorbic Acid 26.32 26.93 2.156 0.130
Ascorbic Acid 25.84 26.37 2.433 0.208
No Ascorbic Acid 26.00 26.54 1.990 0.165
Ascorbic Acid 25.62 26.36 1.772 0.125
Runx2
Day 7
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 14
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Day 21
Monolayer
No Insulin
Insulin
Micromass
No Insulin
Insulin
Table S3.4 – TaqMan CT values for Figure 3.5 with normalised averages and SEM 
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Col2a1 Ct Range Average SE 
Monolayer 
No Insulin 
No Ascorbic 32.38 - 34.63 1.53 0.19 
Ascorbic 32.26 - 33.27 3.42 0.38 
Insulin 
No Ascorbic 31.74 - 33.36 3.16 0.28 
Ascorbic 29.75 - 31.34 5.19 1.27 
Micromass 
No Insulin 
No Ascorbic 32.78 - 33.41 2.17 0.25 
Ascorbic 32.73 - 33.39 4.23 1.71 
Insulin 
No Ascorbic 30.28 - 31.67 5.79 0.74 
Ascorbic 28.28 - 30.13 11.18 0.70 
 
Frzb Ct Range Average SE 
Monolayer 
No Insulin 
No Ascorbic Undetermined   
Ascorbic Undetermined   
Insulin 
No Ascorbic 33.80 - 38.37 2.01 1.01 
Ascorbic 33.84 - 35.39 1.30 0.34 
Micromass 
No Insulin 
No Ascorbic Undetermined   
Ascorbic Undetermined   
Insulin 
No Ascorbic 30.85 - 34.02 5.60 0.97 
Ascorbic 29.45 - 32.34 7.83 1.04 
 
 
  
Grem1 Minimum Ct Maximum Ct Average SE 
Monolayer 
No Insulin 
No Ascorbic Acid 23.37 23.77 5.996 0.224 
Ascorbic Acid 23.49 24.14 5.240 0.534 
Insulin 
No Ascorbic Acid 25.32 25.87 2.045 0.393 
Ascorbic Acid 27.28 27.45 1.071 0.166 
Micromass 
No Insulin 
No Ascorbic Acid 24.30 24.94 2.297 0.267 
Ascorbic Acid 24.92 25.65 3.720 0.570 
Insulin 
No Ascorbic Acid 25.95 26.36 1.500 0.099 
Ascorbic Acid 26.56 27.41 1.012 0.240 
Tgfb1 Min Max Normalised SEM  
Micromass 
No Insulin 
No Ascorbic Acid 27.37 28.74 1.19 0.08 
Ascorbic Acid 27.23 28.05 1.49 0.11 
Insulin 
No Ascorbic Acid 26.84 27.16 1.51 0.22 
Ascorbic Acid 26.96 27.84 2.31 0.28 
Table S3.5 – TaqMan CT values for Figure 3.7 with normalised averages and SEM 
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Col10a1 
Minimum 
Ct 
Maximum 
Ct Average SE 
Monolayer 
No Insulin 
No Ascorbic Acid 35.77 37.98     
Ascorbic Acid 34.14 35.03 0.044   
Insulin 
No Ascorbic Acid 36.19 37.68     
Ascorbic Acid 32.94 33.64 0.160 0.035 
Micromass 
No Insulin 
No Ascorbic Acid 33.50 36.15 0.044   
Ascorbic Acid 36.11 36.62     
Insulin 
No Ascorbic Acid 30.73 31.63 0.367 0.066 
Ascorbic Acid 29.33 29.87 1.162 0.249 
 
 
 
 
 
 
 
 
Runx2 
Minimum 
Ct 
Maximum 
Ct Average SE 
Monolayer 
No Insulin 
No Ascorbic Acid 26.83 27.02 1.439 0.093 
Ascorbic Acid 26.58 26.75 1.722 0.126 
Insulin 
No Ascorbic Acid 27.20 28.06 1.111 0.223 
Ascorbic Acid 27.40 27.68 2.029 0.391 
Micromass 
No Insulin 
No Ascorbic Acid 26.52 27.08 1.213 0.178 
Ascorbic Acid 26.97 27.44 2.309 0.332 
Insulin 
No Ascorbic Acid 26.46 27.10 1.997 0.141 
Ascorbic Acid 26.76 27.53 1.864 0.428 
  
DDR2 Ct Range Average SE 
Monolayer 
No Insulin 
No Ascorbic 27.23 - 29.03 3.43 0.38 
Ascorbic 26.74 - 29.21 4.78 0.61 
Insulin 
No Ascorbic 27.40 - 29.04 2.92 0.82 
Ascorbic 27.88 - 30.64 1.51 0.12 
Micromass 
No Insulin 
No Ascorbic 27.88 - 29.42 2.20 0.16 
Ascorbic 29.25 - 32.05 2.40 0.54 
Insulin 
No Ascorbic 28.86 - 32.51 2.06 0.43 
Ascorbic 28.18 - 30.30 1.71 0.15 
Table S3.6 – TaqMan CT values for Figure 3.8 with normalised averages and SEM 
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Tgfb3 Ct Range Average SE 
Monolayer 
No Insulin 
No Ascorbic 25.65 - 26.80 2.00 0.20 
Ascorbic 26.38 - 27.82 2.01 0.19 
Insulin 
No Ascorbic 27.92 - 29.19 0.81 0.17 
Ascorbic 28.31 - 29.92 0.29 0.05 
Micromass 
No Insulin 
No Ascorbic 26.79 - 28.37 1.01 0.23 
Ascorbic 28.08 - 29.50 0.86 0.16 
Insulin 
No Ascorbic 28.67 - 29.75 0.39 0.04 
Ascorbic 28.45 - 30.05 0.31 0.02 
 
 
  
Alpl 
Minimum 
Ct 
Maximum 
Ct Average SE 
Monolayer 
No Insulin 
No Ascorbic Acid 28.58 28.79 1.796 0.164 
Ascorbic Acid 27.63 27.91 3.140 0.281 
Insulin 
No Ascorbic Acid 27.92 28.72 2.748 0.545 
Ascorbic Acid 27.64 27.73 6.267 0.862 
Micromass 
No Insulin 
No Ascorbic Acid 28.07 29.10 1.473 0.201 
Ascorbic Acid 28.48 28.94 3.370 0.440 
Insulin 
No Ascorbic Acid 26.77 27.40 5.612 0.172 
Ascorbic Acid 27.04 28.44 4.587 1.148 
Table S3.6 (cont.) – TaqMan CT values for Figure 3.8 with normalised averages and 
SEM 
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  Cyr61 Ct Range Average SE 
Monolayer 
No Insulin 
No Ascorbic 28.41 - 30.19 4.29 0.59 
Ascorbic 29.07 - 30.52 4.55 0.15 
Insulin 
No Ascorbic 29.23 - 30.72 3.89 0.65 
Ascorbic 29.80 - 31.10 1.60 0.15 
Micromass 
No Insulin 
No Ascorbic 29.32 - 30.84 3.27 0.49 
Ascorbic 29.43 - 31.54 4.10 1.01 
Insulin 
No Ascorbic 29.71 - 31.21 2.41 0.18 
Ascorbic 29.74 - 31.26 1.76 0.10 
CTGF Ct Range Average SE 
Monolayer 
No Insulin 
No Ascorbic 30.33 - 31.35 12.41 1.91 
Ascorbic 30.24 - 31.54 20.40 0.86 
Insulin 
No Ascorbic 31.80 - 35.52 3.38 1.04 
Ascorbic 32.60 - 34.37 1.80 0.46 
Micromass 
No Insulin 
No Ascorbic 32.05 - 33.51 4.57 0.87 
Ascorbic 32.74 - 34.08 4.01 0.80 
Insulin 
No Ascorbic 32.62 - 34.02 2.52 0.36 
Ascorbic 31.98 - 35.86 2.28 0.70 
Table S3.7 – TaqMan CT values for Figure 3.9 with normalised averages and SEM 
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Minimum Ct Maximum Ct Normalised SEM
Monolayer 30.50 30.96 1.33 0.20
Micromass 31.03 31.51 1.58 0.31
Monolayer 30.61 31.25 1.03 0.18
Micromass 30.07 30.54 1.74 0.48
Monolayer 32.23 36.52 0.16 0.08
Micromass 32.52 33.99 0.44 0.09
Monolayer 28.93 31.29 2.59 0.42
Micromass 31.11 31.84 2.46 0.35
Monolayer 30.56 32.02 1.31 0.25
Micromass 31.07 32.21 2.11 0.25
Monolayer 31.49 31.98 1.01 0.12
Micromass 31.32 31.97 1.19 0.06
Monolayer 30.50 36.52 0.84 0.19
Micromass 30.07 33.99 1.25 0.26
Monolayer 28.93 32.02 1.64 0.28
Micromass 31.07 32.21 1.92 0.23
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Ror2
Vector Only
Clone 1
Clone 2
Clone 3
Minimum Ct Maximum Ct Normalised SEM
Monolayer 31.48 32.98 0.07 0.02
Micromass 34.14 34.18 0.03 0.00
Monolayer 33.14 33.82 0.02 0.00
Micromass 32.81 33.25 0.04 0.01
Monolayer 34.36 34.85 0.01 0.01
Micromass 31.63 32.71 0.12 0.02
Monolayer 34.56 34.69 0.01 0.00
Micromass 38.56 38.56
Monolayer 39.12 39.12
Micromass 39.93 39.93
Monolayer 34.97 38.80 0.01
Micromass 37.00 37.73
Monolayer 31.48 34.85 0.04 0.01
Micromass 31.63 34.18 0.07 0.02
Monolayer 34.56 39.12 0.01 0.00
Micromass 37.00 39.93
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Col2a1
Vector Only
Clone 1
Clone 2
Clone 3
Table S4.1 – TaqMan CT values for Figure 4.1 with normalised averages and SEM 
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Minimum Ct Maximum Ct Normalised SEM
Monolayer 33.35 34.05 0.75
Micromass UndeterminedUndetermined
Monolayer 31.61 31.98 1.33 0.23
Micromass 33.83 34.41 0.65 0.07
Monolayer 31.43 32.40 1.51 0.19
Micromass 33.13 33.21 1.40 0.14
Monolayer 33.04 33.39 0.83
Micromass UndeterminedUndetermined
Monolayer 33.78 34.48 0.95 0.14
Micromass UndeterminedUndetermined
Monolayer UndeterminedUndetermined
Micromass UndeterminedUndetermined
Monolayer 31.43 34.05 1.25 0.15
Micromass 33.13 34.41 1.02 0.18
Monolayer 33.04 34.48 0.75 0.18
Micromass UndeterminedUndetermined
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Adamts5
Vector Only
Clone 1
Clone 2
Clone 3
Table S4.1 (cont.) – TaqMan CT values for Figure 4.1 with normalised averages and SEM 
Minimum Ct Maximum Ct Normalised SEM
Monolayer 34.26 35.02 0.43 0.08
Micromass 34.52 34.89 0.69 0.12
Monolayer 33.68 34.23 0.56 0.02
Micromass 32.08 32.46 2.61 0.70
Monolayer 33.33 35.10 0.47 0.11
Micromass 32.20 32.78 2.94 0.21
Monolayer 32.99 35.96 0.65 0.22
Micromass 34.43 35.04 1.13 0.21
Monolayer 35.02 35.78 0.29 0.04
Micromass 34.23 34.36 1.59 0.18
Monolayer 33.56 35.28 0.77 0.15
Micromass 33.04 33.32 2.12 0.22
Monolayer 33.33 35.10 0.49 0.05
Micromass 32.08 34.89 2.08 0.41
Monolayer 32.99 35.96 0.57 0.11
Micromass 33.04 35.04 1.62 0.18
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Adamts4
Vector Only
Clone 1
Clone 2
Clone 3
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Minimum Ct Maximum Ct Normalised SEM
Monolayer 27.98 29.02 1.00 0.18
Micromass 28.85 29.57 0.98 0.08
Monolayer 27.66 28.30 1.29 0.04
Micromass 27.90 28.58 1.39 0.43
Monolayer 27.73 28.90 1.09 0.06
Micromass 28.12 28.44 1.72 0.04
Monolayer 27.31 29.67 1.42 0.31
Micromass 29.60 29.73 1.29 0.19
Monolayer 29.27 29.97 0.66 0.04
Micromass 29.35 30.30 1.01 0.12
Monolayer 28.54 29.70 0.86 0.09
Micromass 28.48 29.12 1.37 0.08
Monolayer 27.66 29.02 1.13 0.07
Micromass 27.90 29.57 1.36 0.17
Monolayer 27.31 29.97 0.98 0.15
Micromass 28.48 30.30 1.22 0.09
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Ddr2
Vector Only
Clone 1
Clone 2
Clone 3
Table S4.1 (cont.) – TaqMan CT values for Figure 4.1 with normalised averages and SEM 
Minimum Ct Maximum Ct Normalised SEM
Monolayer 29.91 30.12 0.57 0.04
Micromass 30.08 31.17 0.67 0.08
Monolayer 28.24 28.95 1.15 0.02
Micromass 28.49 28.97 1.30 0.35
Monolayer 28.56 29.40 1.05 0.08
Micromass 28.18 28.89 2.22 0.17
Monolayer 27.19 29.98 2.08 0.46
Micromass 29.47 29.90 2.28 0.44
Monolayer 29.60 30.45 0.88 0.04
Micromass 29.95 30.67 1.53 0.08
Monolayer 29.34 30.80 0.85 0.06
Micromass 29.35 30.50 1.08 0.10
Monolayer 28.24 30.12 0.92 0.09
Micromass 28.18 31.17 1.40 0.25
Monolayer 27.19 30.80 1.27 0.24
Micromass 29.35 30.67 1.63 0.22
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Runx2
Vector Only
Clone 1
Clone 2
Clone 3
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Minimum Ct Maximum Ct Normalised SEM
Monolayer 34.37 34.58 0.03 0.00
Micromass 33.87 34.74 0.05 0.00
Monolayer 27.02 28.02 1.41 0.09
Micromass 26.77 27.61 2.00 0.70
Monolayer 26.57 27.83 1.87 0.12
Micromass 26.43 27.25 3.72 0.30
Monolayer 30.14 30.48 0.20 0.08
Micromass 30.92 32.08 0.49 0.17
Monolayer 33.61 35.11 0.04 0.01
Micromass 31.52 32.66 0.31 0.03
Monolayer 33.82 35.94 0.03
Micromass 32.45 33.27 0.12 0.03
Monolayer 26.57 34.58 1.10 0.28
Micromass 26.43 34.74 1.92 0.57
Monolayer 30.14 35.94 0.10 0.04
Micromass 30.92 33.27 0.31 0.07
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Alpl
Vector Only
Clone 1
Clone 2
Clone 3
Table S4.1 (cont.) – TaqMan CT values for Figure 4.1 with normalised averages and SEM 
Minimum Ct Maximum Ct Normalised SEM
Monolayer 31.29 32.06 0.33 0.03
Micromass 31.24 32.56 0.54 0.08
Monolayer 29.94 30.75 0.72 0.02
Micromass 29.52 30.24 1.34 0.33
Monolayer 29.75 31.02 0.78 0.03
Micromass 30.23 30.49 1.32 0.14
Monolayer 27.72 31.31 2.70 0.90
Micromass 29.86 30.26 3.43 0.64
Monolayer 30.59 31.05 0.95 0.02
Micromass 30.62 30.83 2.16 0.26
Monolayer 29.84 31.40 1.11 0.12
Micromass 30.42 31.31 1.03 0.05
Monolayer 29.75 32.06 0.61 0.07
Micromass 29.52 32.56 1.07 0.17
Monolayer 27.72 31.40 1.59 0.38
Micromass 29.86 31.31 2.20 0.40
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Grem1
Vector Only
Clone 1
Clone 2
Clone 3
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Table S4.1 (cont.) – TaqMan CT values for Figure 4.1 with normalised averages and SEM 
Minimum Ct Maximum Ct Normalised SEM
Monolayer 27.19 27.59 0.85 0.01
Micromass 28.69 29.00 0.53 0.02
Monolayer 27.44 27.99 0.56 0.05
Micromass 28.71 29.02 0.29 0.03
Monolayer 27.42 28.24 0.59 0.03
Micromass 28.72 29.35 0.39 0.02
Monolayer 25.74 27.60 2.17 0.45
Micromass 28.61 28.83 1.02 0.15
Monolayer 26.80 27.38 1.58 0.03
Micromass 28.27 28.92 1.09 0.08
Monolayer 26.72 27.39 1.60 0.08
Micromass 27.48 28.31 0.97 0.03
Monolayer 27.19 28.24 0.67 0.05
Micromass 28.69 29.35 0.40 0.04
Monolayer 25.74 27.60 1.78 0.16
Micromass 27.48 28.92 1.03 0.05
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Cyr61
Vector Only
Clone 1
Clone 2
Clone 3
Minimum Ct Maximum Ct Normalised SEM
Monolayer 26.61 26.88 1.71 0.07
Micromass 28.26 28.62 1.07 0.05
Monolayer 27.40 27.98 0.78 0.03
Micromass 29.96 30.38 0.22 0.04
Monolayer 27.73 28.56 0.70 0.06
Micromass 29.66 30.12 0.36 0.00
Monolayer 26.72 28.63 1.28 0.14
Micromass 29.72 29.91 0.81 0.11
Monolayer 27.49 28.01 1.36 0.03
Micromass 29.48 29.84 0.90 0.09
Monolayer 27.34 28.03 1.43 0.10
Micromass 28.35 29.04 0.90 0.07
Monolayer 26.61 28.56 1.07 0.16
Micromass 28.26 30.38 0.55 0.13
Monolayer 26.72 28.63 1.36 0.05
Micromass 28.35 29.91 0.87 0.05
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Ctgf
Vector Only
Clone 1
Clone 2
Clone 3
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Minimum Ct Maximum Ct Normalised SEM
Monolayer 27.76 28.47 1.38 0.08
Micromass 28.71 29.35 1.36 0.03
Monolayer 27.49 27.84 1.57 0.12
Micromass 28.78 29.13 0.89 0.19
Monolayer 27.37 28.69 1.41 0.05
Micromass 29.03 29.06 1.19 0.11
Monolayer 27.68 30.21 1.13 0.20
Micromass 29.85 30.63 1.11 0.13
Monolayer 29.47 30.16 0.70 0.04
Micromass 30.22 30.54 1.07 0.12
Monolayer 28.32 29.71 1.17 0.08
Micromass 28.05 29.24 1.82 0.21
Monolayer 27.37 28.69 1.45 0.05
Micromass 28.71 29.35 1.15 0.09
Monolayer 27.68 30.21 1.00 0.10
Micromass 28.05 30.63 1.33 0.15
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Wisp1
Vector Only
Clone 1
Clone 2
Clone 3
Table S4.1 (cont.) – TaqMan CT values for Figure 4.1 with normalised averages and SEM 
Minimum Ct Maximum Ct Normalised SEM
Monolayer 32.77 33.02 1.05 0.07
Micromass 31.66 32.61 4.20 1.25
Monolayer 34.33 36.12 0.19 0.08
Micromass 33.04 34.84 0.46 0.12
Monolayer 37.42 37.42
Micromass 34.97 36.48 0.19 0.05
Monolayer 32.70 34.70 0.76 0.31
Micromass 33.78 34.23 1.21 0.12
Monolayer 33.77 34.92 0.49 0.21
Micromass 32.93 33.50 2.48 0.68
Monolayer 32.74 33.07 1.66 0.31
Micromass 31.27 31.96 5.21 0.17
Monolayer 32.77 37.42 0.62 0.20
Micromass 31.66 36.48 1.62 0.74
Monolayer 32.70 34.92 0.97 0.22
Micromass 31.27 34.23 2.97 0.63
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Nov
Vector Only
Clone 1
Clone 2
Clone 3
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Table S4.1 (cont.) – TaqMan CT values for Figure 4.1 with normalised averages and SEM 
Minimum Ct Maximum Ct Normalised SEM
Monolayer 27.61 28.10 0.92 0.05
Micromass 26.75 26.93 3.58
Monolayer 26.72 27.45 1.24 0.06
Micromass 26.89 27.46 1.62 0.39
Monolayer 26.16 27.28 1.81 0.03
Micromass 26.87 27.29 2.32 0.13
Monolayer 26.64 29.05 1.26 0.18
Micromass 29.75 30.49 0.68 0.05
Monolayer 28.64 29.38 0.69 0.03
Micromass 29.28 29.80 1.10 0.14
Monolayer 28.36 30.07 0.73 0.14
Micromass 28.72 29.57 0.71 0.02
Monolayer 26.16 28.10 1.32 0.13
Micromass 26.75 27.46 2.37 0.32
Monolayer 26.64 30.07 0.89 0.11
Micromass 28.72 30.49 0.83 0.08
Wnt5a
WNT5A
Clone 4
Clone 5
Clone 6
Vector Only
Wisp2
Vector Only
Clone 1
Clone 2
Clone 3
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Ror2 (Left-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 29.58 30.61 1.21 0.26 
Cytokines 30.01 31.13 1.16 0.19 
WNT5A No Cytokines 31.10 31.60 0.54 0.04 
Cytokines 31.76 32.32 0.32 0.03 
  
Ror2 (Right-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 30.16 31.29 3.77 1.10 
Cytokines 31.62 32.93 0.47 0.05 
WNT5A No Cytokines 29.04 30.98 5.95 2.44 
Cytokines 31.25 32.73 0.57 0.14 
  
Col2a1 (Left-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 27.19 28.02 2.50 0.44 
Cytokines 26.87 28.92 2.58 0.58 
WNT5A No Cytokines 27.17 28.02 2.07 0.43 
Cytokines 28.81 29.93 0.57 0.14 
  
Col2a1 (Right-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 23.30 25.26 3.73 1.70 
Cytokines 26.62 27.96 0.27 0.02 
WNT5A No Cytokines 23.48 25.47 3.33 0.88 
Cytokines 25.86 27.34 0.39 0.07 
  
Adamts4 (Left-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 33.11 34.06 0.48 0.11 
Cytokines 33.87 35.23 0.23 0.05 
WNT5A No Cytokines 32.24 32.58 1.27 0.13 
Cytokines 32.24 32.53 1.28 0.15 
  
Adamts4 (Right-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 33.26 34.34 1.20 0.36 
Cytokines 30.98 32.66 2.70 0.38 
WNT5A No Cytokines 32.91 33.99 1.48 0.23 
Cytokines 30.24 31.93 4.19 0.99 
  
  
Table S4.2 – TaqMan CT values for Figure 4.4 with normalised averages and SEM 
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Ddr2 (Left-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 27.62 27.99 1.06 0.07 
Cytokines 27.52 28.66 1.05 0.07 
WNT5A No Cytokines 27.12 27.19 1.57 0.02 
Cytokines 29.19 29.36 0.40 0.02 
 
Ddr2 (Right-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 25.95 27.31 1.64 0.39 
Cytokines 26.63 28.25 0.54 0.05 
WNT5A No Cytokines 26.39 26.96 1.59 0.18 
Cytokines 26.71 27.73 0.65 0.07 
 
Runx2 (Left-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 28.31 28.99 1.30 0.15 
Cytokines 28.38 29.30 1.35 0.16 
WNT5A No Cytokines 29.03 29.50 0.82 0.06 
Cytokines 30.57 30.94 0.28 0.01 
 
Runx2 (Right-hand Figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 26.37 27.67 2.00 0.46 
Cytokines 27.84 29.59 0.31 0.03 
WNT5A No Cytokines 26.82 27.07 1.84 0.07 
Cytokines 27.93 28.86 0.38 0.04 
 
Cyr61 (Left-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 28.35 29.01 1.01 0.12 
Cytokines 28.23 29.32 1.46 0.45 
WNT5A No Cytokines 28.50 28.59 1.08 0.01 
Cytokines 29.43 30.51 0.43 0.12 
 
Cyr61 (Right-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 28.48 30.96 2.37 0.78 
Cytokines 29.35 30.83 0.61 0.06 
WNT5A No Cytokines 27.70 29.27 3.52 0.86 
Cytokines 29.53 30.62 0.65 0.10 
 
  
Table S4.2 (cont.) – TaqMan CT values for Figure 4.4 with normalised averages and SEM 
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Ctgf (Left-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 30.03 30.84 0.34 0.05 
Cytokines 29.97 31.37 0.36 0.04 
WNT5A No Cytokines 26.82 27.48 2.92 0.35 
Cytokines 29.96 30.50 0.42 0.05 
 
Ctgf (Right-hand figure) Min Ct Max Ct Normalised SEM  
Vector Only No Cytokines 27.62 28.75 2.55 0.76 
Cytokines 28.99 30.24 0.62 0.04 
WNT5A No Cytokines 27.52 29.14 2.51 0.46 
Cytokines 28.57 29.74 0.73 0.09 
 
Nov (Left-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 32.69 33.88 0.43 0.09 
Cytokines 33.21 33.78 0.39 0.05 
WNT5A No Cytokines 29.30 30.77 3.76 1.09 
Cytokines 33.21 33.71 0.33 0.02 
 
Nov (Right-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 31.83 33.91 1.84 0.47 
Cytokines 31.29 32.86 1.71 0.12 
WNT5A No Cytokines 31.75 33.62 2.46 0.62 
Cytokines 30.97 31.91 2.05 0.26 
 
Wisp1 (Left-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 28.56 29.01 1.74 0.13 
Cytokines 28.61 29.87 1.73 0.06 
WNT5A No Cytokines 28.68 29.36 1.40 0.16 
Cytokines 30.52 Undetermined 0.67  
 
Wisp1 (Right-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 30.38 31.81 3.35 0.74 
Cytokines 32.26 33.15 0.71 0.03 
WNT5A No Cytokines 29.91 31.39 3.94 0.73 
Cytokines 31.73 33.94 0.77 0.13 
 
  
Table S4.2 (cont.) – TaqMan CT values for Figure 4.4 with normalised averages and SEM 
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Wisp2 (Left-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 27.31 28.60 1.24 0.21 
Cytokines 27.90 29.24 1.20 0.14 
WNT5A No Cytokines 29.21 30.56 0.56 0.09 
Cytokines 30.25 30.98 0.41 0.03 
 
Wisp2 (Right-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 26.79 28.03 2.74 0.52 
Cytokines 28.46 29.48 0.59 0.07 
WNT5A No Cytokines 26.51 29.11 3.01 0.90 
Cytokines 28.31 28.99 0.72 0.07 
 
Frzb (Left-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 28.14 29.07 2.15 0.40 
Cytokines 27.59 29.89 2.60 0.57 
WNT5A No Cytokines 29.57 30.16 0.87 0.09 
Cytokines 30.82 31.39 0.43 0.05 
 
Frzb (Right-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 25.86 27.12 4.46 0.98 
Cytokines 29.76 30.80 0.21 0.01 
WNT5A No Cytokines 25.51 27.54 5.26 1.41 
Cytokines 28.86 30.42 0.31 0.06 
 
Col10a1 (Left-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 30.91 32.40 1.94 0.50 
Cytokines 31.25 32.96 1.74 0.16 
WNT5A No Cytokines 31.54 32.13 1.55 0.14 
Cytokines 31.13 31.81 1.91 0.32 
 
Col10a1 (Right-hand figure) Min Ct Max Ct Average SEM  
Vector Only No Cytokines 26.35 27.62 3.50 0.86 
Cytokines 28.53 29.28 0.46 0.02 
WNT5A No Cytokines 26.30 28.99 3.33 1.05 
Cytokines 27.66 28.85 0.74 0.13 
 
  
Table S4.2 (cont.) – TaqMan CT values for Figure 4.4 with normalised averages and SEM 
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  Table S4.3 – Effect of WNT5A in the absence of cytokines. Top 50 significantly regulated probes 
are ranked by absolute fold change. Positive and negative fold changes are highlighted in blue 
and orange respectively. Statistically significant (Q ≤ 0.05) and non-significant Benjamin-
Hochberg Q-Values are highlighted in green and red respectively. 
Rank Row Gene Symbol Gene Name +/- FC Absolute FC P-Value BH Q-Value
1 1429900_at 5330406M23Rik RIKEN cDNA 5330406M23 gene 2.7406 2.7406 0.0410 0.9370
2 1442494_at C79242 expressed sequence C79242 2.6546 2.6546 0.0431 0.9370
3 1460096_at 2.6393 2.6393 0.0106 0.9370
4 1448018_at 2.5769 2.5769 0.0361 0.9370
5 1447381_at 2.5409 2.5409 0.0198 0.9370
6 1429804_at Slc22a16
solute carrier family 22 (organic cation transporter), 
member 16
-2.4470 2.4470 0.0120 0.9370
7 1449434_at Car3 carbonic anhydrase 3 -2.4444 2.4444 0.0125 0.9370
8 1456914_at Slc16a4
Solute carrier family 16 (monocarboxylic acid 
transporters), member 4 (Slc16a4), mRNA
2.4160 2.4160 0.0377 0.9370
9 1423396_at Agt
angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8)
-2.4111 2.4111 0.0158 0.9370
10 1437066_at Zbtb20 zinc finger and BTB domain containing 20 2.3780 2.3780 0.0078 0.9370
11 1438009_at Hist1h2ad histone cluster 1, H2ad 2.3680 2.3680 0.0057 0.9370
12 1458452_at Ankrd11
Ankyrin repeat domain 11, mRNA (cDNA clone 
MGC:198846 IMAGE:9054811)
2.3609 2.3609 0.0108 0.9370
13 1417507_at Cyb561 cytochrome b-561 -2.3536 2.3536 0.0030 0.9370
14 1457888_at 2.3355 2.3355 0.0137 0.9370
15 1442418_at B930096F20Rik RIKEN cDNA B930096F20 gene 2.3259 2.3259 0.0342 0.9370
16 1440120_at Gnb2l1
Guanine nucleotide binding protein (G protein), beta 
polypeptide 2 like 1 (Gnb2l1), mRNA
2.3088 2.3088 0.0229 0.9370
17 1438299_at 9230108I15Rik RIKEN cDNA 9230108I15 gene 2.3080 2.3080 0.0322 0.9370
18 1448054_at 2.3043 2.3043 0.0378 0.9370
19 1418486_at Vnn1 vanin 1 -2.2889 2.2889 0.0174 0.9370
20 1447509_at 2.2649 2.2649 0.0397 0.9370
21 1449168_a_at Akap2 A kinase (PRKA) anchor protein 2 2.2399 2.2399 0.0390 0.9370
22 1456821_at 2.2255 2.2255 0.0419 0.9370
23 1458684_at 2.2244 2.2244 0.0088 0.9370
24 1439260_a_at Enpp3
ectonucleotide pyrophosphatase/phosphodiesterase 
3
-2.2076 2.2076 0.0221 0.9370
25 1436905_x_at Laptm5 lysosomal-associated protein transmembrane 5 -2.1958 2.1958 0.0080 0.9370
26 1449419_at Dock8 dedicator of cytokinesis 8 -2.1894 2.1894 0.0038 0.9370
27 1417426_at Srgn serglycin -2.1879 2.1879 0.0075 0.9370
28 1444764_at A130022J21Rik RIKEN cDNA A130022J21 gene 2.1837 2.1837 0.0296 0.9370
29 1446331_at Ptgfr prostaglandin F receptor -2.1814 2.1814 0.0287 0.9370
30 1444611_at -2.1799 2.1799 0.0092 0.9370
31 1441253_at 2.1793 2.1793 0.0181 0.9370
32 1420935_a_at Srrm1 serine/arginine repetitive matrix 1 2.1790 2.1790 0.0298 0.9370
33 1437775_at Dlst
dihydrolipoamide S-succinyltransferase (E2 
component of 2-oxo-glutarate complex)
2.1737 2.1737 0.0021 0.9370
34 1460574_at Fat4 FAT tumor suppressor homolog 4 (Drosophila) 2.1723 2.1723 0.0247 0.9370
35 1443547_at 2.1674 2.1674 0.0039 0.9370
36 1456933_at 2.1526 2.1526 0.0067 0.9370
37 1426316_at 6330416G13Rik RIKEN cDNA 6330416G13 gene -2.1372 2.1372 0.0416 0.9370
38 1427285_s_at Malat1
metastasis associated lung adenocarcinoma transcript 
1 (non-coding RNA)
2.1351 2.1351 0.0109 0.9370
39 1455948_x_at Matn3 matrilin 3 -2.1284 2.1284 0.0023 0.9370
40 1456262_at Rbm5 RNA binding motif protein 5 2.1153 2.1153 0.0285 0.9370
41 1421257_at Pigb
phosphatidylinositol glycan anchor biosynthesis, class 
B
-2.1131 2.1131 0.0266 0.9370
42 1422865_at Runx1 runt related transcription factor 1 2.1055 2.1055 0.0226 0.9370
43 1455139_at AI851716 expressed sequence AI851716 -2.0937 2.0937 0.0149 0.9370
44 1457815_at 2.0886 2.0886 0.0139 0.9370
45 1434325_x_at Prkar1b
protein kinase, cAMP dependent regulatory, type I 
beta
-2.0879 2.0879 0.0454 0.9370
46 1458507_at Rnf216
Ring finger protein 216, mRNA (cDNA clone 
IMAGE:6822422)
2.0846 2.0846 0.0478 0.9370
47 1459687_x_at 2.0798 2.0798 0.0218 0.9370
48 1457653_at 2.0795 2.0795 0.0011 0.9370
49 1451767_at Ncf1 neutrophil cytosolic factor 1 -2.0768 2.0768 0.0089 0.9370
50 1437979_at Zcchc2
Zinc finger, CCHC domain containing 2, mRNA (cDNA 
clone IMAGE:5365587)
-2.0758 2.0758 0.0146 0.9370
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  Table S4.4 – Effect of WNT5A in the presence of cytokines. Top 50 significantly regulated 
probes are ranked by absolute fold change. Positive and negative fold changes are 
highlighted in blue and orange respectively. Statistically significant (Q ≤ 0.05) and non-
significant Benjamin-Hochberg Q-Values are highlighted in green and red respectively. 
Rank Row Gene Symbol Gene Name +/- FC Absolute FC P-Value BH Q-Value
1 1457508_at C430003N24Rik RIKEN cDNA C430003N24 gene 3.2743 3.2743 0.0023 0.6064
2 1458110_at D430030G11Rik RIKEN cDNA D430030G11 gene 3.2695 3.2695 0.0210 0.7138
3 1446736_at 3.2135 3.2135 0.0005 0.4401
4 1437806_x_at Mtch2 mitochondrial carrier homolog 2 (C. elegans) 3.0219 3.0219 0.0178 0.7107
5 1417301_at Fzd6 frizzled homolog 6 (Drosophila) -3.0033 3.0033 0.0397 0.7351
6 1433369_at 8430401P03Rik RIKEN cDNA 8430401P03 gene 2.9924 2.9924 0.0006 0.4401
7 1439036_a_at Atp1b1 ATPase, Na+/K+ transporting, beta 1 polypeptide 2.9785 2.9785 0.0146 0.7107
8 1439929_at 2.9548 2.9548 0.0141 0.7107
9 1447723_at 2.9317 2.9317 0.0407 0.7351
10 1440314_at 2.8488 2.8488 0.0225 0.7138
11 1422962_a_at Psmb8
proteasome (prosome, macropain) subunit, beta type 
8 (large multifunctional peptidase 7)
-2.8430 2.8430 0.0044 0.6698
12 1458916_at 2.8372 2.8372 0.0178 0.7107
13 1449623_at Txnrd3 thioredoxin reductase 3 -2.8284 2.8284 0.0048 0.6698
14 1432114_at 1110035E04Rik RIKEN cDNA 1110035E04 gene 2.8240 2.8240 0.0157 0.7107
15 1445898_at Ggcx gamma-glutamyl carboxylase 2.8111 2.8111 0.0095 0.6948
16 1441816_at 2900056M20Rik RIKEN cDNA 2900056M20 gene 2.7881 2.7881 0.0216 0.7138
17 1438331_at 2.7573 2.7573 0.0143 0.7107
18 1440809_at -2.7288 2.7288 0.0117 0.7107
19 1441516_a_at C130050O18Rik RIKEN cDNA C130050O18 gene -2.7255 2.7255 0.0054 0.6776
20 1420288_at 2.7248 2.7248 0.0197 0.7138
21 1430708_a_at Usp45 ubiquitin specific petidase 45 -2.7155 2.7155 0.0186 0.7138
22 1444992_at AI120166 expressed sequence AI120166 2.6930 2.6930 0.0067 0.6948
23 1459005_at 2.6888 2.6888 0.0494 0.7351
24 1439928_at 2.6395 2.6395 0.0412 0.7351
25 1440231_at Mtap9 microtubule-associated protein 9 -2.6210 2.6210 0.0128 0.7107
26 1460092_at 2.5760 2.5760 0.0350 0.7351
27 1446798_at Map4k3
Mitogen-activated protein kinase kinase kinase kinase 
3, mRNA (cDNA clone IMAGE:3603090)
2.5539 2.5539 0.0222 0.7138
28 1415923_at Ndn necdin -2.5316 2.5316 0.0325 0.7328
29 1447055_at Dnajc11 DnaJ (Hsp40) homolog, subfamily C, member 11 -2.5157 2.5157 0.0184 0.7138
30 1425747_at Dock5 dedicator of cytokinesis 5 -2.5120 2.5120 0.0228 0.7138
31 1459961_a_at Stat3
Signal transducer and activator of transcription 3, 
mRNA (cDNA clone IMAGE:3665873)
2.4956 2.4956 0.0062 0.6948
32 1425555_at Crkrs CDC2-related kinase, arginine/serine-rich 2.4868 2.4868 0.0369 0.7351
33 1445695_at 2.4802 2.4802 0.0021 0.6059
34 1452319_at Zfp82 zinc finger protein 82 -2.4557 2.4557 0.0367 0.7351
35 1458578_at 2.4049 2.4049 0.0271 0.7203
36 1447706_at 2.3986 2.3986 0.0020 0.6059
37 1439109_at Ccdc68 coiled-coil domain containing 68 2.3911 2.3911 0.0375 0.7351
38 1440892_at 2.3762 2.3762 0.0111 0.7078
39 1457930_at Kdm5c lysine (K)-specific demethylase 5C 2.3636 2.3636 0.0333 0.7328
40 1451418_a_at Spsb4
splA/ryanodine receptor domain and SOCS box 
containing 4
-2.3620 2.3620 0.0104 0.6948
41 1446457_at Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 -2.3572 2.3572 0.0151 0.7107
42 1459641_at 2.3485 2.3485 0.0232 0.7138
43 1450611_at Orm3 orosomucoid 3 -2.3385 2.3385 0.0026 0.6064
44 1445068_at Malt1
mucosa associated lymphoid tissue lymphoma 
translocation gene 1
2.3292 2.3292 0.0269 0.7203
45 1440946_at -2.3275 2.3275 0.0048 0.6698
46 1429951_at Ssbp2 single-stranded DNA binding protein 2 2.3217 2.3217 0.0235 0.7138
47 1435575_at Kntc1 kinetochore associated 1 -2.3182 2.3182 0.0061 0.6948
48 1421989_s_at Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 2.3004 2.3004 0.0273 0.7203
49 1424775_at Oas1a 2'-5' oligoadenylate synthetase 1A -2.2924 2.2924 0.0205 0.7138
50 1444378_at 2.2921 2.2921 0.0201 0.7138
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  Table S4.5 – Effect of cytokines in the absence of WNT5A. Top 50 significantly regulated probes 
are ranked by absolute fold change. Positive and negative fold changes are highlighted in blue 
and orange respectively. Statistically significant (Q ≤ 0.05) and non-significant Benjamin-
Hochberg Q-Values are highlighted in green and red respectively. 
Rank Row Gene Symbol Gene Name +/- FC Absolute FC P-Value BH Q-Value
1 1427747_a_at Lcn2 lipocalin 2 3211.3040 3211.3040 1.41E-07 4.46E-04
2 1419075_s_at Saa1 serum amyloid A 1 2256.2703 2256.2703 1.17E-07 4.46E-04
3 1450826_a_at Saa3 serum amyloid A 3 1963.1525 1963.1525 1.38E-09 3.08E-05
4 1450788_at Saa1 serum amyloid A 1 1694.9266 1694.9266 4.69E-07 6.84E-04
5 1436530_at
OTTMUSG0000000097
1
predicted gene, OTTMUSG00000000971 1642.8577 1642.8577 7.02E-07 7.32E-04
6 1449326_x_at Saa2 serum amyloid A 2 638.6769 638.6769 3.01E-06 8.49E-04
7 1419561_at Ccl3 chemokine (C-C motif) ligand 3 569.8519 569.8519 2.48E-06 8.49E-04
8 1421228_at Ccl7 chemokine (C-C motif) ligand 7 463.5318 463.5318 1.20E-05 0.00127659
9 1449824_at Prg4
proteoglycan 4 (megakaryocyte stimulating factor, 
articular superficial zone protein)
444.4955 444.4955 5.64E-06 9.35E-04
10 1450297_at Il6 interleukin 6 441.2112 441.2112 8.44E-06 0.00104345
11 1448881_at Hp haptoglobin 428.0871 428.0871 3.67E-06 8.72E-04
12 1423954_at C3 complement component 3 382.0203 382.0203 1.37E-06 7.32E-04
13 1451344_at Tmem119 transmembrane protein 119 -359.6308 359.6308 1.19E-06 7.32E-04
14 1418945_at Mmp3 matrix metallopeptidase 3 268.9582 268.9582 1.51E-05 0.00131501
15 1428815_at Gstt4 glutathione S-transferase, theta 4 267.4842 267.4842 4.80E-07 6.84E-04
16 1451054_at Orm1 orosomucoid 1 257.2303 257.2303 3.66E-06 8.72E-04
17 1420380_at Ccl2 chemokine (C-C motif) ligand 2 239.3932 239.3932 5.98E-06 9.54E-04
18 1451537_at Chi3l1 chitinase 3-like 1 233.8305 233.8305 7.11E-06 9.89E-04
19 1438665_at Smpd3 sphingomyelin phosphodiesterase 3, neutral -228.3422 228.3422 1.37E-05 0.00128759
20 1434484_at 1100001G20Rik RIKEN cDNA 1100001G20 gene 219.7001 219.7001 6.87E-06 9.89E-04
21 1419530_at Il12b interleukin 12b 155.2335 155.2335 1.69E-05 0.00134199
22 1433924_at -152.1493 152.1493 1.45E-05 0.00130956
23 1455717_s_at Daam2 dishevelled associated activator of morphogenesis 2 -150.8834 150.8834 1.28E-04 0.00275011
24 1449984_at Cxcl2 chemokine (C-X-C motif) ligand 2 147.6220 147.6220 5.01E-06 9.09E-04
25 1420438_at Orm2 orosomucoid 2 142.0294 142.0294 1.66E-06 7.32E-04
26 1449591_at Casp4 caspase 4, apoptosis-related cysteine peptidase 121.0935 121.0935 2.41E-07 4.59E-04
27 1442726_s_at AI845619 expressed sequence AI845619 117.7428 117.7428 4.78E-06 8.83E-04
28 1441855_x_at Cxcl1 chemokine (C-X-C motif) ligand 1 115.5795 115.5795 1.26E-06 7.32E-04
29 1443745_s_at Dmp1 dentin matrix protein 1 -108.1294 108.1294 2.19E-04 0.00335869
30 1431182_at
EG666031 : Hspa8 : 
LOC624853 : 
LOC641192
predicted gene, EG666031 : heat shock protein 8 : 
hypothetical LOC624853 : similar to heat shock protein 
8
108.0675 108.0675 1.02E-04 0.00246132
31 1417314_at Cfb complement factor B 106.8491 106.8491 1.72E-06 7.32E-04
32 1457644_s_at Cxcl1 chemokine (C-X-C motif) ligand 1 105.5933 105.5933 1.35E-04 0.00278365
33 1432523_at Hipk2 homeodomain interacting protein kinase 2 104.0568 104.0568 5.77E-06 9.35E-04
34 1419684_at Ccl8 chemokine (C-C motif) ligand 8 101.7400 101.7400 4.48E-06 8.83E-04
35 1436698_x_at Tmem204 transmembrane protein 204 -99.6293 99.6293 5.62E-06 9.35E-04
36 1438148_at Cxcl3 chemokine (C-X-C motif) ligand 3 99.4725 99.4725 1.13E-04 0.00257189
37 1419394_s_at S100a8 S100 calcium binding protein A8 (calgranulin A) 94.8861 94.8861 2.13E-05 0.00144375
38 1423719_at LOC632073 : U46068
similar to long palate, lung and nasal epithelium 
carcinoma associated 1 isoform 2 : cDNA sequence 
U46068
94.3277 94.3277 1.01E-04 0.00245357
39 1417936_at Ccl9 chemokine (C-C motif) ligand 9 93.3756 93.3756 2.04E-05 0.00143277
40 1443746_x_at Dmp1 dentin matrix protein 1 -91.7840 91.7840 7.72E-04 0.00603247
41 1418126_at Ccl5 chemokine (C-C motif) ligand 5 88.8513 88.8513 2.95E-06 8.49E-04
42 1439423_x_at U46068 cDNA sequence U46068 88.3544 88.3544 1.09E-06 7.32E-04
43 1449153_at Mmp12 matrix metallopeptidase 12 85.1682 85.1682 2.06E-05 0.00143454
44 1425649_at Slc39a14 solute carrier family 39 (zinc transporter), member 14 84.6762 84.6762 4.47E-06 8.83E-04
45 1429947_a_at Zbp1 Z-DNA binding protein 1 82.8222 82.8222 7.94E-05 0.00227951
46 1455993_at Odz4 odd Oz/ten-m homolog 4 (Drosophila) -81.2267 81.2267 8.31E-05 0.00231782
47 1417160_s_at Expi extracellular proteinase inhibitor 79.9065 79.9065 4.02E-06 8.83E-04
48 1426008_a_at Slc7a2
solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 2
75.6727 75.6727 1.65E-07 4.46E-04
49 1456893_at 74.9601 74.9601 3.17E-06 8.52E-04
50 1451922_at Lman1l lectin, mannose-binding 1 like 74.6722 74.6722 3.90E-06 8.83E-04
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  Table S4.6 – Effect of cytokines in the presence of WNT5A. Top 50 significantly regulated 
probes are ranked by absolute fold change. Positive and negative fold changes are highlighted 
in blue and orange respectively. Statistically significant (Q ≤ 0.05) and non-significant Benjamin-
Hochberg Q-Values are highlighted in green and red respectively. 
Rank Row Gene Symbol Gene Name +/- FC Absolute FC P-Value BH Q-Value
1 1427747_a_at Lcn2 lipocalin 2 2563.3347 2563.3347 2.15E-05 0.00116383
2 1419075_s_at Saa1 serum amyloid A 1 1982.0406 1982.0406 5.71E-07 3.84E-04
3 1450788_at Saa1 serum amyloid A 1 1911.3606 1911.3606 1.90E-06 6.54E-04
4 1436530_at
OTTMUSG0000000097
1
predicted gene, OTTMUSG00000000971 1322.0448 1322.0448 1.22E-06 5.41E-04
5 1450826_a_at Saa3 serum amyloid A 3 878.7861 878.7861 0.00121606 0.00682299
6 1449326_x_at Saa2 serum amyloid A 2 760.6014 760.6014 2.07E-07 3.22E-04
7 1419561_at Ccl3 chemokine (C-C motif) ligand 3 638.6044 638.6044 1.08E-07 2.69E-04
8 1449824_at Prg4
proteoglycan 4 (megakaryocyte stimulating factor, 
articular superficial zone protein)
601.2683 601.2683 2.48E-06 7.11E-04
9 1448881_at Hp haptoglobin 589.7481 589.7481 9.13E-07 4.64E-04
10 1450297_at Il6 interleukin 6 552.9445 552.9445 7.22E-07 3.94E-04
11 1423954_at C3 complement component 3 487.5731 487.5731 6.82E-06 8.16E-04
12 1418945_at Mmp3 matrix metallopeptidase 3 396.9287 396.9287 1.48E-06 5.90E-04
13 1421228_at Ccl7 chemokine (C-C motif) ligand 7 370.7286 370.7286 2.82E-06 7.11E-04
14 1451537_at Chi3l1 chitinase 3-like 1 356.2876 356.2876 2.23E-05 0.00118104
15 1451344_at Tmem119 transmembrane protein 119 -315.3444 315.3444 5.76E-06 7.89E-04
16 1428815_at Gstt4 glutathione S-transferase, theta 4 251.7484 251.7484 3.81E-07 3.41E-04
17 1420438_at Orm2 orosomucoid 2 222.2727 222.2727 2.28E-06 7.09E-04
18 1451054_at Orm1 orosomucoid 1 202.6931 202.6931 1.48E-05 0.00105608
19 1417314_at Cfb complement factor B 193.5781 193.5781 6.58E-08 2.45E-04
20 1419530_at Il12b interleukin 12b 178.5912 178.5912 7.36E-06 8.16E-04
21 1420380_at Ccl2 chemokine (C-C motif) ligand 2 176.9120 176.9120 6.74E-06 8.16E-04
22 1449984_at Cxcl2 chemokine (C-X-C motif) ligand 2 173.0926 173.0926 3.78E-06 7.26E-04
23 1434484_at 1100001G20Rik RIKEN cDNA 1100001G20 gene 157.7251 157.7251 1.52E-05 0.00106395
24 1460465_at A930038C07Rik RIKEN cDNA A930038C07 gene -155.4903 155.4903 4.41E-06 7.59E-04
25 1423719_at LOC632073 : U46068
similar to long palate, lung and nasal epithelium 
carcinoma associated 1 isoform 2 : cDNA sequence 
U46068
150.8190 150.8190 5.73E-06 7.89E-04
26 1425649_at Slc39a14 solute carrier family 39 (zinc transporter), member 14 142.0118 142.0118 2.47E-06 7.11E-04
27 1426008_a_at Slc7a2
solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 2
126.5383 126.5383 9.74E-06 9.00E-04
28 1455717_s_at Daam2 dishevelled associated activator of morphogenesis 2 -126.3871 126.3871 6.70E-06 8.16E-04
29 1417936_at Ccl9 chemokine (C-C motif) ligand 9 117.9082 117.9082 1.57E-05 0.00106395
30 1455993_at Odz4 odd Oz/ten-m homolog 4 (Drosophila) -115.5581 115.5581 3.95E-06 7.26E-04
31 1418126_at Ccl5 chemokine (C-C motif) ligand 5 115.0684 115.0684 8.79E-06 8.50E-04
32 1419394_s_at S100a8 S100 calcium binding protein A8 (calgranulin A) 106.2597 106.2597 2.27E-05 0.00118982
33 1448550_at Lbp lipopolysaccharide binding protein 104.4957 104.4957 7.05E-07 3.94E-04
34 1449591_at Casp4 caspase 4, apoptosis-related cysteine peptidase 103.1238 103.1238 2.16E-06 7.09E-04
35 1438665_at Smpd3 sphingomyelin phosphodiesterase 3, neutral -102.4950 102.4950 7.16E-06 8.16E-04
36 1439423_x_at U46068 cDNA sequence U46068 99.2122 99.2122 3.42E-05 0.00140771
37 1430998_at Sqrdl sulfide quinone reductase-like (yeast) 97.3844 97.3844 6.12E-08 2.45E-04
38 1425197_at Ptpn2 protein tyrosine phosphatase, non-receptor type 2 97.1053 97.1053 1.88E-05 0.00110395
39 1441855_x_at Cxcl1 chemokine (C-X-C motif) ligand 1 95.7483 95.7483 1.22E-04 0.00224954
40 1451922_at Lman1l lectin, mannose-binding 1 like 91.6415 91.6415 3.05E-06 7.11E-04
41 1435477_s_at Fcgr2b Fc receptor, IgG, low affinity IIb 90.4095 90.4095 1.62E-07 3.22E-04
42 1438148_at Cxcl3 chemokine (C-X-C motif) ligand 3 89.0340 89.0340 6.60E-05 0.00175383
43 1441516_a_at C130050O18Rik RIKEN cDNA C130050O18 gene -85.0116 85.0116 8.98E-06 8.52E-04
44 1457644_s_at Cxcl1 chemokine (C-X-C motif) ligand 1 84.3500 84.3500 2.28E-06 7.09E-04
45 1417160_s_at Expi extracellular proteinase inhibitor 80.9290 80.9290 4.93E-05 0.00159284
46 1419209_at Cxcl1 chemokine (C-X-C motif) ligand 1 74.9025 74.9025 7.38E-06 8.16E-04
47 1443746_x_at Dmp1 dentin matrix protein 1 -73.1457 73.1457 2.66E-04 0.00317814
48 1449153_at Mmp12 matrix metallopeptidase 12 72.0990 72.0990 2.53E-07 3.22E-04
49 1442726_s_at AI845619 expressed sequence AI845619 71.8896 71.8896 3.24E-06 7.11E-04
50 1433691_at Ppp1r3c
protein phosphatase 1, regulatory (inhibitor) subunit 
3C
-70.8717 70.8717 2.92E-07 3.22E-04
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Rank Row Gene Symbol Gene Name +/- FC Absolute FC P-Value BH Q-Value
1 1439799_at -16.0050 16.0050 0.00088745 0.00571949
2 1442335_at -10.4927 10.4927 0.00017424 0.00265872
3 1437442_at Pcdh7 Protocadherin 7 (Pcdh7), transcript variant 2, mRNA -9.8019 9.8019 9.5848E-05 0.00204591
4 1430893_at 2610016E04Rik RIKEN cDNA 2610016E04 gene 9.6412 9.6412 0.01394941 0.03263388
5 1435787_at Ppm1l protein phosphatase 1 (formerly 2C)-like -8.9455 8.9455 0.00314168 0.01197396
6 1422264_s_at Klf9 Kruppel-like factor 9 8.6721 8.6721 0.00425507 0.01458118
7 1455377_at Ttll7 tubulin tyrosine ligase-like family, member 7 -8.2681 8.2681 0.00131814 0.00715582
8 1452398_at Plce1 phospholipase C, epsilon 1 -8.2459 8.2459 0.00032901 0.00353004
9 1450037_at Usp9x ubiquitin specific peptidase 9, X chromosome -7.8583 7.8583 0.00767457 0.02164671
10 1430834_at Gprin3 GPRIN family member 3 -7.7692 7.7692 0.00869807 0.02346549
11 1429236_at Galntl2
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2
-7.4364 7.4364 0.00101328 0.00614103
12 1440797_at Dlx6os2 Dlx6 opposite strand transcript 2 -7.1202 7.1202 4.55E-05 0.00152586
13 1445492_at 7.0539 7.0539 0.01055106 0.02674227
14 1421477_at Cplx2 complexin 2 -6.9635 6.9635 2.436E-05 0.00121824
15 1443257_at 9630050E16Rik RIKEN cDNA 9630050E16 gene 6.8821 6.8821 0.00291568 0.0114629
16 1447313_at -6.8778 6.8778 0.0089739 0.02395537
17 1427363_at 6.8657 6.8657 0.00332228 0.01243841
18 1447854_s_at Hist2h2be histone cluster 2, H2be -6.4702 6.4702 0.00028808 0.00328966
19 1426546_at Tesk2 testis-specific kinase 2 -6.3263 6.3263 0.00725669 0.02087606
20 1420178_at 6.1460 6.1460 1.0654E-05 0.00094634
21 1439077_at Zxda zinc finger, X-linked, duplicated A -6.1398 6.1398 0.00080325 0.00544791
22 1438352_at 6.1270 6.1270 0.00202856 0.00918042
23 1430581_at Bclaf1 BCL2-associated transcription factor 1 6.0971 6.0971 0.00018969 0.00275892
24 1425220_x_at LOC100038935 hypothetical protein LOC100038935 -6.0751 6.0751 0.01909001 0.04095949
25 1458586_at 5.9533 5.9533 0.011252 0.02797992
26 1444069_at -5.9239 5.9239 0.00153559 0.00778232
27 1458592_at -5.9132 5.9132 0.00043945 0.00405213
28 1458282_at 5.8215 5.8215 0.01253779 0.0302884
29 1440833_at Cdc2l5
cell division cycle 2-like 5 (cholinesterase-related cell 
division controller)
5.7823 5.7823 0.00544289 0.01716588
30 1457529_x_at 5.7786 5.7786 0.020961 0.04407347
31 1439929_at 5.7167 5.7167 0.0012802 0.00703638
32 1435398_at Stxbp5 syntaxin binding protein 5 (tomosyn) -5.7156 5.7156 0.00033593 0.00355812
33 1440934_at 6230409E13Rik RIKEN cDNA 6230409E13 gene -5.6813 5.6813 0.00121665 0.00682461
34 1441187_at E330037M01Rik RIKEN cDNA E330037M01 gene 5.6509 5.6509 0.00751738 0.02135015
35 1433819_s_at Agpat3 1-acylglycerol-3-phosphate O-acyltransferase 3 -5.6200 5.6200 0.00174765 0.00840934
36 1440560_at 5.5874 5.5874 0.00096323 0.0059842
37 1449651_x_at EG668525
PREDICTED: Mus musculus predicted gene, EG668525 
(EG668525), mRNA
5.5680 5.5680 0.00615021 0.01862967
38 1427265_at Bcr breakpoint cluster region -5.5646 5.5646 0.00248726 0.01035933
39 1440417_at D19Ertd409e DNA segment, Chr 19, ERATO Doi 409, expressed 5.4770 5.4770 0.0012998 0.00709878
40 1416893_at Fam107b family with sequence similarity 107, member B 5.4738 5.4738 0.00272887 0.01099781
41 1453361_at Hells helicase, lymphoid specific 5.4031 5.4031 0.00051353 0.00435873
42 1437127_at A630033E08Rik
RIKEN cDNA A630033E08 gene (A630033E08Rik), 
transcript variant 1, mRNA
-5.3335 5.3335 0.01602933 0.03607262
43 1421222_at Fip1l1 FIP1 like 1 (S. cerevisiae) 5.2150 5.2150 0.00079221 0.00540936
44 1440769_at 2010305A19Rik
RIKEN cDNA 2010305A19 gene, mRNA (cDNA clone 
MGC:8003 IMAGE:3585966)
-5.1741 5.1741 0.01461774 0.03374952
45 1433600_at Adra2a adrenergic receptor, alpha 2a -5.1643 5.1643 0.00669055 0.01973726
46 1449006_at Gla galactosidase, alpha 5.0932 5.0932 0.01245876 0.03014507
47 1438331_at 5.0190 5.0190 0.00355731 0.01297982
48 1442332_at 4.9912 4.9912 0.00029235 0.00330176
49 1443354_at -4.9863 4.9863 0.00596998 0.01825335
50 1421851_at Mtap1b microtubule-associated protein 1B -4.9762 4.9762 0.01007685 0.02595078
Table S4.7 – Top 50 genes significantly regulated by cytokines only in presence of WNT5A 
based on significant Q-Value and ranked by absolute fold change. Positive and negative fold 
changes are highlighted in blue and orange respectively 
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Anxa1 Min Ct Max Ct Average SEM  
Vector 
Only 
No Cytokines 23.88 25.26 1.35 0.16 
Cytokines 23.71 24.62 1.12 0.04 
WNT5A No Cytokines 23.72 25.50 1.71 0.40 
Cytokines 23.51 24.47 1.30 0.14 
Matn3 Min Ct Max Ct Average SEM  
Vector 
Only 
No Cytokines 32.28 34.33 7.30 2.95 
Cytokines 36.17 36.17   
WNT5A No Cytokines 32.82 34.89 4.65 1.46 
Cytokines 34.96 38.04 0.67  
Prg4 Min Ct Max Ct Average SEM  
Vector 
Only 
No Cytokines 35.51 39.28   
Cytokines 27.61 29.23 1.77 0.18 
WNT5A No Cytokines 35.78 39.41   
Cytokines 27.09 29.01 2.12 0.54 
Table S4.8 – TaqMan CT values for Figure 4.11 with normalised averages and SEM 
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Figure S4.1 – Detection of human WNT5A-FLAG with specific WNT5A antibody. ATDC5 cells 
were transiently transfected with human WNT5A-FLAG and cell lysates were probed using an 
antibody specific for WNT5A via western blot. Human WNT5A-FLAG = 44.99 kDa. Endogenous 
mouse WNT5A = 42.35 kDa (isoform 1) or 40.89 kDa (isoform 2). Predicted molecular weights 
based on amino acid sequence. 
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Table S5.1 – TaqMan CT values for Figure 5.4 B 
Min Max NormalisedSEM
28.26 29.78 0.08 0.02
Ins + Asc Removed 22.48 24.39 2.66 0.09
Ins + Asc Retained 22.91 23.93 1.97 0.13
27.42 29.96 0.11 0.05
Ins + Asc Removed 22.77 23.37 3.94 0.19
Ins + Asc Retained 23.28 24.56 2.40 0.11
Col2a1
Plastic
Non-induced
From Micromass Culture
Type II Collagen
Non-induced
From Micromass Culture
Figure S5.1 – WNT5A decreases speed of migration in cytokine-stimulated ATDC5 cells on 
type II collagen compared to WNT3A. Experiment performed twice and significance observed 
in both experiments 
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